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SUMMARY
The HSV-1 genome is 152 kbp in length and contains at least 74 distinct genes. About 
half of the genes are individually not essential for viral growth in cell culture but most 
appear to be required for efficient viral replication and pathogenesis in experimental 
animal systems. The availability of the complete DNA sequence of HSV-1 since 1988 
has made it possible to target any gene for mutation, including those that had been 
previously inaccessible to conventional genetic analysis.
A cosmid-based recombination system for producing HSV-1 mutants has been 
developed recently. The inserts from a set of five cosmids, each about 40 kbp in size, 
which together contain the entire HSV-1 genome, are co-transfected into BHK C13 cells 
to yield wt virus via recombination processes. One cosmid containing a gene of interest 
can be mutated, and replacement of the wt cosmid in the set by the mutated cosmid 
results in mutant progeny after co-transfection. This approach has a number of 
advantages over traditional methods of mutagenesis, particularly in allowing minimal 
alterations to be introduced and in permitting the generation of mutants in the absence of a 
wt background.
The aim of this project was to expand the use the cosmid-based system of mutagenesis to 
analyse HSV-1 genes UL14, UL15, UL16 and UL17 and to investigate the phenotypes 
of mutants obtained.
The technique used takes advantage of the observation that digestion of covalently closed 
DNA molecules in the presence of ethidium bromide by restriction enzymes with multiple 
recognition sites preferentially yields full length linear molecules after a single site is 
cleaved. An appropriate cosmid (cos24) was linearised with the restriction enzyme 
A sp llS , which cleaves at the sequence G’GTACC, leaving a 5’ overhang. Treatment 
with T4 DNA polymerase in the presence of the four deoxynucleotide triphosphates, 
followed by religation, resulted in a 4 bp insertion, thus altering the reading frame of the 
gene from that point onwards. A spl 18 has seven sites in cos24, and mutant cosmids 
were made with a 4 bp insertion in UL14, UL15 and UL17, in addition to UL6 and 
UL7.
Since these genes may be essential in cell culture, a number of candidate complementing 
cell lines were produced by three different strategies. These were generated using either 
cos24 (containing genes UL1 to UL21), a plasmid containing genes UL14 to UL18, or
Summary
plasmids containing UL14, UL15 or UL17 individually. Overall, 122 candidate cell 
lines were produced, and 40 were tested to see if they could complement the mutation by 
transfection with the appropriate mutant cosmid sets. BHK C l3 cells were also 
transfected. Following transfection, all of the progeny generated from these cell lines 
and BHK C13 cells were wt revertants, presumably owing to loss of the 4 bp insertion 
by intramolecular recombination. This indicates that the cell lines tested are not able to 
complement the defects and that UL14, UL15, and UL17 are essential for viral 
replication in cell culture.
Proteins whose sequences are present in databases may be identified by newly developed 
techniques involving mass spectrometry. Proteins are separated by SDS-PAGE and 
electroblotted onto a membrane, then proteins of interest are excised and treated with 
trypsin. The peptides produced are subjected to laser desorption mass spectrometry, and 
the resulting masses from the spectrum are compared to the predicted tryptic products 
from proteins in a database. Using this method, evidence was obtained that the protein 
products of UL17 and UL14 may be present in small amounts in HSV-1 virions.
Two independent UL16' viruses were available in the laboratory at the commencement of 
this work, and a further four independent UL16' mutants were also produced. These six 
mutants were characterised in cell culture and the effects of the lesions on neurovirulence 
and latency were investigated using a mouse model.
The mutants produce smaller plaques on BHK C13 cells and yield less virus than wt and 
a revertant. The small plaque size and low yield were dependent on the particular site of 
the mutation within UL16. The mutants were able to adsorb as efficiently as wt, but 
were slightly reduced in their ability to bind and penetrate cell, they were not significantly 
temperature sensitive or cell type-specific. Particle counts by electron microscopy 
revealed that they have a high particle to plaque forming unit (pfu) ratio (i.e. they produce 
the same amount of particles but fewer are infectious).
Analysis of the mutants was carried out using a mouse model. After inoculation of virus 
into the cranium, wt virus produced from the parental cosmid set was fully neurovirulent 
but the UL16' viruses were less virulent than wt (i.e. they killed fewer animals at each 
dose). Footpad inoculations were carried out to investigate the ability of the mutants to 
replicate at the periphery and to establish and reactivate from latency. The mutants were 
able to establish and reactivate from latent infection, but less efficiently than wt.
Summary
In conclusion, although UL16 mutants are viable in cell culture they have a high particle 
to pfu ratio, yield less virus than wt and produce smaller plaques. The results from 
experiments involving infection of mice indicate that the UL16 protein has a role in 
neurovirulence and latency.
C on ten ts
CONTENTS
Abbreviations.................................................................................................................. i
List of Figures and Tables............................................................................................ vi
Chapter 1 - Introduction
1.1. THE FAMILY HERPESVIRIDAE
1.1.1. General properties...................................................................................................... 1
1.1.2. Biological properties.................................................................................................... 1
1.1.3. Genome features........................................................................................................ 2
1.1.4. Classification and evolution....................................................................................... 2
1.2. HUMAN HERPESVIRUSES
1.2.1. Biological properties....................................................................................................4
1.2.2. Genome structures.....................................................................................................6
1.3. THE GENOME OF HSV-1
1.3.1. General properties......................................................................................................6
1.3.2. Genome structure....................................................................................................... 6
1.3.3. Genetic content............................................................................................................7
1.3.4. Genetic variability........................................................................................................ 8
1.3.5. Gene functions.............................................................................................................8
1.4. THE INFECTIOUS CYCLE OF HSV-1...............................................................9
1.5. HSV-1 MUTANTS.............................................................................................11
1.5.1. Plaque morphology...................................................................................................... 11
1.5.2. Temperature sensitivity.............................................................................................. 12
1.5.3. Host range..................................................................................................................... 13
1.5.4. Immune cytolysis..........................................................................................................13
1.5.5. Drug resistance............................................................................................................ 13
1.5.6. Selectable markers...................................................................................................... 14
1.5.7. Detectable markers..................................................................................................... 14
1.5.8. Tn5 transposon............................................................................................................15
1.5.9. Cre-/ox system ............................................................................................................. 15
1.5.10. Cosmids..........................................................................................................................15
1.6. CONTROL PROCESSES
1.61. Temporal regulation of gene expression................................................................ 17
1.6.2. Vmw65 (VP16)............................................................................................................17
1.6.3. Immediate early genes.................................................................................................18
Vm w175..................................................................................................19
Vm w110..................................................................................................19
Vmw63....................................................................................................20
Vmw68....................................................................................................21
Vmw12....................................................................................................21
1.6.4. Early g e n e s ...................................................................................................................22
1.6.5. Late g e n e s .................................................................................................................... 22
1.6.6. Other aspects of control
Viral proteins......................................................................................... 23
Host proteins......................................................................................... 24
C on ten ts
1.7. DNA METABOLISM
1.7.1. Nucleotide metabolism and DNA repair.....................................................................25
1.7.2. DNA replication..............................................................................................................26
1.7.3. Origins of DNA replication.......................................................................................... 27
1.7.4. Gene requirements for DNA replication.................................................................. 27
1.7.5. Cleavage and packaging of replicated DNA........................................................... 28
1.8. VIRION STRUCTURE
1.8.1. Core................................................................................................................................. 29
1.8.2. Capsid.............................................................................................................................29
1.8.3. Tegument........................................................................................................................ 30
1.8.4. Envelope..........................................................................................................................32
1.8.5. Virus assem bly.............................................................................................................33
1.9. HSV-1 PATHOGENESIS
1.9.1. Animal models...............................................................................................................33
1.9.2. Viral determinants........................................................................................................34
1.9.2.1. Glycoproteins................................................................................................................ 35
1.9.2.2. Proteins involved in DNA replication......................................................................... 35
1.9.2.3. Others.............................................................................................................................35
UL56.........................................................................................................35
US1........................................................................................................... 36
RL2........................................................................................................... 36
UL48.........................................................................................................36
UL41.........................................................................................................36
UL46 or UL47..........................................................................................36
US3........................................................................................................... 36
RL1 (ICP34.5)..........................................................................................37
1.10. HSV-1 LATENCY..........................................................................................................38
1.10.1. Animal models...............................................................................................................38
1.10.2. Sites of latency.............................................................................................................39
1.10.3. State of the latent genom e......................................................................................... 39
1.10.4. Establishment and maintenance of latency.............................................................40
1.10.5. Gene expression during latency...............................................................................41
1.10.6. Function of the LATs....................................................................................................42
1.10.7. Reactivation of latent infection.................................................................................. 42
1.10.8. In vivo models............................................................................................................... .43
1.11. AIMS OF THE THESIS................................................................................................ 44
1.11.1 Background....................................................................................................................44
G enes...................................................................................................... 44
Cosmids................................................................................................... 45
1.11.2 A im s................................................................................................................................ 46
Chapter 2 - Materials
2.1. Cells and viruses..........................................................................................................47
2.2. Cell culture growth media............................................................................................ 47
2.3. Bacterial strains...........................................................................................................49
2.4. Bacterial growth m edia.............................................................................................. 50
2.5. Radiochemicals............................................................................................................ 50
2.6. Enzymes.........................................................................................................................51
2.7. Chemicals...................................................................................................................... 51
2.8. Plasmids.........................................................................................................................51
2.9. Protein blotting for mass spectrometric analysis...................................................52
52
53
53
54
55
55
55
56
57
58
60
60
60
62
62
62
62
63
63
63
63
64
64
64
64
65
65
66
66
66
67
67
67
68
68
68
68
.69
,69
.69
.70
.70
.70
.71
.71
Protein gels
(i) Single concentration (acrylamide/bisacrylamide)
(ii) Single concentration (acrylamide/DATD).............
(iii) Gradient (acrylamide/bisacrylamide)..................
BHK C13 transfections.......................................................................
Agarose gel electrophoresis.............................................................
Small scale DNA preparation.............................................................
Southern blotting.................................................................................
Western blotting...................................................................................
DNA sequencing.................................................................................
Other buffers.......................................................................................
Immune precipitation............................................................................
HSV-1 DNA preparation.....................................................................
Miscellaneous.......................................................................................
3 - Methods
Cell culture............................................................................................
Virus stocks........................................................................................
Titration of virus stocks.....................................................................
Picking plaques....................................................................................
Particle counts.....................................................................................
Virus absorption
(a) 4°C............................................................................
(b) 37°C..........................................................................
Virus penetration................................................................................
One-step growth curve....................................................................
Multi-step growth curve....................................................................
Radiolabelling of virus particles.......................................................
Radiolabelling infected cells
(a) Long term labelling................................................
(b) Pulse labelling..........................................................
Binding of virus to cells.....................................................................
Infected cell DNA.................................................................................
Southern Blotting
(a) Labelling of probe..................................................
(b) Transfer of DNA....................................................
(c) Hybridisation...........................................................
Blotting by centrifugation and rapid hybridisation.......................
Polyacrylamide gel electrophoresis
Single concentration gels
(a) Acrylamide/bisacrylamide....................................
(b) Acrylamide/DADT...................................................
Gradient g e l....................................................................
Staining gels with Coomassie brilliant blue....................................
Preparation of virions and L-particles............................................
Fractionation of virions and L-particles.........................................
Blotting polyacrylamide gels for mass spectrometric analysis.
Mass spectrometric analysis of virion proteins..........................
Transformation of bacterial cells with plasmid or cosmid DNA
(a) Heat shock of E. coli DH5a cells.......................
(b) DMSO shock of E. coli XL-1 cells......................
(c) Electroporation.......................................................
Small scale preparation of DNA
(a) Alkaline lysis..........................................................
(b) STET lysis..............................................................
C on ten ts
3.24. Producing glycerol stocks of cosmids or plasmids..............................................71
3.25. Restriction endonuclease digestion........................................................................72
3.26. Partial digestion of cosmids in the presence of ethidium bromide.................... 72
3.27. Production of blunt ends and ligation of cosmid or plasmid DNA..................... 72
3.28. Agarose gel electrophoresis.................................................................................... 72
3.29. Purification of restriction fragments from agarose gels
(a) Electroelution..................................................................................73
(b) Sephaglas...................................................................................... 73
(c) Spin-X tu b es................................................................................. 73
3.30. Transfection of BHK C13 cells
Regenerating virus............................................................................... 74
(i) Calcium phosphate precipitation and DMSO shock.................74
(ii) Lipofection....................................................................................... 74
Constructing complementing cell lines.............................................. 74
3.31. Determination of differences in plaque area......................................................... 75
3.32. Effect of interferon......................................................................................................75
3.33. HSV-1 DNA preparation.............................................................................................75
3.34. In vitro transcription and translation........................................................................76
3.35. Immune precipitation....................................................................................................76
3.36. Western blotting.......................................................................................................... 77
3.37. Analysis of viral growth in vivo ...............................................................................77
(a) Neurovirulence...............................................................................77
(b) Latency........................................................................................... 78
3.38. DNA sequencing......................................................................................................... 78
(a) DNA preparation and ligation..................................................... 78
(b) Transformation of E. coli............................................................ 79
(c) Preparation of DNA templates....................................................79
(d) DNA sequencing reactions.........................................................79
(e) Gel electrophoresis...................................................................... 80
Chapter 4 - Results
4.1. COSMIDS CONTAINING MUTATIONS IN UL14, UL15 AND UL17
4.1.1. Status of oriL in the cosmid s e t ................................................................................ 81
4.1.2. Regeneration of wt virus............................................................................................82
4.1.3. Construction of mutant cosmids............................................................................... 82
4.1.4. Candidate complementing cell lines......................................................................... 83
a. Cos24 cell line....................................................................................83
b. 8A cell line..........................................................................................83
c. p14, p15 and p17 cell lines............................................................. 84
4.1.5. Generation of viruses................................................................................................ 84
a. Cos24 cell line....................................................................................84
b. 8Acell line..........................................................................................84
c. p14, p15 and p17 cell lines............................................................. 85
4.1.6. Generation of virus from the mutant UL7 cosmid set....................................85
4.1.7. Mass spectrometric analysis and identification of proteins...............................85
4.1.8. Assessm ent of an antibody potentially identifying the UL17 protein.............. 86
4.2. CHARACTERISATION OF UL16’ MUTANT VIRUSES
4.2.1. UL16 'MUTANTS..............................................................................................88
4.2.1.1. Production of mutants.................................................................................................88
4.2.1.2. Mutant genotypes.........................................................................................................88
C on ten ts
4.2.2. IN VITRO ANALYSIS OF UL16' MUTANTS.................................................... 90
4.2.2.1. Plaque area.................................................................................................................. 90
4.2.2.2. Growth characteristics..............................................................................................92
4.2.2.3. Growth on different cell lines................................................................................... 93
4.2.2.4. Particle:pfu ratio.......................................................................................................... 94
4.2.2.5. EM analysis.................................................................................................................. 94
4.2.2.6. Temperature sensitivity............................................................................................. 95
4.2.2.7. Efficiency of adsorption and penetration.............................................................. 95
4.2.2.8. Binding of virus to cells..............................................................................................96
4.2.2.9. Effect of interferon treatment on virus yield........................................................ 96
4.2.3. IDENTIFICATION OF THE UL16 PROTEIN...........................................................98
4.2.3.1. Western blotting and Immune precipitation.......................................................... 98
4.2.3.2. Pulse labelled infected cells....................................................................................98
4.2.3.3. In vitro transciption and translation....................................................................... 99
4.2.3.4. Mass spectrometric analysis..................................................................................100
4.2.4. IN VIVO ANALYSIS OF UL16’ MUTANTS..........................................................101
4.2.4.1. Neurovirulence........................................................................................................... 101
4.2.4.2. Latency........................................................................................................................103
Chapter 5 - Discussion
5.1. Background................................................................................................................. 106
5.2. Cosmid-based mutagenesis of UL14, UL15 and UL17.......................................107
5.3. Identification of proteins............................................................................................109
5.4. In vitro characterisation of UL16' virus................................................................. 110
5.5. In vivo characterisation of UL16' virus.................................................................. 112
5.5.1. Neurovirulence............................................................................................................112
5.5.2. Latency........................................................................................................................ 113
5.6. Analysis of mutants using animal m odels............................................................ 114
References 116
A b b re v ia tio n s
Abbreviations
A adenine
ACV acyclovir
AIDS acquired immune deficiency syndrome
APS ammonium persulphate
ATP adenosine triphosphate
Ara A arabinoside A
BPB bromophenol blue
bp base pairs
BSA bovine serum albumin
BUdR 5-bromodeoxyuridine
C cytosine
cAMP cyclic adenosine monophosphate
CAV cell-associated virus
cDNA complementary DNA
Ci Curie
CIP calf intestinal phosphatase
cpe cytopathic effect
cpm counts per minute
cos cosmid
CRV cell-released virus
Da daltons
° degrees Celsius
DATD N.N’-diallyltartardiamide
dATP 2'-deoxyadenosine-5'-triphosphate
dCTP 2'-deoxycytidine-5'-triphosphate
dGTP 2'-deoxyguanosine-5'-triphosphate
dTTP 2'-deoxythymidine-5'-triphosphate
ddATP 2f3'-dideoxyadenosine-triphosphate
ddCTP 2'3'-dideoxycytidine-triphosphate
ddGTP 2'3'-dideoxyguanosine-triphosphate
ddTTP 2'3'-dideoxythymidine-triphosphate
DE delayed early
del deletion
DMSO dimethyl sulphoxide
DNA deoxyribonucleic acid
DNase deoxyribonuclease
dNTPs deoxynucleotide triphosphates
DR direct repeat
DRG dorsal root ganglion
DTT dithiothreitol
dUTPase deoxyuridine triphosphate nucleotidohydrolase
E early
E.coli Escherichia coli
EDTA ethylenediaminetetra-acetic acid
EM electron microscopy
EtBr ethidium bromide
EtOH ethanol
FCS foetal calf serum
FP foot pad
G guanine
i
A b b re v ia tio n s
g gram
gp glycoprotein
h hour
HCF host cell factor
HEPES N-2-hydroxyethyl piperazine-N'-2-ethane sulphonic acid
HRP horseradish peroxidase
hsp heat shock protein
IC intracranial
ICP infected cell polypeptide
IE immediate early
IFN interferon
IP intraperitoneal
Ig immunoglobulin
IPTG isopropyl-p-D-thiogalactoside
IRL internal long repeat
IRS internal short repeal
IU intraurethral
IV intravaginal
k kilo (i.e. 103)
kbp kilobase pair
L late
LL leaky late
L-particle light particle
1 litre
LAT latency-associated transcript
M molar
mg milligram
min minute
ml millilitre
mM millimolar
moi multiplicity of infection
Mr relative mobility
mRNA messenger RNA
fiCi microcurie
M-g microgram
p,M micromolar
NBCS new born calf serum
neo neomycin (G418)
NGF nerve growth factor
NPT non-permissive temperature
NP40 Nonidet P40
OBP origin-binding protein
Oct octamer-binding protein
OD optical density
ORF open reading frame
orii origin of replication in UL
oris origin of replication in Rs
PAGE polyacrylamide gel electrophoresis
PBS phosphate-buffered saline
PCR polymerase chain reaction
PEG polyethylene glycol
pfu plaque forming unit
Pi post-infection
A b b r e v ia t i o n s
PI pre-immume
PMSF phenylmethylsulphonylfluoride
poly (A) polyadenylic acid
PT permisive temperature
PVP polyvinylpyrrolidone
R purine base
R1 large subunit of ribonucleotide reductase
R2 small subunit of ribonucleotide reductase
RE restriction enzyme
RNA ribonucleic acid
RNase A ribonuclease A
rpm revolutions per minule
RR ribonucleotide-reductase
RT room temperature
SDS sodium dodecyl sulphate
snRNP small nuclear ribonucleoprotein particle
ssb single-stranded DNA binding protein
syn syncitial
T thymidine
TBF TATA box-binding factor
TCA trichloroacetic acid
TEMED N, N, N', N' -tetramethlyethylene diamine
TFA trifluoroacetic acid
TFIIB transcription factor IIB
TG trigeminal ganglion
TIF transinducing factor
Tris Tris (hydroxymethyl) aminomethane
TK thymidine kinase
TRl long terminal repeat
TRS short terminal repeat
ts temperature sensitive
Tween 20 polyoxyetheylene sorbitan monolaurate
U unique
uL long unique
Us short unique
UV ultraviolet
V volts
vhs virion host shutoff
Vmw molecular weight in kDa of HSV-induced polypeptides
vol volume
VP virion protein
v/v volume/volume
wt wild type
w/v weight/volume
wAv weight/weight
X-gal 5-bromo-4-chloro-3-indolyl-|3-D-galactopyranoside
A b b re v ia tio n s
Cell lines
BHKC13 baby hamster kidney cells clone 13
BSC-1 monkey epithelial cell line
CV1 monkey fibroblastoid cell line
HeLa human epithelial cell line
HFL cells human foetal lung cell line
MDCK canine epithelial cell line
MeWo human fibroblastoid cell line
Vero cells African green monkey kidney cell line
Herpesviruses
Virus name Common ICTV
abbreviation designation
Herpes simplex virus type 1 HSV-1 HHV-1
Herpes simplex virus type 2 HSV-2 HHV-2
Varicella-zoster virus VZV HHV-3
Epstein-Barr virus EBV HHV-4
Human cytomegalovirus HCMV HHV-5
Human herpesvirus 6 HHV-6 HHV-6
Human herpesvirus 7 HHV-7 HHV-7
Kaposi’s sarcoma-associated herpesvirus KSHV (HHV-8)
Equine herpesvirus 1 EHV-1 EHV-1
Equine herpesvirus 2 EHV-2 EHV-2
Herpesvirus saimiri HVS SHV-2
Channel catfish virus CCV IHV-1
Simian herpesvirus B virus CHV-1
Bovine herpesvirus 2 BHV-2 BHV-2
Pseudorabies virus PRV SHV-1
Cottontail rabbit herpesvirus LHV-1 LHV-1
Marek’s disease virus MDV GHV-2
Murine cytomegalovirus MCMV MHV-13
Herpesvirus ateles HVA AHV-2
Herpesvirus of turkey HVT MHV-1b
a bMu rid herpesvirus 1. Meleagrid herpesvirus 1.
A b b re v ia tio n s
One and three letter abbreviations for amino acid residues
Amino acid Three letter One letter
code code
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic acid Asp D
Cysteine Cys C
Glutamine Gin Q
Glutamic acid Glu E
Glycine Gly G
Histidine His H
Isoleucine lie 1
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine Val V
v
Figures and Tables
List of Figures and Tables
Page3
Fig. 1. HSV-1 virion structure .............................................................................................. ap1
Fig. 2. Types of herpesvirus genome structure...................................................................fp2
Fig. 3. Phylogenetic tree........................................................................................................ap3
Fig. 4. Human herpesvirus genome structures.................................................................ap6
Fig. 5. Arrangement of genes in the HSV-1 genome...........................................ap7
Fig. 6. Representation of the replicative cycle of HSV-1............................................... ap9
Fig. 7. Vmw65 transactivator complex fromation.................................................ap17
Fig. 8. Differences between IE, E and L promoters......................................................... ap22
Fig. 9. Functions involved at the DNA replication fork................................................... ap27
Fig. 10. Organisation of UL26 and UL26.5 and derivation of VP21,
VP22a and VP24........................................................................................................fp30
Fig. 11. Models of viral tegumentation, envelopment and egress................................... fp33
Fig. 12. Transcripts expressed during latency.................................................................... ap41
Fig. 13. Location of cosmid inserts with respect to the HSV-1 genome........................ap81
Fig. 14. Status of or/L in cos46............................................................................................. ap81
Fig. 15. Status of oriL in wt and reconstructed viruses.............................................fp82
Fig. 16. Kpn\ restriction profiles of parental cosmids........................................................ap82
Fig. 17. Kpn\ (Asp718) and SnaBI sites in cos24...............................................................ap82
Fig. 18. Identification of mutant cosmids by RE analysis................................................. ap82
Fig. 19. The structure of plasmid p8A, containing UL14-UL18........................................ fp83
Fig. 20. The structures of p14 and p17................................................................................ap84
Fig. 21. The structure of p15.................................................................................................ap84
Fig. 22. Genotype of virus generated from the UL14' cosmid set.....................................ap84
Fig. 23. Genotype of virus generated from one p8A cell line...........................................ap84
Fig. 24. Genotype of virus generated form the UL7' cosmid set..................................... fp85
Fig. 25. Identification of proteins using mass spectrometric analysis............................ fp86
Fig. 26. Mass spectrometric analysis of proteins a and b which comigrate with UL47ap86
Fig. 27. Mass spectrometric analysis of protein c...............................................................ap86
Fig. 28. Positions of insertion mutations in UL16............................................................... 85
Fig. 29. Genotypes of UL16' mutants 1a and 1b................................................................ ap89
Fig. 30. Genotype of UL16' mutants 1c, 1 d, 2a and 3 a ......................................................ap89
Fig. 31. Confirmation of the lesion in mutant 2a by sequencing..................................... ap89
Fig. 32. Differences in plaque size....................................................................................... ap91
Fig. 33. Status of recovered viruses after co-transfection of UL16‘ 1a DNA and a
plasmid containing wt UL16.................................................................................... fp92
Fig. 34. High and low multiplicity growth curves of wt and mutant viruses................... ap93
vi
Figures and Tables
Fig. 35. Low multiplicity growth curve of wt and mutant viruses................................... ap93
Fig. 36. Virus adsorption........................................................................................................ ap96
Fig. 37. Virus penetration......................................................................................................ap96
Fig. 38. Binding of virus to cells...........................................................................................ap96
Fig. 39. Western blot of wt and UL16' virions and virus infected......................................ap98
Fig. 40. Candidate UL16 protein in wt, cosw/1, mutant 1a and 1b infected cells
(labelled with [35S]-methionine)..............................................................................ap98
Fig. 41. In vitro transcription and translation of plasmids containing UL16
(labelled with [35S]-methionine)..............................................................................ap99
Fig. 42. In vitro transcription and translation of plasmids containing UL16
(labelled with [35S]-cystine)......................................................................................ap99
Fig. 43. Confirmation of the in vitro transcription and translation product of
plasmid p1 by truncation of the gene................................................................... ap99
Fig. 44. Virus recovered from the brains of mice infected with mutant 1b..................ap103
Fig. 45. Confirmation of a novel C/a I site in mutant 1b................................................... ap103
Fig. 46. Reactivation of viruses from latency.....................................................................fp104
Fig. 47 Genotypes of reactivated viruses from ganglia of mice infected with
UL16' 1a or 1b........................................................................................................... ap104
Fig. 48. Reactivation of viruses from latency.....................................................................ap104
Fig. 49. Genotype of virus reactivated from ganglia of mice infected with
UL16' mutants.............................................................................................................ap105
Fig. 50. Genotype of reactivated virus from the ganglia of mice infected with
UL16'1a mutant......................................................................................................... ap105
Fig. 51. Alignment of the amino acid sequence of the HSV-1 UL16 protein and its
counterparts in the three herpesvirus subfamilies................................................ap107
Table 1. Herpesvirus genome structures.......................................................................... fp2
Table 2. Genetic content of the fully sequenced herpesviruses.................................ap2
Table 3. Mis-classified herpesviruses................................................................................ fp3
Table 4. Human herpesviruses...........................................................................................fp4
Table 5. Features of HSV-1 genes................................................................................... ap8
Table 6. Immediate early genes involved in control processes....................................fp18
Table 7. HSV-1 DNA replication genes..........................................................................ap27
Table 8. Capsid components...........................................................................................ap29
Table 9. Properties of HSV-1 glycoproteins...................................................................ap32
Table 10A. Glycoprotein genes involved in pathogenesis.............................................. ap34
Table 10B. DNA replication genes involved in pathogenesis...........................................ap34
Table 10C. Other gene involved in pathogenesis.............................................................ap34
Table 11. Animal models of latency................................................................................ ap38
Table 12. In vitro models of latency..................................................................................ap43
Figures and Tables
Table 13. UL16 ' mutants......................................................................................................... 89
Table 14. Relative plaque areas........................................................................................... 90
Table 15. Relative plaque areas on BHK C13 cells..........................................................91
Table 16. Relative plaque areas on BHK cells...................................................................92
Table 17. Growth on different cell lines.............................................................................. 93
Table 18. Particle:pfu ratio.................................................................................................... 94
Table 19. Viral yields at three different temperatures on BHK C13 cells........................95
Table 20. Virus yields from cells pretreated with interferon.............................................96
Table 21. Fate of IC injected mice - experiment 1 ........................................................... 101
Table 22. Fate of IC injected mice - experiment 2 ........................................................... 102
Table 23. Summary of LD5o values from two experiments................................................ 103
Table 24. Fate of FP injected mice......................................................................................104
a ap=after the page number shown; fp=facing the page number shown
Chapter 1
Introduction
Chapter 1: Introduction
1.1. THE FAMILY HERPESVIRIDAE
1.1.1. General properties
The Herpesviridae is a large family of eukaryotic viruses. To date over 100 have been 
identified, infecting vertebrate hosts ranging from fish to man (Roizman and Sears, 
1993) and probably at least one invertebrate host, the oyster (Comps and Cochennec, 
1993). The viruses exhibit a high degree of host specificity and a wide range of 
pathological properties. A single host species can be host to several herpesviruses - for 
example, there are eight herpesviruses associated with humans. Most herpesviruses 
have been discovered in husbanded animals where large groups live in close contact.
Herpesviruses are defined by the structural features of their virions. A large linear 
double-stranded DNA molecule is located within an icosahedral capsid approximately 
100-110 nm in diameter. The capsid is embedded in an amorphous proteinaceous 
matrix (the tegument), which is in turn surrounded by a lipid envelope containing viral 
glycoproteins (Fig. 1). During productive infection, viral DNA is transcribed, 
replicated and packaged into capsids in the nucleus. The capsids then acquire tegument 
and envelope prior to leaving the infected cell. In addition, all herpesviruses examined 
to date have the ability to establish latent infections in their natural host, and 
subsequent reactivation of virus can occur to cause a second round or even recurrent 
rounds of recrudescent disease.
1.1.2. Biological properties
The herpesviruses are versatile and well adapted pathogens, causing diseases whose 
pathology may range from inapparent to life-threatening.
It is common for primary or recrudescent infections to be inapparent or slight in the 
natural setting. Under certain conditions, however, particularly those resulting in a 
degree of immune suppression, herpesviruses can cause serious or even fatal disease. 
For example, 25% of mortality in bone marrow recipients results from interstitial 
pneumonitis caused by HCMV infection (White and Fenner, 1986).
Several herpesviruses have been implicated in various types of cancer. For example, 
MDV causes a T-cell lymphoma in chickens (Fenner et al., 1987), and EBV is 
implicated in Burkitt’s lymphoma and nasopharyngeal carcinoma in humans (Epstein et 
al., 1964; Evens and Niederman, 1991).
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Capsid
Tegument
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Glycoprotein spikes
Fig. 1. HSV-1 virion structure
Electron cryomicrograph of an HSV-1 virion. Three distinct substructures can be seen; the capsid 
(including the core), the surrouning tegument and the outer lipid envelope which contains glycoprotein 
spikes (magnification is approximately 230,000). Original photograph provided by F.J. Rixon.
IR IR T RT R
Fig. 2. Types of herpesvirus genome structure
The six types of herpesvirus genome structu re are shown (See Tab le 1 for description and examples). The 
genomes are notdraw n to scale. Unique and repeatreg ions are shown as horizontal lines and rectangles, 
respectively. The orientations o f repeats are shown by arrows. The nomenclature used to designate regions of 
the HSV-1 genome is shown at the foot o f the figure. Reproduced from Davison and Clements, 1996.
Table 1. Herpesvirus genome structures
Class Description Isomers Example
1 Single direct repeat at termini. 1 CCV; HH V-6; M C M V
2 M ultiple direct repeats o f  a short sequence at the termini 
in variable copy number.
1 HVS
3 A s 2, w ith a variable number o f  the terminal repeats in 
inverse orientation internally.
4 LHV-1
4 A s 2, w ith m ultiple direct repeats o f  a different sequence 
in variable copy number internally.
1 EBV
5 Unique regions U s and U L flanked by inverted repeats 
TR l/IR l and TRS/IR S.
2 major, 2 
minor or 
2 only
PRV;VZV; EHV-1
6 Unique regions U s and U L flanked by inverted repeats 
T R l /IR l  and TR S/IR S. Short sequence (a  sequence) 
repeated directly at the termini and indirectly at rthe 
junction between IR, and IRS.
4
equimolar
H SV -1; H SV -2; 
HCM V
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Although herpesviruses normally infect a single species, some can cause more severe 
disease in non-natural hosts. For example, B virus, which is related to HSV-1, infects 
monkeys and has similar pathological effects to HSV-1 infection in humans, but causes 
fatal ascending paralysis and encephalitis in humans (Fenner et al, 1987). Also, PRV, 
a herpesvirus of swine, can infect cattle, sheep, goats, dogs and cats. Infection of cattle 
results in “mad itch”, and death can occur a few hours after symptoms appear. PRV- 
infected dogs show many classic symptoms of rabies, and infection is invariably fatal 
(Fenner et al., 1987).
1.1.3. Genome features
Herpesviruses genomes range in size from 125-250 kbp and contain 70 to 200 genes 
(Roizman and Sears, 1990, 1993). All genomes investigated in sufficient detail contain 
direct or inverted repeat sequences located internally or at the genome termini. The six 
main types of genome structures, differing in the size and relative arrangement of 
repeated and unique sequences, are shown in Fig. 2 and Table 1.
Herpesvirus genomes range in base composition from 31-75% G+C (Roizman and 
Batterson, 1985; McGeoch, 1989; Roizman and Sears, 1993) and G+C residues may be 
distributed non-uniformly throughout the genome: for example, the terminal repeats in 
HVS have a much higher G+C content than the unique region. Table 2 summarises the 
features of the ten herpesvirus genomes whose complete sequences have been 
published.
1.1.4. Classification and evolution
Classification of herpesviruses into three subfamilies, the Alpha-, Beta and Gamma- 
herpesvirinae, by the International Committee on Taxonomy of Viruses (ICTV) is 
based on biological criteria (Roizman et al., 1981). The subfamilies have been divided 
further on the basis of additional biological and genetic data (Roizman et al., 1992). 
Members of the Alphaherpesvirinae are characterised by a short replicative cycle, 
which results in the rapid spread of infection in cell culture and the mass destruction of 
susceptible cells. They tend to have a wide host range in cell culture, and most form 
latent infections in sensory ganglia. They are subdivided into the Simplexvirus and 
Varicellovirus genera, the former including HSV-1, HSV-2 and BHV-2, and the latter 
VZV, EHV-1 and PRV. The Betaherpesvirinae have a long replicative cycle, a narrow 
host range in cell culture, and can establish latent infections in secretory glands, 
lymphoreticular cells and kidney cells. Infection results in the production of 
characteristically enlarged infected cells (cytomegalia). They are divided into three 
genera: Cytomegalovirus, Muromegalovirus and Roseolovirus, exemplified by HCMV,
2
Table 2. Genetic content of the fully sequenced herpesviruses
Virus ICTV
d esign ation
S ubfam ily Genus Genetic
group
G enom e
structure
Size
(kbp)
G+C
%
References
HSV-1 HHV-1 A lph ah erpesvirin ae Simplexvirus «, 6 152 6 7 M cGeoch et a l ,  
1988.
v z v HHV-3 A lph ah erpesvirin ae Varicellovirus 5 125 4 6 Davison and Scott, 
1986.
EHV-1 EHV-1 A lph ah erpesvirin ae Varicellovirus ®2 5 150 57 Telford et al., 1992
HCMV HHV-5 Betaherpesvirinae Cytomegalovirus P. 6 230* 5 7 Chee et al., 1990.
HHV-6 HHV-6 Betaherpesvirinae R oseolovirus P2 1 160 4 3 Gompels et al., 
1995.
EBV HHV-4 G am m aherpesvirinae Lymphocryptovirus Y, 4 172” 6 0 Baer el al., 1984.
HVS SHV-2 G am m aherpesvirinae Rhadinovirus y2 2 155“ 4 6 Albrecht et al., 
1992.
EHV-2 EHV-2 G am m aherpesvirinae Rhadinovirus y2 1 184 57 Telford et a l ,  1995.
CCV IHV-1 None N one None 1 134 5 6 D avison, 1992
1 Laboratory isolate, clin ical isolates are 13 kbp larger (Quinnan et al., 1983; Kemble et cil., 1996). 
h Repeat elem ents are present in variable number. Deletion o f  12 kbp relative to other E B V  strains 
(Parker et al. , 1990).
Repeat elem ents are present in variable number.
Table 3. Mis-classified viruses
V irus B io log ica l
c la ssifica tio n
G enetic
classification
Reference
HHV-6 Gammaherpesvirinae Betaherpesvirinae Lawrence et al., 1990
MDV Gammaherpesvirinae A Iphaherpesvirinae Buckmaster et a l, 1988
HVT Gammaherpesvirinae Alphaherpesvirinae Buckmaster et a l, 1988
EHV-2 Betaherpesvirinae Gammaherpesvirin ae Telford et a l, 1993
CCV A Iphaherpesvirinae None Davison, 1992
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MCMV and HHV-6, respectively. The Gammaherpesvirinae exhibit a restricted host 
range and the duration of the reproductive cycle is variable. Latent infection often 
occurs in lymphoid tissue. The Lymphocryptovirus genus includes EBV which shows 
specificity for B-lymphocytes, and the Rhadinovirus genus includes HVA and HVS, 
which are restricted to New World primates and grow in T-lymphocytes.
For practical purposes, the use of biological criteria in herpesvirus classification has 
been superseded by genetic data derived from sequence analysis. This involves 
consideration of similarities between encoded proteins and the gene order, and has been 
facilitated by the availability of complete DNA sequences for several herpesviruses 
(see Table 2) and substantial incomplete sequence information for many other 
herpesviruses. Genetic data largely support the biological classification scheme, and 
relatively few viruses have been wrongly classified. There are five instances where a 
virus which has similar biological properties to members of one subfamily is most 
closely related genetically to another subfamily (Table 3). Three of these five viruses 
were initially classified as members of the Gammaherpesvirinae because they are 
lymphotropic.
Genetic data provide an insight into viral evolution. Herpesviruses are highly 
divergent, and it is clear that evolution of the herpesviruses has proceeded through 
mutational and recombination al processes. The latter category involves large scale 
genomic rearrangements, gene duplications, generation of repeated sequence elements 
and changes in the extent and copy number of these elements. Gene deletion and 
importation of non-herpesvirus genes also appears to have occurred (McGeoch, 1989; 
McGeoch and Cook, 1994).
A common evolutionary origin for the herpesviruses is strongly supported by the 
observation that the three subfamilies contain a subset of about 40 “core” genes that are 
conserved by criteria of similarities in encoded amino acid sequences or genomic 
position (McGeoch, 1989; Davison, 1993). McGeoch and Cook (1994) and McGeoch 
et al. (1995) presented data consistent with the idea that herpesviruses have evolved 
with their hosts, and have proposed an evolutionary timescale (Fig. 3). CCV, however, 
lacks specific sequence similarities to mammalian and avian herpesviruses, but recent 
data on capsid structure (Booy et al., 1996) and virion protein composition (Davison 
and Davison, 1995) support the view that mammalian, avian and fish herpesviruses 
share a common evolutionary source.
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Fig. 3. Phylogenetic tree
A phylogenetic tree for the herpesviruses derived from sequence comparisons, with a time scale 
(millions of years before present) based on the hypothesis that the viruses have cospeciated with their 
hosts. Broken lines indicate regions of lower confidence. Reproduced from McGeoch et al. (1995).
Table 4. Human herpesviruses
V i ru s ICTV
D e s i g n a t i o n
S u b f a m i l y Ge nus G e n e t i c
g r o u p
G e n o m e
t y p e
S i z e
( k b p )
G+C %
HSV-1 HHV-1 Alphaherpesvirinae Sim plexvirus a , 6 152259 67
HSV-2 HHV-2 Alphaherpesvirinae Sim plexvirus a , 6 -  154000 69
VZV HHV-3 Alphaherpesvirinae Varicellovirus O; 5 124884 46
EBV HHV-4 Gammaherpesvirinae Lym phocryptovirus Yi 4 172282“ 60
HCMV HHV-5 Betaherpesvirinae C ytom egalovirus P, 6 2 2 9 3 5 4 b 57
HHV-6 HHV-6 Betaherpesvirinae Roseolovirus P: 1 159321 43
HHV-7 HHV-7 Betaherpesvirinae R oseolovirus ft 1 144861 40
KSHV HHV-8 Gammaherpesvirinae Not yet designated y2 Not known Not known Not
known
Repeat e lem en ts are present in variable numbers. The sequenced strain has a deletion o f  12 kbp relative to other 
strains (Parker e t  al . ,  1990). 
b Laboratory iso late: C lin ical iso la tes are 13 kbp larger ( Quinnan e t  al . ,  1983; Kem ble et al.,  1996).
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1.2. HUMAN HERPESVIRUSES
1.2.1. Biological properties
Features of the eight different herpesviruses that have been recognised in humans are 
summarised in Table 4.
Primary infection with HSV-1 is usually asymptomatic, and infection is virtually 
universal in human populations. In rare circumstances, however, severe primary 
symptoms can occur, including conjunctivitis, keratitis and acute necrotizing 
encephalitis. A lifelong latent infection is established in neurons of the sensory ganglia 
and reactivation can be periodically induced following a number of stimuli including 
stress, exposure to UV light and immune suppression (Hill et al., 1978), giving rise to 
oro-facial lesions. HSV-2 is transmitted sexually, and causes genital lesions on 
reactivation, but the clinical pathologies associated with HSV-1 and HSV-2 are not 
strictly separated (Nahmias et a l, 1991). HSV-2 reactivation usually occurs more 
frequently than that of HSV-1 (Timbury, 1991; Whitley, 1990).
VZV produces two different diseases: varicella (chickenpox) upon primary infection 
and zoster (shingles) after reactivation (Gelb, 1990). Chickenpox is a generally benign 
disease characterised by fever and a vesicular rash, and is seasonally distributed, the 
highest incidence occurring in late winter and early spring. The virus is transmitted by 
inhalation of infectious respiratory secretions. Complications are rare, but the disease 
may be more severe in adults, where pneumonia is common. Latency is normally 
established in the dorsal root or cranial nerve ganglia, and reactivation, which usually 
occurs many years after primary infection, results in painful vesicles in the area of skin 
innervated by the affected ganglion. The incidence of reactivation increases with age 
(Timbury, 1991).
HCMV infection is normally symptomless, but infection of the foetus via the mother 
can cause deafness and mental retardation. HCMV is one of the commonest 
opportunistic infections of immunocompromised individuals, and is the major viral 
complication in bone marrow and organ transplantation, where the virus can be 
acquired from the donor organ and result in retinitis and pneumonia (Timbury, 1991). 
The virus is thought to be spread by salivary contact but may be transmitted sexually 
(Emery and Griffith, 1990). Unlike latent infections established by HSV-1 and VZV, 
those of HCMV are more like chronic infections because virus can be readily recovered 
from saliva, urine, semen or cervical secretions for long periods of time. The 
intermittent nature of virus shedding and fluctuations in antibody levels suggest that
4
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asymptomatic reactivation occurs throughout life. HCMV establishes latency in 
lymphocytes or polymorphonuclear leukocytes (Ho, 1991).
EBV was initially detected in lymphoblasts from Burkitt’s lymphoma (Epstein, 1964), 
a highly malignant B-cell lymphoma common in African children which shows a 
striking geographical distribution and is virtually confined to areas where there is 
endemic malaria. EBV was later found to be the causative agent of infectious 
mononucleosis (glandular fever), particularly in young adults, and in the 
immunocompromised individual EBV can result in severe lymphoproliferative disease 
where organs are infiltrated by immature B lymphocytes. EBV has also been 
associated with nasopharyngeal carcinoma, since viral DNA has been isolated from 
malignant epithelial cells of the tumour. This tumour also shows a marked 
geographical and racial distribution and it is particularly common among southern 
Chinese people. The selective distribution of these tumours suggests the influence of 
genetic and environmental factors as well as EBV infection in the progression towards 
disease (Miller, 1990; Timbury, 1991).
HHV-6 was initially isolated from the peripheral blood leukocytes of AIDS patients 
and patients with lymphoproliferative disorders (Salahuddin et a l, 1986). It grows in B 
and T cells in vitro. Infection is widespread and there is a high incidence of antibody in 
the normal population. Infection is thought to occur early in life via saliva (Harnett et 
al., 1990). The virus is the causative agent of exanthema subitum (roseola infantum), 
which is characterised by fever and a mild facial rash in young children (Yamanishi et 
al., 1988). The virus is genetically related to HCMV (Lawrence et al., 1990) and 
consists of two closely related genotypes, HHV-6 A and B, of which only the latter has 
been associated with roseola (Dewhurst et al., 1993).
HHV-7 was isolated from CD4+ T cells of healthy individuals by Frenkel et al. (1990). 
Infection is widespread and is acquired early in childhood. HHV-7 is related to HHV-6 
(Bememan et al., 1992), and is also associated with roseola (Portolani et a l, 1995).
KSHV (HHV-8) was identified by Chang et al. (1994) as a new herpesvirus associated 
with Kaposi’s sarcoma. The DNA from this virus has also been recovered from rare 
body cavity-based lymphomas (Cesarman et al, 1995).
5
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1.2.2. Genome structures
The genome structures of the human herpesviruses are shown in Fig. 4. They represent 
four of the six types of genome structure previously described in Section 1.1.3. The 
structure of the KSHV genome is unknown.
 ^ -------------
1.3. THE GENOME OF HSV-1
1.3.1. General properties
The genome of HSV-1 strain 17 is composed of a linear molecule of double-stranded 
DNA containing 152,260 bp (McGeoch et al., 1985; 1986; 1988). The DNA is not 
methylated (Low et al, 1969) and has an average base pair composition of 68.3% G+C, 
although the G+C content is not uniform throughout the genome, being higher in the 
repeat regions. There is a single unpaired base at each 3’ terminus (Mocarski and 
Roizman, 1982), and there is no protein covalently linked to the termini.
1.3.2. Genome structure
The HSV-1 genome consists of two covalently linked components, L and S (Sheldrick 
and Berthelot, 1974; Delius and Clements, 1976; Roizman, 1979). The L and S 
components consist largely of unique sequences, U l (107.9 kbp) and Us (13 kbp), each 
flanked by inverted repeats, R l (9 kbp) and Rs (6.5 kbp) (McGeoch et a l, 1988). The 
sequences of R l  and Rs are unrelated with the exception of a direct repeat (the a 
sequence) of approximately 400 bp located at the termini (see Fig. 4). One copy of the 
a sequence is present at the S terminus and although one copy is usually present at the 
L terminus, some molecules contain more. The a sequence is also present at the L-S 
joint, usually as a single copy but sometimes as more (Wagner and Summers, 1978). 
Recombination between the repeat sequences results in inversion of U l and Us 
(Sheldrick and Berthelot, 1974), and DNA extracted from virions consists of four 
equimolar populations differing with respect to the relative orientations of the two 
components (Hayward et a l, 1975). Inversion is aided by the presence of the a 
sequences (Davison and Wilkie, 1983; Poffenberger etal., 1983).
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F ig. 4. Human herpesvirus genom e structures
Sizes and structures of the human herpesvirus genomes are shown to scale. Unique and repeat 
regions are shown as horizontal lines and rectangles, respectively. The orientations of repeats are 
shown by arrows. The nomenclature used to designate regions of the HSV-1 genome is shown at the 
top of the figure. Reproduced from Davison (1993).
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1.3.3. Genetic content
Seventy-one genes were predicted to be present in the HSV-1 genome by McGeoch et 
al. (1985, 1986,1988). Their arrangement is shown in Fig. 5. This was acknowledged 
to be a conservative estimate since genes which are highly spliced, completely or 
almost completely contained within another gene or very small might have escaped 
identification. Indeed, an additional four genes have been identified: UL26.5, UL49A 
(or UL49.5), US8.5 and RL1. UL26.5 is contained completely within the UL26 ORF 
(Liu and Roizman, 1991a,b), and encodes a protein which corresponds to the C- 
terminal region of the UL26 protein. UL49A encodes a predicted protein translation 
product of only 91 residues (Barker and Roizman, 1992; Barnett etal., 1992). US8.5 is 
also a small gene which partially overlaps US8 and US9 (Georgopoulou et al., 1993; 
1995). Despite a large number of sequence errors, Chou and Roizman (1990) proposed 
a gene (0^34.5, encoding ICP34.5) in RL in HSV-1 strain F. The corresponding gene in 
HSV-1 strain 17, RL1, was later identified after correction of two errors in the 
published sequence (McGeoch and Barnett, 1991).
Thus, the genome is proposed at present to contain 58 genes in UL, 13 in Us, two in R l 
and one in Rs; a total of 74 distinct genes. This number may rise further, as a number 
of novel proteins have been identified. Martinez et al. (1996a,b) proposed a second 
protein encoded within UL12 (UL12.5), which corresponds to the C-terminal portion of 
the UL12 protein. Lagunoff and Roizman (1994, 1995) identified a protein-coding 
region in R l (ORF P) which contains 248 codons and is almost completely antisense to 
RL1 (ICP34.5). Ward et al. (1996) proposed a novel protein encoded antisense to 
UL43 (UL43.5). The status of these potential additional genes, however, remains 
uncertain for various reasons.
The majority of the HSV-1 genome is potentially protein-coding. Most genes are 
expressed as unspliced mRNAs whose expression is controlled by temporal class- 
specific promoters and which terminate at eukaryotic polyadenylation signals 
containing the canonical AATAAA motif. Partially overlapping transcripts sharing a 
common polyadenylation site are common: for example US5, US6 and US7. HSV-1 
has four genes that are incontrovertibly expressed as spliced mRNAs, two (UL15 and 
RL2) with introns in protein-coding regions and two (US1 and US 12) sharing a 
common spliced 5’ non-coding leader in Rs (Wagner, 1994). There is evidence that 
some genes specify low-abundance spliced mRNAs in addition to the major unspliced 
transcripts, for example, minor variants of the UL44 and UL30 transcripts. In contrast 
to the four major spliced transcripts, however, the significance of these minor variants
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Fig. 5. Arrangem ent of g en es  in the HSV-1 genom e
The genome is shown in six panels, each 25 kbp long except the last. Inverted repeats are denoted by 
the thicker parts of the genome outline and protein-coding regions are shown as shaded horizontal 
arrows. For the sake of clarity, the prefixes “UL” (58 genes) and "US” (13 genes) have been omitted 
from the gene nomenclature given below the genome; see Fig. 4 for the locations of these regions. The 
major LAT RNA, presumed to be derived from a stable intron generated from a larger transcript, is also 
indicated by a horizontal arrow. Genes RL2 and UL15 contain three and two exons, respectively. 
Possible polyadenylation sites for mRNAs are indicated by vertical arrows above and below the 
genome for right and left oriented genes respectively. The locations of or/s and or/L are shown by white 
rectangles above the genome. Reproduced from Davison (1990).
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is not clear. In addition, the latency-associated transcripts (LATs), described in more 
detail in Section 1.10, are spliced.
The HSV-1 genome contains three origins of replication, one in U l (oriL), located 
between genes UL29 and UL30, and one in Rs (oris; two copies). There is 
considerable homology between the sequences of oris and oriL, but whereas oriL 
contains a perfect 144 bp palindrome the oris palindrome is less extensive (Weller et 
al, 1985). Further details are given in Section 1.7.
1.3.4. Genetic variability
Differences in RE profiles between HSV-1 strains have two main causes: base 
substitution, which may add or eliminate restriction endonuclease cleavage sites; and 
variability in the number of repeated sequences, which results in size variability of 
restriction enzyme fragments.
Restriction endonuclease site polymorphism has been used in epidemiological studies 
of HSV transmission in the human population. For example, Sakoaka et al. (1994) 
compared the restriction patterns of HSV-1 strains from six countries and found that 
they vary from country to country and that HSV-1 strains from within the same ethnic 
group are more closely related. They also suggested that the virus co-evolves with its 
host and that the rate of mutation is 3.5 x 10'8 per site per year, a rate which 
corresponds to that proposed by McGeoch and Cook (1994) for much longer 
evolutionary periods (see Section 1.1.4.).
Several of the 19 sets of tandem reiterations which are present in the HSV-1 genome 
can vary in the copy number of repeat elements. The a sequence can also vary in copy 
number at the L-S junction and L terminus.
1.3.5. Gene functions
Table 5 contains information about the status in cell culture and proposed functions of 
HSV-1 genes. The functions of the majority of herpesvirus genes have been identified 
by direct genetic and biochemical experimentation, and computer-aided comparisons of 
predicted amino acid sequences with databases have also facilitated the identification 
of a few gene functions.
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Table 5. Features of HSV-1 genes
Gene* S ta tu sb Protein  function References to mutants
RL1 NE Neurovirulence factor (ICP34.5). Bolovan et al,  1994; Brown et al., 1994; 
Perng et al., 1993, 1995 a,b, 1996.
RL2 NE IE protein; transcriptional regulator 
(ICPO, VmwllO).
Everett, 1989; Stow and Stow, 1986; Chen 
etal., 1991.
LAT NE Latency-associated transcript; probably 
not protein coding.
Block et al., 1990; Deshmane etal., 1993, 
1995; Perng et al., 1994; Maggioncabla et 
al., 1994.
UL1 E Glycoprotein L; complexes with 
glycoprotein H (UL22).
Hutchison etal., 1992a; Roop etal., 1993.
U L2 NE Uracil-DNA glycosylase. Pyles and Thompson, 1994.
UL3 NE Function unknown Baines and Roizman, 1991.
UL4 NE Function unknown. Baines and Roizman, 1991.
UL5 E Component of DNA helicase-primase 
complex; possesses helicase motifs.
Wu et al., 1988, Zhu and Weller, 1992a, b; 
Bloom and Stevens, 1994.
UL6 E Minor capsid protein. Weller et al., 1987; Patel etal., 1996.
U L7 E? Function unknown.
U L8 E Component of DNA helicase-primase 
complex.
Carmichael and Weller, 1989; Sherman et 
al., 1992
UL9 E Ori-binding protein essential for DNA 
replication.
Olivo etal., 1988; Arbuckle and Stow, 
1993; Abbots and Stow, 1993.
U L 10 NE Virion surface glycoprotein M. McLean e ta l ,  1991, 1993; Baines and 
Roizman, 1991.
U L 11 NE Myristylated tegument protein; role in 
virion envelopment.
MacLean et al., 1989; 1992; Baines and 
Roizman, 1992.
U L 12 (E) Deoxyribonuclease; role in 
maturation/packaging of DNA.
Weller etal., 1990; Shao etal., 1993
U L 13 NE Tegument protein; probable protein 
kinase.
Coulter et al., 1993; Overton etal., 1994.
U L 14 ? Function unknown.
U L 15 E Role in DNA packaging; putative 
terminase component.
Poon and Roizman, 1993; Baines et al., 
1994.
U L 16 NE Function unknown. Baines and Roizman, 1991.
U L 17 E? Function unknown.
U L 18 E Capsid protein (VP23); component of 
intercapsomeric triplex.
Desai et al., 1993.
U L 19 E Major capsid protein (VP5); forms 
hexons and pentons.
Weller et al, 1987; Desai etal., 1993;
UL20 E/NE Integral membrane protein; role in egress 
of nascent virions;host range phenotype; 
syn locus.
Baines etal., 1991; MacLean etal.,  1991.
U L 21 NE Tegument protein. Baines etal., 1994a.
U L 22 E Virion surface glycoprotein H; 
complexes with glycoprotein L (UL1); 
role in cell entry.
Desai et al., 1988; Dargan and Subak-Sharp, 
1991; Wilson etal., 1994.
UL23 NE Thymidine kinase. Coen et al., 1989; Hay et al., 1995.
U L 24 NE Function unknown; syn locus. Jacobson et al., 1989a.
U L 25 E Capsid-associated tegument protein. Addison etal., 1984; Thopmson et al., 
1995; Ali etal., 1996.
U L 26 E Protease, acts in virion maturation; N- 
terminal portion is capsid protein VP24.
Preston e ta l ,  1992, 1993; Register and 
Shafer, 1996; Godefray and Guenet, 1995; 
Desai et al., 1994.
U L 2 6 .5 (E) Internal protein of immature capsids 
(VP22a); processed by UL26 protease.
Preston etal., 1992; Thomsen e ta l ,  1995; 
Kennard etal., 1995.
U L 27 E Virion surface glycoprotein B; role in 
cell entry; syn locus.
Cai et al,  1987; Highlander e ta l ,  1989; 
Yahasz and Stevens, 1993.
U L 28 E Role in DNA packaging. Addison et al,  1990; Tengelson et 
al., 1993.
U L 29 E Single-stranded DNA-binding protein 
(ICP8).
Gao et al., 1989.
U L 30 E Catalytic subunit of replicative DNA 
polymerase; complexes with UL42.
Stow, 1993; Digard etal.,  1993.
U L 31 E? Function unknown.
U L 32 E? Function unknown.
U L 33 E Role in DNA packaging. Al-Kabaisi etal., 1991; Cunningham et al., 
1993.
U L 34 E? Membrane-associated phosphoprotein; 
substrate for US3 protein kinase.
U L 35 E? Capsid protein (VP26); located on tips of 
hexons.
U L 36 E Very large tegument protein. Batterson etal., 1983.
U L 37 E? Tegument protein.
U L 38 E Capsid protein (VP19C) ; component of 
intercapsomeric triplex.
Flanagen etal., 1991; Guzowski and 
Wagner, 1993.
U L 39 E/NE Ribonucleotide reductase large subunit 
(ICP6, Vmwl36, Rl).
Goldstein and Weller, 1988a, b; Jacobson 
etal., 1989.
UL40 E/NE Ribonucleotide reductase small subunit 
(Vmw38, R2).
Preston etal.,  1988a.
UL41 NE Tegument protein; host shut-off factor. Fenwick and Everett, 1990; Read et al,  
1993.
U L 42 E Subunit of replicative DNA polymerase 
which increases processivity and 
complexes with UL30 protein.
Gottleib et al,  1990; Gottleib and 
Challberg, 1994.
UL43 NE Function unknown; probable integral 
membrane protein.
McLean e ta l ,  1991.
UL44 NE Virion surface glycoprotein C; role in 
cell entry.
Herold e ta l ,  1991; Dargan and Subak- 
Sharpe, 1991.
UL45 NE Tegument/envelope protein. Visalli and Brandt, 1991, 1993.
UL46 NE Tegument protein; modulates IE gene 
transactivation by UL48 protein.
Barker and Roizman, 1990; Zhang and 
McKnight, 1991, 1993.
UL47 NE Tegument protein; modulates IE gene 
transactivation by UL48 protein.
Barker and Roizman, 1990; McLean et al., 
1990; Zhang and McKnight, 1991, 1993.
UL48 E Tegument protein; transactivates IE 
genes (VP16, Vmw65, a-TIF).
Ace et al., 1989; Harris and Preston, 1991; 
Valyinagy etal.,  1991a.
UL49 ? Tegument protein.
U L 49A NE? Envelope protein disulphide-linked to 
tegument.
Romanelli et al., 1992.
U L 50 NE Deoxyuridine triphosphatase. Fisher and Preston, 1986; Pyles et al,  
1992.
U L 51 (E) Function unknown. Barker and Roizman, 1990.
U L 52 E Component of DNA helicase-primase 
complex.
Goldstein and Weller, 1988c; Crate et al,  
1989; Klinedinst and Challberg, 1994.
UL53 (E) Glycoprotein K. Ramaswamy and Holland, 1992; Moyal et 
al., 1992.
U L 54 E IE protein; post-translational regulator of 
gene expression (ICP27, Vmw63).
McCarthy etal., 1989; Rice et al., 1993.
UL55 NE Function unknown. Block etal., 1991; Nash and Spivack, 
1994.
UL56 NE Function unknown. Rosen-Wolf etal., 1991; Nash and Spivack, 
1994.
RSI E IE protein; transcriptional regulator 
(ICP4, Vmwl75).
Preston, 1979; Patterson etal., 1990.
US1 E/NE IE protein; function unknown (ICP22, 
Vmw68); host range phenotype.
Post and Roizman, 1981; Sears etal., 1985; 
Poffenberger etal., 1993.
US2 NE Function unknown. Longnecker and Roizman, 1987.
US3 NE Protein kinase; phosphorylates UL34 
protein.
Purves e ta l ,  1991; Nishiyama etal., 1992.
US4 NE Virion surface glycoprotein G. Longnecker and Roizman, 1987; Balan et 
al., 1994.
US5 NE Proposed glycoprotein J. Weber et al., 1987; Balan et al., 1994.
US6 E Virion surface glycoprotein D; role in 
cell entry.
Ligas and Johnson, 1988; Johnson and 
Ligas, 1988.
US7 NE Virion surface glycoprotein I; complexed 
with glycoprotein E (US 8) in Fc receptor.
Johnson etal., 1988; Balan etal., 1994.
US8 NE Virion surface glycoprotein E; complexed 
with glycoprotein I (US7) in Fc receptor.
Johnson e ta l ,  1988; Balan et al., 1994.
US8A NE Function unknown. Georgopoulou e ta l ,  1995.
US9 NE Virion protein. Umene, 1986; Frame, 1986.
USIO NE Virion protein. Longnecker and Roizman, 1987.
US11 NE Virion protein; ribosome-associated in 
infected cell.
Roller and Roizman, 1992.
US12 NE IE protein (ICP47, Vmwl2); role in 
preventing antigen presentation.
Longnecker and Roizman, 1986; Hill et al., 
1995; Johnson et al., 1995.
a = Core genes are shown in bold type.
b = The status of each gene in cell culture is indicated: E = essential, NE = non-essential, E? = probably essential, 
NE? = probably non-essential, (E) = a mutant is viable, but very disabled, E/NE= non-essential under certain 
conditions, ? = unknown. E genes are those for which mutants have been constructed that require 
complementing cell lines or those for which attempts to generate insertion mutants using the cosmid system 
have yielded only wt, essential genes have also been identified by ts mutants. E? genes are those where 
attempts to derive a mutant by plasmid recombination have failed. NE? genes are those where data are 
available for alphaherpesviruses other than HSV-1.
Adapted from McGeoch et al. (1993).
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The majority of HSV-1 genes can be considered in four main functional categories: 
control (see Section 1.6); DNA replication and packaging (see Section 1.7); structure 
and assembly (see Section 1.8); pathogenesis and latency (see Section 1.9 and 1.10). 
The HSV-1 “core” genes (i.e. genes which are found in all three herpesvirus families) 
are identified by bold type in Table 5, and most fall into the first three categories.
The status of HSV-1 genes (i.e. their importance in viral growth in cell culture) has 
been examined by the production of mutants, as described in Section 1.5. About half of 
the HSV-1 genes are individually dispensable, for growth in cell culture, but most 
appear to be required for efficient viral replication and pathogenesis in animal models 
(Baines and Roizman 1991; McGeoch and Schaffer, 1992; McGeoch and Barnett, 
1993).
 ♦ -------------
1.4. THE INFECTIOUS CYCLE OF HSV-1
This section provides a thumbnail guide to the processes involved at each stage of the 
HSV-1 lifecycle (Roizman and Batterson, 1987; Everett, 1987b; Wagner, 1994; 
Campadelli-Fiume, 1994: Roizman and Sears, 1987, 1990, 1993; Beers et a l, 1994; 
Fraser et al, 1991, 1992; Steiner and Kennedy, 1993; Rixon, 1993). Each process is 
discussed in more detail in later sections. Fig. 6 illustrates the life cycle of HSV-1.
Initial association of HSV-1 with the host cell is mediated by viral glycoproteins, which 
also have important roles in adsorption and penetration of the virus (see Section 1.8). 
The virus envelope fuses with the plasma membrane, the nucleocapsid is released into 
the cytoplasm and migrates to the nucleus where the DNA enters via the nuclear pores. 
At least some of the tegument proteins also enter the nucleus, although the process by 
which this occurs is not clear (see Section 1.8). Transcription, replication of viral DNA 
and capsid assembly take place in the nucleus.
Gene expression occurs in three main phases: immediate early (IE or a), early (E or p) 
and late (L or y). The operational definition of these genes is based largely on inhibitor 
studies. An EE gene is one whose transcription is independent of viral and cellular 
protein synthesis. E genes are activated by IE gene products and are expressed before 
the onset of DNA replication. L genes are dependent on functional IE and E proteins
9
Free Viru&
Release
Budding
Assembly
Adsorption Entry into 
cytoplasm \
Productive
Infection
Tr**
DNA replication'
Late g en e  
expression
^31
Oltfl.«$'O/
.O'
Transport 
to nucleus
r
|  Decision
Immediate early 
g e n e  expression
Early g en e  
expression
Establishment 
of latency
p
M aintenance  
of latency
I LAT 
I transcripts
Reactivation 
from latency
Fig. 6. R epresentation of the replicative cycle of HSV-1
Reproduced from Davison and Clements (1996).
Chapter 1: Introduction
and are only produced in quantity following the onset of DNA replication. They have 
been subdivided into “leaky late” (y^ and “true late” (y2). Expression of the former 
occurs at low levels before the onset of viral replication but becomes maximal 
afterwards. The latter are expressed only after DNA replication commences (see 
Section 1.6).
Three of the five IE genes regulate the expression of early or late genes directly or 
indirectly (Honess and Roizman, 1974). E gene products include enzymes involved in 
DNA replication, nucleotide metabolism and,some glycoproteins, while L genes 
encode many of the virion proteins. The latter class includes the tegument protein 
Vmw65, which is the major transactivator of IE genes (O'Hare, 1993) (see Section 1.6).
Genomic DNA is circularised by direct ligation of the termini, and viral DNA synthesis 
is initiated in the nucleus from oris and oriL to produce DNA in an endless 
conformation, probably as head-to-tail concatamers, by a rolling circle mechanism 
(Roizman, 1979; Jacob et al, 1979). Replicated DNA is cleaved specifically into unit- 
length molecules at the a sequence and packaged into preformed capsids (see Section 
1.7). The process by which the capsid acquires tegument and envelope is not fully 
understood; two proposed models are described in Section 1.8. The envelope is 
derived from altered host membranes containing viral glycoproteins, which are 
processed to their mature forms in the Golgi apparatus. Virions are released from the 
cell by exocytosis (see Section 1.8).
Productive infection leads to the induction of a number of viral and host proteins which 
specifically alter the metabolism of the cell to confer a replicative advantage to the 
virus. Upon entry into the cell, a tegument component, virion host shutoff protein (vhs, 
encoded by UL41) causes rapid inhibition of host macromolecular synthesis (see 
Section 1.6.6.). A late shutoff function also occurs which is dependent on viral RNA 
and protein synthesis (Fenwick, 1984), but the mechanism is poorly understood. The 
production of heat shock proteins and interferons is also induced in response to 
infection, but, at least in cell culture, the lytic lifecycle is not aborted and the cell is 
eventually destroyed (see Section 1.6).
In addition to the lytic cycle of infection, HSV-1 is able to establish a latent infection in 
dorsal root ganglia (DRG). The switch between the lytic and latent states depends on 
complex viral and cellular interactions. During latency, genomic DNA is retained in a 
circular (or concatemeric) state in association with nucleosomes, and transcription 
occurs only from a small region of the genome, producing the latency-associated
10
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transcripts (LATs) from RL (see Fig. 5). HSV-1 can remain in a latent state for the 
lifetime of the host and can be reactivated by appropriate stimuli resulting in further 
limited rounds of lytic infection which usually produce oro-facial lesions. Details of 
latency are given in Section 1.10.
1.5. HSV-1 MUTANTS
In earlier years, HSV-1 mutants were generated without detailed knowledge of the viral 
genes and were selected on the basis of a range of properties including plaque 
morphology, temperature sensitivity, host range properties and resistance to immune 
cytolysis or antiviral compounds. Sections 1.5.1-1.5.5 describe the production of 
mutants using these methods. Since the determination of the complete HSV-1 DNA 
sequence it has been possible to target any gene for specific mutation, including genes 
previously inaccessible to genetic analysis, using selectable or detectable marker genes. 
Plasmid-based methods (Section 1.5.6-1.5.9) allow mutations to be introduced easily at 
specifically targeted sites, and can also be used to generate revertants, thus allowing 
phenotypic changes to be associated directly with the mutation. However insertions 
can be quite large and may affect more than just the target gene. The major advantage 
of the cosmid-based system (Section 1.5.10) is that it allows for mutants to be isolated 
in the absence of wt virus. Also, since a marker gene is not required, mutations 
containing minimally disruptive changes (e.g. insertions or deletions of only a few base 
pairs) may be introduced. Revertants are not easily produced with the cosmid system, 
however, association between mutation and phenotype can be established by making 
several independent mutants in the same gene. Sections 1.5.6-1.5.10 describe the 
production of mutants with lesions in specific genes using these methods.
1.5.1. Plaque morphology
Ejercito et al. (1968) first described variants that induced cell fusion and resulted in the 
production of giant multinucleate cells or syncitia (syn plaques). They concluded that 
differences in plaque morphology invariably coincided with changes in the surface 
properties of the virions. Non-syncitial plaques consist of a localised area of rounded 
cells, and in syn plaques many cells are fused into a polykaryocyte (Timbury et al, 
1974). Syncitial mutants have been mapped to at least seven different loci in HSV-1
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genome (Marsden, 1987), and at least five correspond to genes encoding glycoproteins 
or putative membrane proteins.
1.5.2. Temperature sensitivity
Temperature sensitive (ts) mutants are conditional lethal mutants whose replication is 
impaired at one temperature, the non-permissive temperature (NPT), but unimpaired at 
another temperature (usually lower), the permissive temperature (PT), while replication 
of wt virus is not significantly impaired at either temperature (Schaffer et al., 1970). 
This type of mutant has formed the backbone of the majority of genetic investigations 
carried out on HSV-1. Ts mutants are still used today; indeed, a ts mutant of UL15 was 
described recently by Poon and Roizman (1993).
In principle, any gene can be mutated to code for a ts gene product, but only ts 
mutations in genes which are indispensable to the virus lytic cycle are isolated by 
normal selection procedures. Ts mutations usually cause non-functionality because 
substitution of wt amino acids results in an alteration in protein conformation or 
stability at the NPT. Although spontaneous ts mutants have been reported (Manservigi, 
1974), there are two principal methods for inducing mutants in vitro. In the first, a 
virus or viral DNA is treated with a substance that directly modifies the DNA: for 
example, nitroso-guanidine or UV light. The second and most widely used procedure 
involves treating infected cells with mutagens. Most ts mutants of HSV-1 have been 
isolated by treatment of cells with 5-bromodeoxyuridine (BUdR) (Subak-Sharpe, 1969) 
which is incorporated into DNA in place of thymidine, but base pairs with a guanine 
residue to cause replacement of the original T-A pairing by a G-G base pair in the next 
replication cycle (Freeze, 1963). These methods of making ts mutants are technically 
simple but have a number of disadvantages. The concentration of mutagen to be used 
must be accurately determined so that mutants are produced at a greater frequency than 
would occur spontaneously but without inducing multiple mutants. Also, the sites at 
which mutations are introduced cannot be selected.
One general problem with ts mutants, however produced, is their tendency to “leak” or 
revert. Leakage is the result of a small amount of functional protein being produced at 
the NPT. Reversion of a ts mutation, usually the result of a single base substitution, 
may give back the original wt sequence or another base which effectively replaces the 
wt base. Revertants can also occur by a change in another codon which counteracts the 
original change. Despite these problems, the use of ts mutants has been very important 
in investigating gene function.
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1.5.3. Host range
Wt HSV-1 cannot replicate in dog kidney cells, although the virus absorbs and 
penetrates the cell. A host range mutant that could replicate in these cells was first 
described by Aurelian and Roizman (1964), and appeared to be able to overcome a 
block at the stage of nucleocapsid envelopment. This mutant was obtained without 
knowledge of the site or type of mutation and was of limited utility, but certain 
mutations introduced more recently into specific genes have been shown to result in a 
restriction to certain cell types. Thus, US1 deletion mutants can only replicate in Vero 
cells, while UL20 deletion mutants form small plaques in human tkr cells but fail to 
form plaques in Vero cells (Post and Roizman 1981; Baines et al, 1991).
1.5.4. Immune cytolysis
Immune cytolysis mediated by antibody and complement is directed against viral 
glycoproteins present on the surface of infected cells; particularly glycoprotein B (gB), 
gC and gD. Machtiger et al. (1980) described mutants that contained lesions in surface 
glycoproteins and were resistant to immune cytolysis. Tests with a ts mutant of HSV-1 
defective in glycoprotein synthesis at the NPT demonstrated that infected cells 
maintained at this temperature were not lysed when reacted with antibody and 
complement. In other studies, monoclonal antibodies specific for HSV-1 or HSV-2 
glycoproteins have been used to select variants that are resistant to neutralization 
(Holland et a l, 1983).
1.5.5. Drug resistance
Many drug resistant mutants were isolated during evaluation of compounds as potential 
antiviral agents. The majority of drug-resistant mutants identified so far contain 
mutations in UL23 ( tk) or UL30 (DNA polymerase). The main types of drug used to 
produce mutants are nucleoside analogues such as BUdR, which is incorporated in 
place of thymidine causing a base pair replacement (Jamieson et a l, 1974), arabinoside 
A which inhibits HSV-1 DNA polymerase (Coen et a l,  1982), and acyclovir which 
acts as a chain terminator during viral DNA synthesis. Pyrophosphate analogues such 
as phosphonoacetate inhibit viral DNA polymerase via the pyrophosphate binding site 
(Purifoy and Powell, 1977).
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1.5.6. Selectable markers
The isolation of mutants is greatly facilitated by the introduction of selectable marker 
genes into the HSV-1 genome. Under selective pressure, only recombinants carrying 
the marker are able to grow. A number of markers are available; the most commonly 
used is HSV-1 tk. Specific deletions of viral sequences can then be made at the site 
where the marker is inserted.
TK' virus can be selected using acyclovir or thymidine arabinoside treatment of 
infected TK+ or TK* cells (Mocarski et al, 1980), or by BUdR treatment of TK* cells. 
TK+ virus can be isolated by overlaying infected TK* infected cells with HAT medium 
(contains hypoxanthine, aminopterin, thymidine) (Compione-Piccardo et al., 1979; Post 
etal., 1981).
Post and Roizman (1981) described a general technique for introducing deletions into 
the genome using plasmid recombination. This method is an extension of the marker 
rescue technique and involves cotransfection of a plasmid containing a mutated gene 
into cells with wt viral DNA. Recombination between the wt and mutated DNA results 
in the production of a mutant virus. Recombinants are identified and isolated by a 
number of methods. Initially, tk is inserted at the target site in a genome containing a 
deletion in the natural tk gene, selecting for TK+ progeny. Then the introduced tk gene 
and sequences flanking the insertion site are deleted by a second recombination step, 
selecting for TK* virus.
Another selectable marker is the neomycin resistance gene (Neidhardt et al., 1987). 
Mutant progeny are selected on the basis of their ability to grow in the presence of 
neomycin.
1.5.7. Detectable markers
The most widely used detectable marker is E. coli lacZ (Goldstein and Weller, 1988a). 
Insertion of this marker allows recombinants to be detected as blue plaques in the 
presence of 5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside (X-gal), against a 
background of clear wt plaques. This method is widely used, but has a few 
disadvantages. Since lacZ is large (~4 kbp), insertion into a gene may disrupt flanking 
genes, so that the resulting phenotype could be due in part to an effect on expression of 
a neighbouring gene rather than the target gene. Also, slow-growing mutants may be 
difficult to detect in the presence of a large wt background. Some advantages of the 
method include the ability to carry out a second step of mutagenesis so that the initial
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lacZ  insertion can be replaced by a deletion, and the production of revertants by 
replacing lacZ by wt sequences.
1.5.8. Tn5 transposon
Weber et al. (1987) reported a simple insertional mutagenesis system for inactivation 
of HSV-1 genes, but specific genes could not be targeted The bacterial transposon 
Tn5 carrying a kanamycin resistance marker was inserted randomly in E. coli into 
plasmids. Cotransfection of plasmids with wt virus resulted in mutant progeny. 
Random insertion of Tn5 resulted in truncation of the corresponding gene product, 
owing to the presence of a stop codon in all three reading frames at the transposon 
termini.
1.5.9. Cre-lox system
Gage et al. (1992) described a cell-free recombination system for site-specific 
integration of multigenic shuttle plasmids into the herpesvirus genome, which takes 
advantage of the C t q - I o x  site-specific recombination machinery of bacteriophage PI. A 
plasmid containing the 34 bp loxP recombination site but lacking herpesvirus 
sequences was inserted at a loxP site previously engineered into PRV. Recombination 
occurred in a mixture containing viral DNA, plasmid, and the Cre recombinase. 
Transformation of the mixture into suitable eukaryotic cells allowed rescue of 
infectious recombinant viruses, which were identified on the basis of a blue plaque 
phenotype derived from expression of lacZ in the shuttle plasmid. The plasmid was 
stably maintained in the viral genome and, since the Cre recombination reaction is 
reversible, the inserted shuttle plasmid could be recovered from the viral genome 
producing rescued wt viruses. This method is useful only for mutation of a single locus 
of particular interest, not a means of obtaining mutants throughout the genome.
1.5.10. Cosmids
Van Zijl et al. (1988) reported the ability to generate PRV from subgenomic regions 
cloned as fragments of about 40 kbp into cosmids. Sets of four or five overlapping 
cosmid clones together comprising the complete viral sequence generated viral plaques 
after transfection of the inserts into pig kidney cells. Southern blot analysis revealed no 
differences between parental and reconstituted virus, and no differences were observed 
in the biological properties exhibited by the reconstituted virus as tested by infection of 
piglets. Cosmids can be manipulated in vitro in a similar manner to plasmids and
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mutations transferred to viruses without the need for selection or extensive screening 
procedures since no wt background is generated. Even mutants with poor replicative 
capacities or carrying multiple gene alterations can be obtained in a single transfection 
step.
de Wind et al. (1990) described a method of linker insertion mutagenesis of single 
genes in PRV Us. An oligonucleotide containing translational stop codons in all 
reading frames was inserted at quasi-random sites into a cosmid and viral mutants were 
then obtained. This technique takes advantage of the observation that digestion of 
circular DNA molecules in the presence of ethidium bromide by restriction enzymes 
with multiple recognition sites preferentially yields full length linear molecules (Parker, 
1980).
Since the cosmid system was developed for PRV, similar systems have been described 
for other herpesviruses, including HSV-1 (Cunningham and Davison, 1993), VZV 
(Cohen and Seidel, 1993), EHV-1 (Dr E.A.R. Telford, unpublished data), BHV-1 
(Ananvoranich et al., 1995) and HCMV (Kemble et a l, 1995). Cunningham and 
Davison (1993) generated three sets of HSV-1 cosmids, each of which was capable of 
yielding plaques after digestion with Pacl to release the inserts and transfection into 
BHK cells. They constructed viral mutants containing frameshift mutations in either or 
both of genes UL2 and UL44, which are not essential for growth in cell culture. They 
also produced a mutant with a frameshift mutation in UL33, an essential gene involved 
in DNA packaging, by transfecting a complementing cell line.
The use of modem methods for constructing mutants such as plasmid-based or cosmid- 
based systems allows for the production of mutants with lesions at specific sites. 
Genes of particular interest can be targeted, and this has lead to the generation of a 
battery of mutants with lesions in many of the HSV-1 genes. These have been used in 
many laboratories to identify and characterise gene functions.
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1.6. CONTROL PROCESSES
1.6.1. Temporal regulation of gene expression
HSV-1 gene expression is temporally regulated, with three major classes of proteins 
expressed in a cascade (Honess and Roizman, 1974; Clements et al., 1977). Immediate 
early (EE or a )  proteins reach maximal levels of production at 3-4 h pi, and some are 
required for switching on the other classes of proteins (Honess and Roizman, 1975; 
Preston et al., 1978). Early (E or p) proteins reach maximal levels of production at 5-7 
h pi and require the presence of IE proteins for induction. These include non-structural 
components, for example, herpesvirus specified enzymes including thymidine kinase, 
DNA polymerase and DNase. Late (L or y) proteins require the presence of IE and E 
proteins, are produced late in infection, and encode many of the major structural 
components. Some late proteins are made in small amounts prior to DNA replication, 
while others are strictly produced after replication (Honess and Roizman, 1974; 
Clements et al., 1977; Jones and Roizman, 1979). Initiation of the transcription cycle 
is brought about by the action of the tegument component Vmw65, which is the major 
transactivator of EE genes; as such it begins the cascade of IE, E and L gene expression.
1.6.2. Vmw65 (VP16)
Vmw65 is encoded by UI>48 and functions as both an essential structural component of 
the tegument and as a major transactivator of IE genes. There are between 500-1000 
molecules of Vmw65 present in the virion which are transported to the nucleus after 
viral entry into cells (Spear et al., 1972; Heine et al., 1974).
The five IE genes are transactivated by Vmw65 via a specific target sequence 
(TAATGARAT) upstream of their promoters. To form stable complexes with these 
sites, Vmw65 requires at least two cellular factors, Octl and HCF (host cell factor). 
Fig. 7 illustrates the process of Vmw65 activation. In summary, the multiprotein 
complex responsible for IE gene induction is initiated through Octl binding to a region 
containing the TAAT sequence within the Vmw65 target sequence. The Vmw65/HCF 
complex binds to the Octl/DNA complex and is stabilised by specific interactions 
between Vmw65 and the Octl POU-homeo domain and between Vmw65 and the 
GARAT sequences of the TAATGARAT site. HCF may act to stabilise Vmw65 in a 
conformation with the highest affinity for DNA binding or by interaction with Octl 
(O'Hare, 1993). The formation of the complex locates the acidic activation domain of 
Vmw65 near the IE gene TATA box, where it activates transcription possibly by 
promoting the assembly of an initiation complex.
17
0C T 1
P O U -
S p ecific
ATGCTAATGARAT
OCT1
S p ecific
ATGCTAATGARAT
©
V m w65
Acidic C terminus
HCF
V m w65
Acidic C terminus
HCF
Vm w65OCT1
P O U -
S p ecific Acidic C terminus
ATGCTAATGARAT TATA
Fig. 7. Vmw65 transactivator complex formation
Cellular protein 0ct1 binds to the TAAT region of the Vmw65 activation sequence. HCF binds to 
Vmw65, and this complex then binds to the Oct1/DNA complex at the GARAT sequence. The formation 
of the complex locates the acidic C terminus of Vmw65 in the region of the TATA box which promotes 
assembly of the initiation complex.
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The C-terminus of Vmw65 is highly enriched in acidic amino acids; acidic domains 
have been implicated as transcriptional activators in other systems (Sadowski et al., 
1988). The acidic region is thought to promote assembly of an initiation complex 
containing the TATA box binding factor (TBF) topologically altered for productive 
initiation. The requirement for IE transactivation can be separated from complex 
assembly on the TAATGARAT site, since deletion of the acidic domain has no effect 
on assembly of the complex but abolishes transactivation (Greaves and O’Hare, 1989). 
The C-terminus of Vmw65 was shown to function as a transactivator independently of 
the complex when fused to the DNA-binding domain of the yeast transcription factor 
GAL4 (Sadowski e ta l., 1988; Cousens, 1989).
Kristie and Roizman (1987) were first to demonstrate that a host cell protein binds to 
the IE upstream regions and suggest that it could be involved in Vmw65 
transactivation. This protein was later identified as Octl (O’Hare et al., 1988), a 
transcription factor implicated in the regulation of a number of cellular genes (Stem et 
al., 1989). Octl is a member of a subclass of homeodomain proteins, the POU 
proteins, which share a highly related 150-160 residue POU domain (Ruvkun and 
Finney, 1991). The POU domain is divided into two regions, the POU-homeo domain, 
which includes three helices and a POU-specific domain. Helix 3 of the POU-homeo 
domain is the major DNA binding region which makes contact across the TAAT region 
of TAATGARAT, and the POU-specific domain contacts the ATGC sequence 
immediately upstream of the TAAT sequence (Herr, 1992). Mutations in GARAT 
have no effect on Octl binding but abolish formation of the Vmw65 complex. Vmw65 
binds to Octl via helix 2 of the POU-homeo domain and to the GARAT sequence 
(Stem and Herr, 1991).
A direct interaction between Vmw65 and HCF was demonstrated in the absence of 
Octl or the TAATGARAT element. This suggests that the first step in the multi­
protein complex assembly is the binding of HCF directly to Vmw65, an interaction 
which may take place in the cytoplasm. The Vmw65/HCF complex neither binds 
strongly to DNA nor detectably interacts with Octl alone, but does bind via the 
GARAT sequence following Octl binding to TAAT (O’Hare, 1993).
1.6.3. Immediate early genes
The five IE genes - RL2 (encoding VmwllO), RSI (encoding Vmwl75), US1 
(encoding Vmw68), UL54 (encoding Vmw63) and US 12 (encoding Vmwl2) (see 
Table 6) - all have roles in control processes.
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Table 6. Immediate early genes involved in control processes.
HSV-1
gene
Glasgow system 
Gene Product
Chicago system 
Gene Product
Size on 
SDS-PAGE
(kDa)
Size from 
sequence 
(Da)
Role
RSI IE1 V m w llO aO ICPO 110 78452 Non-specific transactivator of 
all classes o f genes.
UL54 IE2 Vmw63 a l l ICP27 63 55376 Late gene expression. Post 
translational regulation.
RL2 IE3 V m w l75 a 4 ICP4 175 132835 Major transactivator of IE,E 
and L genes.
US1 IE4 Vmw68 a l l ICP22 68 46521 Late gene expression. Host 
range phenotype.
U S12 IE5 V m w l2 a4 7 ICP47 12 9791 Involved in inhibition of 
antigen presentation.
Adapted from Everett (1987).
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Vmw175
Vmwl75 is the major transcriptional regulatory protein and is essential for viral growth 
(Preston, 1979) and transcriptional activation of E and L genes. It exerts its repressing 
and activating actions through interactions with general transcription factors (TBP and 
TFHB) as well as by binding to DNA (Smith, 1993). It was reported to be present in 
the tegument of purified HSV-1 virions (Yao and Courtney, 1989), but is actually 
predominantly found in L-particles (described in Section 1.8.3) (McLauchlan and 
Rixon, 1992).
The target sequence to which Vmwl75 binds (ATCGTC) is present in the RSI 
promoter (Faber and Wilcox 1986; 1988), facilitating autoregulation of Vmwl75 
expression (Roberts et al, 1988; DeLuca and Schaffer, 1988). The region of Vmwl75 
which is involved in DNA binding, transactivation and repression has been located near 
the N-terminal end of the protein between amino acid residues 275-495, and mutations 
in this region showed a reduction in these functions (Patterson and Everett, 1988a; 
1988b; Shepard et al, 1989; Patterson etal., 1990). Vmw 175 has five domains, two of 
which (1-314 residues and 1225-1298 residues) are not essential for function. Another 
two (351-484 residues and 485-496 residues) are essential for transcriptional activation 
and repression. DNA binding occurs via one of these and the other contains nuclear 
localisation sites. Another domain (497-1224 residues) also contains nuclear 
localisation sites
Vmw110
RL2 contains three exons and the spliced transcript encodes VmwllO (Perry et al, 
1986), a potent activator of the expression of all three classes of viral genes, as well as 
a number of cellular genes (Everett, 1984b; Cai and Schaffer, 1989, 1992). VmwllO 
has the ability to enhance the expression of any gene that exhibits a basal level of 
transcription, and can act by itself or synergistically with Vmw 175 (Everett, 1984b, 
1986, 1988a). It acts without apparent DNA sequence specificity and is itself regulated 
by Vmw 175 (Resnick et al, 1989).
Vmwl 10 is not essential for viral growth in cell culture but at low moi deletion mutants 
show a growth defect which is overcome at high moi (Stow and Stow, 1986). The 
major determinant of transactivation maps to a cysteine-rich region encoded in the 
second exon (Chen et al, 1991) which is conserved in VmwllO counterparts in other 
alphaherpesviruses. Two regions of Vmwl 10, are essential for function: residues 105- 
222 and residues 638-775. Residues 105-222 contain unique zinc binding motifs.
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Vmw 175 acts in concert with and may physically interact with VmwllO to stimulate 
transcription (Everett, 1984b; Knipe and Smith, 1988; Yoa and Schaffer, 1994). 
VmwllO alone is not sufficient to transactivate early gene transcription and it is 
thought to mediate transactivation by interacting with a cellular factor, the interacting 
domain encoded by the first two exons (Weber and Wigdahl, 1992).
VmwllO appears to play a major role in reactivation from latency. Mutants lacking 
Vmwl 10 are unable to stimulate latent viral genomes to reactivate in an in vitro latency 
system (Russell et al, 1987a), and expression of VmwllO from a heterologous vector 
facilitates reactivation (Harris et a l, 1989) (see Section 1.10.8). Also, VmwllO 
mutants are impaired in their ability to reactivate from latency in animal models 
(Clements and Stow, 1989; Cai et al, 1993). Davido and Leib (1996) showed that 
VmwllO promoter elements which are important for VmwllO expression and 
virulence are dispensible for the establishment of and reactivation from latency.
Vmw63
Vmw63 affects late gene expression through a post-transcriptional mechanism (Smith 
et al, 1992; Sandri-Goldi and Mendoza, 1992). This mechanism is poorly understood, 
but may involve processing at the 3’ poly A signal of late transcripts (McLauchlan et 
al, 1992), or inhibition of splicing (Schroder et al, 1989; Sandri-Goldin and Mendoza, 
1992; Hardwich and Sandri-Goldin, 1994; Hardy and Sandri-Goldin, 1994). Two 
regulatory regions have been identified, an activator region (residues 240-434) and a 
repressor region within the C-terminal 78 residues which contains a putative zinc- 
binding domain (Vaughn et al, 1992; Rice et al, 1993). Vmw63 has been shown to 
bind RNA directly (Ingram et a l , 1996).
A ts mutant in Vmw63 over-expressed E gene products but did not synthesize 
detectable amounts of L mRNAs (Sacks et al, 1985). An analysis of deletion mutants 
showed that Vmw63 is necessary for L gene expression and the down-regulation of IE 
genes (Sacks et al, 1985; McCarthy et al, 1989; Curtin and Knipe, 1993). There is 
also evidence from plasmid transfection studies that, in the presence of VmwllO and 
Vmw 175, Vmw63 can repress E promoters and enhance L promoters (Everett, 1986; 
Rice and Knipe, 1988; Su and Knipe, 1989; McMahan and Schaffer, 1990). Vmw63 
can act synergistically with Vmwl75 and VmwllO to stimulate or repress gene 
expression.
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Vmw63 may contribute to the overall shutoff of host gene expression by virtue of its 
ability to inhibit pre-mRNA splicing. Since splicing is widespread in the host cell 
genome and rare in HSV-1, Vmw63 might enable selective expression of viral mRNA 
(Sandri-Goldin and Mendoza, 1992). Infection of cells with wt virus but not Vmw63 
mutants leads to the redistribution of components of the spliceosome termed small 
nuclear ribonucleoprotein particles (snRNPs) from their diffuse speckled pattern in the 
nuclei of uninfected cells to discrete clusters on the nuclear periphery (Martin et al, 
1987; Phelan et al, 1993). Since Vmw63 is required for inhibition of host cell splicing 
and is localised in the redistributed snRNP-containing nuclear structures (Phelan et al., 
1993; Hardy and Sandri-Goldin, 1994), it was proposed that redistribution of snRNPs 
by Vmw63 is related to the inhibition of host cell splicing. However, a Vmw63 ts 
mutant can redistribute snRNPs without inhibiting splicing (Sandri-Goldin et a l, 
1995).
Vmw68
Vmw68 has a role in determining host range and in L gene regulation (Sears et al,
1985). Vmw68 mutants grow normally on Vero cells (Post and Roizman, 1981), but 
grew poorly in cell lines such as HFLs (Sears et al, 1985; Poffenberger et al, 1993). 
Expression of E proteins is delayed and the expression of L proteins is delayed and 
substantially reduced.
Vmw12
Vmwl2 is a cytoplasmic protein (Marsden et a l, 1982), which is non-essential for 
growth in cell culture (Longnecker and Roizman, 1986; Umere, 1986; Brown and 
Harland, 1987). A role for Vmwl2 in preventing antigen presentation to CD8+ T- 
lymphocytes has been described (York et al, 1994; Johnson et a l, 1995). Hill et al. 
(1995) have shown that Vmw 12 binds to TAP (transporter associated with antigen 
processing) and prevents peptide translocation into the endoplasmic reticulum. It binds 
to a site which includes the peptide binding domain of TAP and remains bound to this 
site in a stable fashion, thus preventing antigen presentation by competitive binding 
(Tomazin eta l., 1996; Ahn etal., 1996).
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1.6.4. Early genes
Following expression of IE proteins a more complex population of viral mRNAs 
becomes abundant prior to viral DNA replication, specified by genes which map 
throughout the genome (Wagner, 1985). They do not contain an obvious conserved 
class-specific sequence analogous to TAATGARAT in IE genes, although a number of 
regulatory elements have been identified in promoters of early genes such as UL23 (tk 
gene) and US6 (gD gene) (see Fig. 8), including a TATA box upstream of the 
transcriptional start site, GA- and GC- rich regions and a CAAT box (McKnight et al., 
1985; Everett, 1983, 1984a; Eisenberg et al., 1985; El-Kareh et al., 1985; Jones et al., 
1985; Graves etal., 1986).
E genes exhibit a variation in their kinetics of expression and as a result have been 
divided into two subgroups, early (E or pj) and delayed early (DE or p2). For example, 
gD is expressed as an early protein but it is not synthesised maximally until after the 
onset of viral DNA replication (Gibson and Spear, 1983), and thus may be viewed as a 
DE gene (Roizman and Batterson, 1985; Wagner, 1985). This property may simply 
reflect an increased template copy number.
The tk and gD promoters have been shown to contain Vmw 175 binding sites 
(Imbalzano et al., 1990; Tedder et al., 1989), but binding of Vmwl75 to the tk  
promoter is not necessary for transactivation (Imbalzano et al., 1990), and removal of 
three binding sites in the gD promoter does not affect the efficiency of gD transcription 
during a normal HSV-1 infection (Smiley etal., 1992). Mutational analysis of many E 
promoters and promoter regulatory regions has failed to define specific sequences 
involved in transactivation by VmwllO or Vmwl75. Transactivation of E gene 
expression by IE proteins may be mediated indirectly through their interactions with 
certain cellular transcription factors (Everett, 1986; Eisenberg et al., 1985; Coen et al., 
1986).
1.6.5. Late genes
Most L genes encode structural proteins of the virion. Some L proteins, termed leaky 
late or yp are detectable in small amounts prior to viral DNA replication and then in 
larger amounts after DNA replication: for example the major capsid protein encoded by 
UL19 (Costa et al., 1985). Others, termed true late or y2 are not detected prior to DNA 
replication (Roizman and Batterson, 1985; Wagner, 1985; Johnson et a l, 1986): for 
example, the capsid protein encoded by UL38 (Flanagan et al., 1991) and the US 11 
protein (Johnson etal., 1986).
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Fig. 8. Differences between IE, E and L promoters
The scale in residues upstream of the RNA cap site is given as a guide to the position of the various 
elements. IE promoters contain a cap site, a TATA box, distal promoter sequences within 100 bases of 
the cap site and a far upstream regulatory element. E promoters include only the distal and proximal 
promoter sequences while L promoters may consist simply of a TATA box and cap site on a 
replicating (i.e. on-containing) template. Adapted from Everett (1987a).
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L promoters do not have any obvious conserved class-specific sequence and seem to 
have a simpler structure than E promoters (Everett, 1984a,b) (see Rg. 8). Mutational 
analysis of the promoters of US 11 and UL44 (gC) demonstrated that the presence of a 
TATA box and a cap site, in combination with a cis-acting ori, were sufficient for full 
expression (Johnson and Everett, 1986a; Homa et al., 1986). Deletion of the regulatory 
regions of the US6 gene (gD) to leave a TATA box and cap site resulted in conversion 
of the gene from E to L regulation (Johnson and Everett, 1986a,b).
Experiments with DNA synthesis inhibitors and DNA-negative ts mutants 
demonstrated that L gene expression is dependent on viral DNA synthesis (Honess and 
Roizman, 1974; Holland et al., 1980; Conley et al., 1981; Pederson er al., 1981) in 
addition to presence of E and IE proteins. The role of viral DNA replication is unclear, 
but the increase in template copy number is likely to contribute towards an increase in 
L gene expression. L gene expression may also be activated as a result of structural 
changes occurring during the replication process (Johnson and Everett, 1986a; 
Mauromara-Nazos and Roizman, 1987).
1.6.6. Other aspects of control 
Viral proteins
Several tegument proteins appear to play important roles in enhancing viral infectivity. 
One major component of the tegument is the protein encoded by UL48, the major 
transactivator of IE genes, Vmw65 (see Section 1.6.2.). In addition, virion host shut- 
off protein (vhs), encoded by UL41, is a tegument protein which acts to shut off host 
macromolecular synthesis (Roizman and Roane, 1964). Vhs is a phosphoprotein which 
accumulates late in infection (McLauchlan et al., 1992) and is not required for virion 
assembly (Smibert and Smiley, 1990). Vhs inhibits cellular protein synthesis and 
glycosylation of host proteins, decreases ribosomal RNA production and reduces the 
stability of cellular mRNAs (Read and Frenkel, 1983; Wagner and Roizman, 1969; 
Spears et al., 1970). The latter effect is not limited to pre-existing cellular mRNAs, as 
vhs also induces destabilisation and degradation of viral IE, E and L mRNAs (Fenwick 
and Everett, 1990a,b). Vhs may act as a nuclease, cause dissociation of ribosomes from 
RNA leaving it more vulnerable to attack by preexisting ribonucleases or activate a 
cellular nuclease (Fenwick and Everett, 1990a,b). Also, vhs can bind to Vmw65 
(Weinheimer et al., 1992) and may prevent Vmw65 from entering the multiprotein 
complex on the EE TAATGARAT element (Smibert et al., 1994).
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A well as v/zs-induced host shutoff it appears that an uncharacterised independent late 
shut off function also functions during infection (Fenwick and Clark, 1982; Fenwick et 
al, 1984).
Protein kinases may act on proteins which have a role in the initiation of viral infection 
and in this way exact a measure of control. The potential protein kinase encoded by 
UL13 was identified as a virion component by Cunningham et al. (1992). This protein 
contributes to mRNA instability in infected cells (Overton et al., 1994) although the 
ability to induce mRNA instability may not require phosphorylation of vhs since 
phosphorylation was unaffected in virions from a UL13 mutant (Overton et al, 1994). 
The protein kinase encoded by US3 phosphorylates the UL34 protein and may also 
exert some control should it also phosphorylate any viral proteins involved in control.
Other viral proteins may also influence control processes. These include Vmw63, 
which contributes to the shut-off of host gene expression by inhibiting RNA splicing 
(see Section 1.6.3) (Hardwick and Sandri-Goldin, 1995). The C-terminus of RL1 is 
required to prevent the premature shut-off of protein synthesis in infected cells (Chou 
and Roizman, 1994). This protein may act to prevent the stress response in infected 
cells which would lead to inhibition of protein synthesis (see Section 1.9). Also, the 
tegument proteins encoded by UL46 and UL47 modulate DE gene transactivation by 
Vmw65 (UL48).
Host proteins
Cells under stress produce heat shock proteins (hsps), and the synthesis of other cell 
proteins is down-regulated. The high degree of amino acid sequence homology among 
hsps and the fact that they are normally present in organisms that are not under stress 
conditions suggests that they function in normal cellular operations, but that they are 
required to a greater extent under stress conditions. Two hsps, hsplQ and hsp90, act as 
molecular chaperones mediating the correct assembly of other polypeptides (Ellis, 
1990). It has been proposed that hsps not only mediate protein assembly but also 
promote disassembly of proteins that have been damaged as a result of stress (Pelham,
1986).
Hsp 70 alone is transiently induced by HSV-1 infection (Philips e ta l ,  1991). 
Notarianni and Preston (1982) demonstrated that the over-expression of IE 
polypeptides during infection with the mutant tsK (which contains a temperature- 
sensitive lesion in RSI) at the NPT led to increased synthesis of hsp 70, and later it was
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shown that overproduction of mutant Vmw 175 was responsible for the induced stress 
response (Russell et al., 1987a). Later, Russell eta l. (1987b) suggested that 
accumulation of hsplO was important in eliminating non-functional forms of Vmw 175 
or neutralising their damaging effects, rather than merely resulting from viral IE protein 
accumulation.
The interferons are a group of proteins that are not normally expressed but are 
produced in response to a range of stimuli, including viral infection. They are released 
from virus-infected cells and bind to interferon receptors on neighbouring cell 
membranes. There are two types of interferon receptors: one for IFNa and IFNp and 
the other for EFN) (Branca and Baglioni, 1981). Binding of IFN activates transcription 
of a defined set of cellular genes, many of which are involved in the establishment of 
an antiviral state (Lengyel, 1982; Fellous et al., 1982; Samuel, 1991; Sen and Lengyel, 
1992).
IFN-a has been shown to inhibit HSV-1 replication at the level of IE gene transcription 
(Oberman and Panet, 1988; DeStasio and Taylor, 1990), while cellular genes are 
insensitive (Mittnacht et al., 1988; Oberman and Panet, 1989; DeStasio and Taylor,
1990). Researchers have consistently found that adsorption, penetration and uncoating 
of HSV-1 is unaffected in cells pre-treated with IFN (Oberman and Panet, 1988; 
DeStasio and Taylor, 1990). The reduction in HSV-1 IE mRNA levels occurs as a 
result of an inhibition of transcription initiation rather than of transcript elongation or 
mRNA degradation (Mittnacht et al., 1988; DeStasio and Taylor, 1990).
 ♦ -------------
1.7. DNA METABOLISM
1.7.1. Nucleotide metabolism and DNA repair
HSV-1 specifies a number of enzymes which have roles in nucleic acid metabolism and 
DNA repair and as such are important in DNA replication. Many of these enzymes are 
not required for viral growth in cell culture but have been shown to be important in 
neurovirulence and latency (see Section 1.9).
The alkaline nuclease (encoded by UL12) is involved in the cleavage of DNA 
concatemers and in resolving replicative intermediates produced during DNA
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replication. It complexes with the UL29 gene product (Weller et al., 1990; Thomas et 
a l, 1992). It is required for efficient virus production in cell culture and has 5’-3’ 
exonuclease activity (Strobel-Fidler and Francke, 1980; Chou and Roizman, 1989). 
Uracil-DNA glycosylase (encoded by UL2) is involved in DNA repair and proof 
reading (Caradonna et al, 1987; Mullaney et al., 1989; Pyles et al., 1994). It removes 
uracil residues from DNA arising from misincorporation or from spontaneous 
deamination of cytosine residues. Ribonucleotide reductase (RR) is a tetramer of two 
molecules of the UL39 protein and two molecules of the UL40 protein, and converts 
ribonucleotides to the corresponding deoxyribonucleotides, thus supplementing the 
pool of substrates for DNA synthesis (Goldstein and Weller, 1988; Jacobson et al., 
1989; Paradis et al., 1989; Idowu et al., 1992). Thymidine kinase (encoded by UL23) 
phosphorylates thymidine and deoxycytidine to TMP and dCMP (Jamieson and Subak- 
Sharpe, 1974; Efstathiou et al, 1989; Coen et al., 1989), which are then converted to 
the triphosphates by cellular enzymes. Deoxyuridine triphosphatase (dUTPase) 
(encoded by UL50) hydrolyses dUTP to dUMP and pyrophosphate, thus reducing 
misincorporation of uracil residues into DNA and supplementing the pool of dUMP 
which can be converted to dTMP by cellular thymidylate synthase (Caradonna and 
Cheung, 1981; Fisher and Preston, 1986; Pyles et al., 1992).
HSV-1 was thought to specify a DNA ligase (Sparelari, 1976), which could join the 
Okazaki fragments produced by discontinuous synthesis on the lagging strand, and a 
topoisomerase (Muller et al., 1985). No viral genes, however, have been shown to 
encode these functions.
1.7.2. DNA replication
HSV-1 DNA replication is first detected in cells at 3 h pi, peaks at about 9-11 h and is 
virtually completed by 16 h (Wilkie, 1973). Replication initially occurs at discrete sites 
within the infected cell nucleus called “replication compartments”, and then at later 
times the nucleus becomes filled with replicating DNA (Quinlan et al., 1984). The 
current model of DNA replication proposes that following entry into the nucleus, the 
DNA circularises (Jacob and Roizman, 1977) by ligation of the terminal a sequences 
(Davison and Wilkie, 1983), is replicated by a rolling circle mechanism involving 
continuous production of one strand of DNA and discontinuous synthesis of the other 
(Roizman, 1979) to generate multiple head-to-tail concatemers (Jacob et al., 1979). 
The concatemeric DNA is then cleaved into unit-length molecules and packaged into 
preformed capsids (see Section 1.7.5).
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1.7.3. Origins of DNA replication
The HSV-1 origins of replication were identified in a number of ways, including 
electron microscopic studies, which provided evidence for the existence of two origins 
of DNA synthesis in the HSV-1 genome, one near the center of UL (on ) and the other 
in Rs (o ry  (Friedmann et al., 1977) and by analysis of defective interfering genomes 
which are spontaneous deletion mutants of wt genomes containing origins of 
replication and packaging signals (Frenkel et al., 1976; Schroder et al., 1976). The 
origins have been defined as those sequences that must be present in a fragment of 
HSV DNA for it to be amplified in permissive cells transfected with the fragment and 
transfected or infected with a helper virus (Vlazny et al., 1981).
It is now known that there are three origins of replication in a single HSV-1 DNA 
molecule (see Section 1.4) (see Fig. 5): oriL ( one copy) and oris (two copies). Both 
oris and oriL contain A+T rich palindromes and share considerable homology. OriL is a 
perfect 144 bp palindrome, but oris palindrome is less extensive (Weller et al, 1985). 
Oris is divided into a core region which is 90 bp in size and contains an almost perfect 
45 bp palindrome and an 18 bp region containing A and T residues (Stow and 
McMonagle, 1983) and surrounding sequences which enhance DNA replication (UL9 
binding sites) (Stow, 1992).
The significance of three origins of replication within the HSV-1 genome is unclear 
since mutational analysis has confirmed that all three origins together are not required 
for viral DNA replication in cell culture. OriL (Polvino-Bodnar et al., 1987) and at 
least one copy of oris (Longnecker and Roizman, 1986) but not both copies (Smith et 
al., 1989) are dispensable and oriL is not required for establishment and reactivation 
from latency in mice (Polvino-Bodnar et al., 1987). The origins appear to be 
functionally equivalent (Lockshon and Galloway, 1988) and it is likely that any two of 
the three is sufficient in vivo. However, Igarashi et al. (1993) successfully deleted both 
oris sequences with little effect on viral yields or viral DNA acummulation in infected 
cells, and thus none of the three may be uniquely required.
1.7.4. Gene requirements for DNA replication
Seven HSV-1 genes are essential for viral DNA replication: UL5, UL8, UL9, UL29, 
UL30, UL42 and UL52 (Schaffer et al, 1987; Wu et al, 1988). The function of each 
is described in Table 7. Fig. 9 illustrates the current model of events occurring at the 
replication fork. These proteins form complexes which are required for efficient 
replication.
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Table 7. HSV-1 DNA replication genes
F u n c t i o n G en e D e t a i l s R efe ren ce
Origin-binding
protein.
UL9 Binds to ori via the sequence 
CGTTCGCACTT. Possible hclicase activity  
and role in assem bly o f  the pre-initiation 
com plex w hich leads to the initiation o f  DNA  
synthesis.
Abbots and Stow , 1995; 
O livio , 1988; Elias et al., 
1990; K off e ta l . ,  1991; 
Gorbalenya et al., 1989; 
Fierer and Challbcrg, 
1992; Elias et al., 1990.
D N A  polymerase. 
(1:1 com plex)
U L30
UL42
Functions as the the replication subunit and 
also has proof reading 3 ’-5 ’ exonuclease 
activity and 5 ’-3 ’ exonuclease and RNasc 
activity. C om plexed to the U L42 protein via  
the C-terminus.
Has DNA binding activity and is thought to 
stabilise the binding o f  the U L30 protein to 
the template, leading to the production o f  
longer DNA products.
Chartrand el al., 1980; 
Ostrander and Cheng, 
1980; Crute and Lehman, 
1989; G allo et al., 1988; 
Digard et al., 1993; 
Marsden e ta l . ,  1983; 
G ottlieb et al., 1990; 
M ace and Alberts, 1984.
Hclicase and 
primase (unction. 
(1:1:1 com plex)
UL5
UL52
UL8
ATPasc and hclicase activities arc probably 
associated with U L5 since it shares m otifs 
w ith a superfamily o f  DNA and RNA  
helicases. U L5 does not act as a hclicase in 
the absence o f  U L52.
U L52 and U L5 form a com plex with enzym e 
activity indistinguishable from that ol the 
three protein com plex.
Is not required for enzym e activity, but may 
play a role in efficient nuclear uptake and 
stabilise the association between primer RNA  
and template D N A .
Crute e t al., 1988; 1989; 
W u e ta l . ,  1988; 
Hodgman, 1988; Dodson  
et al., 1989; Calder and 
Stow , 1990; Calder et al., 
1992; Sherman et al., 
1992.
Single-stranded 
DNA-binding  
protein (ssb).
UL29 Binds to and stabilises regions o f  ssD N A  at 
the replication fork. The C-terminal region 
contains D NA -binding sites.
B ayliss et al., 1975; 
Pow ell et al., 1981; G allo  
e ta l . ,  1989.
LEADING
STRAND
DNA helicase and primase 
(UL5, UL8, UL52)
ssb
(UL29)
r T=RNA
DNA polymerase 
(UL30, UL42)
LAGGING
STRAND
Fig. 9. Functions involved at the DNA replication fork
Adapted from a model provided by ND Stow.
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1.7.5. Cleavage and packaging of replicated DNA
Replication produces “endless” DNA which must be cleaved into unit-length molecules 
for packaging. The signal for cleavage has been determined as the a sequence. 
Tandem reiterations of the a sequence are found at the L-terminus and the L-S joint 
region of the genome, but only a single copy is found at the S terminus (Wilkie, 1976; 
Wagner and Summers, 1978). The functions of the a sequence include circularisation 
of the genome following infection, site-specific recombination and cleavage/packaging 
of the DNA (Davison and Wilkie, 1983; Poffenberger and Roizman, 1985). Although 
the sequence of the a sequence varies between strains (Davison and Wilkie, 1981; 
Mocarski and Roizman, 1981; 1982), two conserved regions (pad and pac2) located 
about 30 bp from each end of linear genomes appear to be essential for the cleaving and 
packaging process (Varmuza and Smiley, 1985; Deiss et al, 1986).
Replicated DNA is packaged into preformed capsids, since mutants defective in 
packaging still assemble capsids (Al-Kobaisi et al, 1991; Addison et al, 1984; 1990). 
Packaging mutants also fail to cleave replicated DNA into unit lengths, indicating that 
cleavage and packaging are closely linked (Preston et al, 1983). The scaffolding 
proteins VP22a and VP21 which are present in immature capsids are lost at the time of 
DNA packaging (Gibson and Roizman, 1972) (see Section 1.8.2). Deiss et al. (1986) 
proposed that a protein binds to an a sequence and in turn binds to a site on the capsid. 
The DNA is then injected into the capsid until a second a sequence in the same 
orientation as the first is reached, whereupon cleavage occurs. The model suggests that 
the region of DNA packaged is related to the distance between two direct repeats of the 
a sequence (Deiss et a l, 1986; Roizman and Sears, 1993). The internal a sequences 
can be deleted without fully inhibiting packaging (Poffenberger and Roizman, 1985; 
Jenkins and Roizman, 1986).
Two viral gene products, Vmw273 (encoded by UL36) and a protein encoded by an as 
yet unidentified gene, have been shown to interact with the a sequence (Chou and 
Roizman, 1989), and it is possible that these function in the cleavage and packaging of 
DNA. There are also a number of other viral genes that play a role in cleavage and 
packaging since viruses with mutations in these genes produce of capsids but fail to 
package viral DNA. These include, UL6 (Weller et a l, 1987; Patel et al, 1996), UL12 
(Shao et al, 1993; Weller et al, 1990), UL15 (Poon and Roizman, 1993; Baines et al, 
1994), UL25 (Addison et al, 1984), UL26 (Preston et al, 1983), UL28 (Addison et a l , 
1990; Tengelson et a l, 1993), UL32 (Coen et al, 1984) and UL33 (Al-Kobaisi et al,
1991) (see Table 5 for details).
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1.8. VIRION STRUCTURE
1.8.1. Core
Cryoelectron microscopy has shown that the core contains the viral genome in a tightly 
packed structure envisaged as a “ball of yam” (Booy et al., 1991). Early observations 
suggesting that the DNA is present in a toroidal manner around a central protein core 
(Furlong et al, 1972) were probably artifactual.
1.8.2. Capsid
The core is surrounded by an icosadeltahedral capsid which is 125 nm in diameter and 
is composed of five major proteins (Schrag et al, 1989). This shell is made up of 162 
capsomers: 150 hexavalent (hexons) and 12 pentavalent (pentons) capsomers arranged 
in an icosahedral lattice with the pentons located at the vertices and the hexons at the 
capsid faces and edges (Rixon, 1993). Cryoelectron microscopy has shown that all of 
the capsomers are cylindrical with central channels extending from the outside to the 
inside of the capsid. The hexons have six-fold symmetry and pentons have five-fold 
symmetry, and all of the capsomers are connected in groups of three by trigonal 
nodules or triplexes on the capsid surface (Schrag et al, 1989; Booy et al, 1991).
Three types of capsid may be isolated from virus infected cells (Gibson and Roizman, 
1972; Rixon, 1993): A (empty), B (intermediate) and C (full) (see Table 8). C capsids 
eventually form mature virions. A capsids contain the five capsid proteins of C 
capsids but lack DNA and are thought to be the end products of abortive DNA 
packaging (Newcomb and Brown, 1991). B capsids also lack DNA and contain the 
five proteins present in A capsids plus two additional scaffolding proteins which are 
lost during DNA packaging. There are two types of B capsid, small cored and large 
cored. It is thought that the large cored capsids become small cored and are then able 
to have DNA packaged into them (Rixon, 1993). C capsids may be derived from B 
capsids.
Capsid proteins assume the icosahedral structure spontaneously when a critical 
concentration of viral structural proteins is obtained in the nucleus (Pertuiset et al,
1989). Thomsen et al. (1994) and Tatman et al. (1994) investigated the assembly of 
HSV-1 capsids using a set of recombinant baculoviruses, each expressing one of the 
seven capsid proteins. Co-expression of six genes, UL18 (VP23), UL19 (VP5), UL35 
(VP26), UL38 (VP19C), UL26 (VP21, VP24) and UL26.5 (VP22a), resulted in 
formation of capsids in insect cells that were indistinguishable in appearance and
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Table 8. Capsid components
P r o te in G en e R o le A
ca p sid
B
c a p sid ca p sid
C o p yMr J
n u m b er3
V P5 UL19 M akes up the hexons and 
pentons.
+h + + 960
V P19C UL38 Com ponent o f the 
intercapsomeric triplex.
+ + + 320
V P23 UL18 Com ponent o f the 
intercapsomeric triplex.
+ + + 640
V P 24 UL26
(5’ portion)
Protease. + + + 147 ± 67
VP21 UL26
(3 ’ portion)
Scaffolding protein. c + - 87 ± 4 2
V P22a U L26.5 Scaffolding protein. - + - 1153
± 1 6 9
V P26 UL35 Located on the tips o f  the 
hexons.
+ + + 900
D NA - - + 1
a Copy numbers are empirical (±SD ) or precise (from a combination o f  empirical and theoretical data) 
(N ew com b et al., 1993). 
h Present. 
c N ot present.
mRNA
►
U L26 ORF
V P 2 4
mRNA
3 0 7
---------------------------------------►
U L 26.5  ORF 6 1 0 ^
W Z /7 //Z /7 7 7 Z 7 7 //? .
V P 2 2 a
Fig. 10. Organisation of UL26 and UL26.5 and derivation of VP21, VP22a and VP24
The UL26 ORF is denoted as an open rectangle and encodes proteins VP24 and VP21 (shaded rectangles), 
which are produced following cleavage at the sites indicated by arrows. The UL26.5 ORF (hatched 
rectangle) is contained entirely within UL26. Cleavage by the protease (VP24) at the site indicated 
produces VP22a. The numbers refer to amino acid residues in UL26. Adapted from Preston etal .  (1994).
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protein composition from those made during HSV-1 infection. Capsid assembly did 
not take place in the absence of UL18, UL19 or UL38, but absence of UL35 had no 
effect. Assembly in the absence of the UL26 gene products resulted in a large core 
phenotype and some intact capsid shells were formed in the absence of the major 
scaffolding protein VP22a. Omission of both UL26 and UL26.5 resulted in the 
formation of large numbers of partial or deformed capsid shells.
Genetic and structural studies suggest that the UL26 and UL26.5 proteins are important 
in the early stages of capsid assembly. UL26 encodes a protease (VP24) which cleaves 
within the UL26 protein to produce another scaffolding protein (VP21). UL26.5 is 
contained entirely within the UL26 ORF. The encoded protein is cleaved by VP24 to 
produces the scaffolding protein VP22a (see Fig 10). VP22a, the most abundant 
protein in B capsids, is thought to form a scaffold around which the capsid assembles 
(Preston et al., 1994). Insertion of the DNA molecule results in loss of VP21 and 
VP22a, and subsequent tegumentation and envelopment results in the formation of 
mature virions (Rixon, 1993).
There are thought to be minor capsid proteins which have yet to be identified. The 
protein encoded by UL6 has recently been shown to be a capsid component (Patel and 
MacLean, 1995). It is is essential in cell culture (Patel et al., 1996), and is required for 
DNA cleavage and packaging, but it is not known whether this is due to a direct role in 
these processes or as an indirect result of its possible structural role.
1.8.3. Tegument
The tegument contains the proteins encoded by UL11, UL13, UL21, UL25, UL36, 
UL37, UL41, UL45, UL46, UL47, UL48 and UL49 (see Table 5) in addition to several 
others whose genetic origins are yet to be identified.
The observation that some tegument proteins have roles in control processes, including 
Vmw65 (Section 1.6.2.) and vhs (Section 1.6.6.), suggests that others may have roles 
which enhance the viral life cycle when introduced into the cell by virus particles. It is 
possible, for example, that a subset of tegument components contributes towards 
maintaining structure while others are carried into the cell in order to function in 
control processes.
Following adsorption and penetration of the virus (see Section 1.8.4.), the nucleocapsid 
is released into the cytoplasm and transported to the nucleus (Batterson et al., 1983) via
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host cell microfilaments (Lycke et al, 1984). At the nuclear membrane, DNA release 
precedes disassociation of the capsid. The DNA enters the nucleus via the nuclear 
pores by a process that is not dependent on the presence of viral proteins (Hummeler et 
al., 1969). De novo RNA and protein synthesis are not required for uncoating, and this 
process may depend on a structural component of the vims or a cell enzyme (Hochberg 
and Becker, 1968). It has been shown that the tegument protein Vmw273 (MacNabb 
and Courtney, 1992), encoded by UL36 is essential for uncoating (Batterson et al., 
1983).
L-particles are virion-like enveloped structures that lack the capsid and core but contain 
most of the proteins normally found in virions, in addition to a few proteins absent 
from virions (Szilagyi and Cunningham, 1991; Rixon et al., 1992; McLauchlan and 
Rixon, 1992). They are released in equal amounts with virions from infected cells in 
cell culture. The assembly of L-particles occurs independently of virion maturation 
(Rixon et al, 1992), indicating that tegument formation is not dependent on capsid 
assembly (McLauchlan and Rixon, 1992).
The role of L-particles in the viral life-cycle is not known, but they have been shown to 
be as efficient as virions at delivering functional tegument proteins into cells 
(McLauchlan et al., 1992). This suggests that they could influence the infectious 
process by increasing the supply of tegument-derived helper functions. Vmw 175 is 
present in L-particles in significant amounts and its transactivating function could be 
significant at early stages of infection (McLauchlan and Rixon, 1992). Vmw65 in L- 
particles could also produce added transactivating activity. The role of L-particles in 
vivo has not been determined.
Yang and Courtney (1995) suggested that the host cell type influences the amount of 
Vmwl75 and VmwllO associated with the tegument of virions and L-particles. 
Virions released from Vero and Hep2 cells contain high levels of Vmw 175 and 
Vmwl 10, wheras low levels of these proteins were produced in BHK C13 cells. Also, 
Vmw 175 levels were high only in L-particles from BHK C13-infected cells. Thus the 
availability of transactivating proteins in the L-particles may only be important in some 
cell types.
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1.8.4. Envelope
The viral envelope has a trilaminar appearance (Epstein, 1962), and the presence of 
lipid was demonstrated by the sensitivity of virions to lipid solvents and detergents 
(Asher et al, 1969; Spear and Roizman, 1972). It is derived from patches of altered 
cellular membranes (Morgan et al., 1959) as the capsid and tegument buds through the 
nuclear or Golgi apparatus membrane (Torrisi et al., 1992).
So far HSV-1 has been shown to encode 10 glycoproteins (gJ has not yet been 
identified) (see Table 9). Their functions include adsorption, penetration, membrane 
fusion, envelopment, prevention of superinfection and egress. Glycoproteins are also 
involved in the immune response, and gE and gl together produce the IgG Fc binding 
component which may prevent recognition of the virus and infected cells by the host 
immune response. At least two non-glycosylated proteins are present in the envelope: 
UL49A (Barnett etal., 1992; R. Adams, personal communication) and the UL11 
protein which resides in the tegument but is also associated with the envelope via a 
myristoyl moiety (MacLean etal., 1992).
Entry of HSV-1 into a cell involves a number of events at the cell surface. Initial 
association with the host cell is mediated by the association of gC with heparin sulphate 
proteoglycans on the cell surface (WuDunn and Spear, 1989; Kaner, 1990; Shieh et al.,
1992). gC appears to be principally involved in adsorption of the virus to the cell 
surface (Kuhn et al., 1990; Herold et al., 1991), but gD and gB may also play a role 
since monoclonal antibodies against these can inhibit binding to the cell surface (Kuhn 
et al., 1990). However, there must also be an alternative pathway to gC binding, since 
mutants lacking gC can still attach with reduced efficiency (Herold et al., 1991). 
Adsorption via fibroblast growth factor receptors (Kaner et al., 1990) is restricted to a 
minority of cell types (Shieh and Spear, 1991; Muggeridge et al., 1992).
Penetration occurs by fusion of the virion envelope with the plasma membrane of the 
cell, and at least five glycoproteins, gB, gD, gH, gK and gL, are involved (Cai et al., 
1987; Ligas and Johnson, 1988; Desai et al., 1988; Fuller and Spear, 1987; Fuller et al., 
1989; Hutchison et al., 1992a; Roop et al., 1993). gB, gD, and gH are essential in cell 
culture. gK plays a role in controlling virus induced cell fusion and mutants are not 
viable (MacLean et al., 1991). gL plays a role in the production of the functional gH 
(Hutchison et al., 1992b). Although there is no definite molecular model for the fusion 
event, several results have indicated that gD may interact with a cellular receptor after 
initial binding of gC to heparan sulphate, since the resistance of cell lines to infection 
expressing large amounts of gD suggests that gD sequesters a receptor (Campadelli-
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Table 9. Properties of HSV-1 glycoproteins
. . HSV-1 glycoprotein
g B gC g D gE gG gH g l gJ gK gE gM
E ncoded by gene U L 27 U L 44 U S6 U S8 U S 4 U L 22 U S7 U S5 U L 53 UL1 U L 10
Present in a - ,  (3- 
and y -h erp esv iru ses
+a _b - - - + - - - + +
E ssen tia l for 
r ep lica tio n
+ - + - - + - - + + -
Present in v irions + + + + + + + ? c - + +
M ed iates
a d so rp tio n
+ + + - ? - - ? - - 7
E ssen tia l for 
p en etra tio n
+ - + - - + - - 7 + -
Primary role in cell 
fu s io n
+ - - - ? ? ? 7 + 7 7
N eu tra lization + + + + + + + ? 7 7 7
C ell-m ed iated
im m u n ity
+ + + + + ? 7 ? ? 7 ?
a Yes 
h N o
c Not known
A d a p ted  from  D a v iso n  and C le m e n ts  (1 9 9 6 ) .
C Y T O P L A S MN U C L E U S
( A)
T egument 
Proieins
(B)
T egument 
Proteins
Fig. 11. Models for viral tegumentation, envelopment and egress.
Two models, (A) and (B), are proposed. In (A), assembled capsids bud into the inner nuclear 
membrane and then out into the cytoplasm, where they acquire the tegument and then the envelope 
by budding through a cytoplasmic membrane (probably the Golgi), or (B), they gain the tegument 
before budding through the inner nuclear membrane, and gain the membrane from here. The virion is 
then released from the cell by exocytosis. Reproduced from Rixon (1993).
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Fiume et al, 1988; Johnson and Spear, 1989). Also, infection of cells can be prevented 
by prior exposure to UV-inactivated wt virus but not a gD' mutant (Ligas and Johnson, 
1988). The interaction of gD with a receptor is required for virus entry but not for 
adsorption which occurs whether or not the gD receptors are blocked (Ligas and 
Johnson, 1988; Johnson and Ligas, 1988). The precise roles of gD, gB and gH in viral 
penetration are not known. Moreover, it is possible that tegument proteins may 
participate in the molecular interactions required for penetration, since a ts mutant of 
UL25, which encodes a tegument protein, is deficient in penetration at the NPT 
(Addison er al, 1984).
1.8.5. Virus assem bly
Assembly of the tegument can be uncoupled from capsid assembly (McLauchlan and 
Rixon, 1992), but the mechanisms by which tegument proteins come together is 
unknown. The preformed tegument probably joins to the capsid and then undergoes 
envelopment. The envelope is derived from altered host cell membranes containing 
viral glycoproteins which may require further processing to reach their mature state 
(Spear, 1985). Two models of viral egress have been proposed (Fig. 11). Assembled 
capsids may acquire the tegument in the cytoplasm and then the envelope by budding 
through a cytoplasmic membrane (probably the Golgi), or they may gain the tegument 
in the nucleus and gain the membrane by budding from here. The virion is then 
released from the cell by exocytosis (Rixon, 1993). Recently, Browne et a l  (1996) 
presented evidence that viruses loose their initial membrane by fusion at the outer 
nuclear membrane endoplasmic reticulum and acquire their final membrane at the 
Golgi or post-Golgi compartment, as in model A (Fig. 11).
1.9. HSV-1 PATHOGENESIS
1.9.1. Animal models
HSV-1 causes a variety of diseases ranging from superficial cutaneous lesions to 
encephalitis in humans (Whitley, 1985). Various animal models have been used to 
study pathogenicity, including mice, rabbits and guinea pigs. Genes involved in 
pathogenesis in vivo have been analysed in these models by inoculation of wt virus or 
mutants at various sites: most commonly, the footpad, ear, eye, peritoneum or directly
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into the cranium. The pathogenicity of mutants is usually expressed as the titre of virus 
required to kill 50% of animals. Severity of disease can also be assessed, by measuring 
weight loss, determining the physical appearance of the animal, and by quantification 
of the production of visible lesions. In this way a number of host factors important in 
pathogenesis have also been identified, including the immune response (McKendall et 
al, 1979; Nash et al, 1985), interferons (Lopez et al, 1985), the condition of skin and 
mucous membranes (Sprecher and Becker, 1982), the age of the animal (Ben-Hur et 
al, 1983) and the route of inoculation (Dix etal., 1983).
1.9.2. Viral determinants
Many viral gene products affect pathogenicity, including glycoproteins, enzymes 
involved in DNA replication and repair, and the protein products of genes UL56, US 1, 
RL2, UL48, UL41, UL46, UL47, US3 and RL1. The animal models used to date to 
identify the genes involved in pathogenesis and to determine their roles are detailed in 
Table 10 A-C. There is no doubt that there are more genes important in pathogenesis 
still to be identified. It should be noted that the avirulence of many of these mutants 
may be due to their poor replication ability.
Table 10 A-C summarises the studies that have been carried out using mutants to 
identify virulence determinants. All of the studies carried out for each gene have been 
included except for those where a large amount of data is available and two to four 
main studies have been discussed (UL23, UL39/40, RL1, RL2 and UL48). Most 
studies have been done using only a single mutant or variant, in 4-15 mice per dilution 
of virus, and results were usually reported for a single experiment. Many of the reports 
used intertypic recombinants between HSV-1 and HSV-2. These are of limited value 
since precise genotypes were not determined, and other mutations may have 
contributed towards the virulence phenotype. Other mutants tested contained insertions 
or deletions generated specifically, but the link between genotype and phenotype was 
not established by the use of revertants (i.e. mutants rescued in vitro to wt).
In Table 10 A-C it can be seen that a wide range of experimental procedures have been 
used to investigate the roles of genes in pathogenesis. Systems differ in the type of 
animal used, the site of inoculation, the strain of virus, the type of mutant and the titres 
tested. The age and general state of health of the animals is also an important variable. 
Many workers did not produce revertants, and thus the observed effect cannot be 
confidently linked to the interrupted gene. Also, in the latency experiments, many 
workers did not test the genotype of the reactivated virus and so cannot be sure that the
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Chapter 1: Introduction
mutant and not a revertant arising in vivo is reactivating. Thus care is needed when 
interpreting data from the current literature since the investigations may not have been 
sufficiently thorough. A few good studies have been reported, but many suffer from 
the failings described. A summary of the data (discussed in greater detail in Chapter 5) 
is described below.
1.9.2.1. Glycoproteins
Glycoproteins play an important role in the early stages of the virus life cycle, 
including adsorption and penetration (see Table 9). All of those investigated except gC 
(UL44) are required for growth in the CNS (Johnston et al., 1986; Dix et a l, 1983; 
Sunstrum et al., 1988), although only three have been shown to be essential for virus 
growth in cell culture (gB, gD and gH) (see Table 10A). Because of the role of 
glycoproteins in adsorption and penetration, the failure of mutants to cause pathology 
in mice may be due to the failure of cell-to-cell spread, so that mutants may be able to 
replicate at the periphery but are unable to spread to the CNS.
1.9.2.2. Proteins involved in DNA replication
The DNA polymerase (UL30), the UL5 protein (part of the helicase/primase activity), 
TK (UL23), RR (UL39/UL40), dUTPase (UL50) and the UL2 protein have roles in 
pathogenicity (see Table 10B). UL30 variants are less neurovirulent than wt, UL5 
mutants are also avirulent but establish latency efficiently. TK is not essential for the 
establishment of latency but mutants fail to reactivate. RR mutants are less virulent 
and cannot form reactivatable latent infections in mice, but neurovirulence is not 
impaired in the guinea pig. A dUTPase mutant has a reduced ability to establish and 
reactivate from latency and is less virulent, but it has been established that the mutation 
also affected the UL49A promoter. A UL2 mutant is avirulent, can establish latency 
but reactivates poorly.
1.9.2.3. Others
Table IOC lists other genes involved in virulence and latency.
UL56
Analysis of an intertypic recombinant showed that UL56 is involved in neurovirulence, 
but an insertion mutant was later found to be as virulent as wt by IP inoculation and
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could establish and reactivate from latency normally. Further investigation is required 
to determine the true role of the UL56 protein in vivo.
US1
Use of a Vmw68 mutant indicated that US1 contributes to virulence, to the ability of 
the virus to replicate at the site of infection and to the ability to establish and reactivate 
from latent infection.
RL2
Vmwl 10 mutants show reduced virulence compared to wt. They can establish latency 
but Vmwl 10 is thought to be important for reactivation. Several groups have come to 
different conclusions, one Vmwl 10 mutant failed to reactivate without induction, 
another reactivated but at a reduced efficiency while a third reactivated the same as wt. 
In an in vitro latency system (see Section 1.10) reactivation only occurs when Vmwl 10 
is available.
UL48
Investigations using the Vmw65 mutant ml814 (see Section 1.10) have revealed that 
the mutant can establish latency and reactivate normally. The virulence is greatly 
reduced compared to wt.
UL41
Vhs mutants did not grow as well as wt in the brains of mice, and established and 
reactivated from latent infection at a reduced level.
UL46 or UL47
The use of mutants with a deletion in UL46 or UL47 revealed that although these genes 
are non-essential in cell culture, they are required for neurovirulence. The UL46 and 
UL47 proteins are involved in the modulation of Vmw65 activity, and the effect may 
be linked to this role since Vmw65 mutants are avirulent. The mutants have no effect 
on ocular pathogenicity.
US3
A lacZ  insertion mutant of HSV-2 has shown route-dependent avirulence, being 
virulent via the eye or IC but avirulent via FP or IP inoculation. The mutant can 
establish and reactivate from latency as efficiently as wt. An HSV-1 mutant has yet to 
be analysed in vivo.
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RL1 (ICP34.5)
Thompson et a l (1983) located a determinant of neurovirulence in HSV-1 RL. The 
gene involved, RL1 (^34.5) encodes a protein of 284 residues in strain F (Chou and 
Roizman, 1990) and 263 residues in strain 17+ (Dolan et al, 1992).
In cell culture, RL1 mutants replicate as wt viruses on some cell lines (e.g. Vero cells) 
whereas on others, including the human neuroblastoma cell line SK-N-SH, host and 
viral protein synthesis is inhibited early in infection and all protein synthesis ceases 
several hours before normal completion of the replicative cycle. Also, growth of 
mutants is impaired on mouse embryo fibroblast 3T6 cells (Chou and Roizman, 1994).
The RL1 protein (ICP34.5) is expressed early in infection, although the use of 
inhibitors of DNA synthesis reduced production slightly. The C-terminal domain 
possesses striking homology to a mouse protein MyD116 induced during cell 
differentiation (McGeoch and Barnett, 1991), a Chinese hamster protein, GAAD34, 
which is induced by growth arrest and DNA damage (Chou and Roizman, 1994) and an 
African swine fever virus protein which is thought to have a role in host range 
determination (Sussman et al, 1992). These homologous genes may have a role in 
blocking apoptosis in terminally differentiated cells.
ICP34.5 is a major neurovirulence determinant that seems to work by limiting the 
response of the host cell to infection in preventing the stress response which normally 
leads to total shut down of protein synthesis and programmed cell death (Chou and 
Roizman, 1992). Recently He et a l (1996) have shown that the C-terminus of 
MyD116 can substitute for the corresponding domain of ICP34.5 and successfully 
preclude premature shut-off of total protein synthesis.
In the absence of ICP34.5, HSV-1 fails to multiply in the CNS of mice following 
intracerebral inoculation, although limited replication was detected in the urogenital 
tract after intravaginal inoculation (Spivack et al, 1995). Mutants also fail to replicate 
in the neurons of the peripheral nervous system although they are capable of 
establishing and reactivating from latency (Robertson et a l, 1992). Spivack et a l  
(1995) investigated the behaviour of ICP34.5 mutants in a mouse model of latency, and 
concluded that ICP34.5 may have a role in reactivation that is independent from LAT. 
Pemg et a l  (1995) reported the involvement of ICP34.5 in virulence using the rabbit 
eye model. A deletion mutant appeared to establish and maintain latency but with 
much lower efficiency than wt virus, and ICP34.5 was not essential for spontaneous 
reactivation.
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The situation concerning RL1 is complicated by the recent identification of a novel 
expressed open reading frame, ORF P, on the opposing strand, which has 248 codons 
and is almost completely antisense to RL1 (Lagunoff and Roizman, 1994). Mutations 
in RL1 will also interrupt ORF P and so the effects observed with RL1 mutants may 
not be due to disruption of RL1 alone.
1.10. HSV-1 LATENCY
All herpesviruses examined to date have the ability to establish and maintain latent 
infections (Roizman and Sears, 1987) and can exist for extended periods of time in 
infected individuals. The basic concept of HSV-1 latency is the maintenance of 
circular or concatameric, extrachromosomal viral DNA in the nuclei of neuronal cells 
and limited transcription from these genomes. Latency can be divided into several 
stages: viral replication at the peripheral site of infection, transport of the viral particles 
to the nervous system, establishment of latent infection, maintenance of the latent state 
and reactivation. In true latent infection, virus cannot be detected until reactivation and 
replication take place, whereas persistent infection produces a low level of virus 
throughout infection, often with asymptomatic shedding.
1.10.1. Animal models
Several animal models have facilitated studies of HSV-1 latency, the most frequently 
used of which are mice, rabbits and guinea pigs. It is important to note, however, that 
no single model can mimic the situation in humans.
Following inoculation of the animal with HSV-1, latency is established in tissues 
enervating the site of inoculation. Latent virus can then be reactivated by exposing the 
animal to various stimuli, including UV light or heat shock, or by explantation of the 
ganglia and cocultivation with permissive cells. The models of latency described in 
Table 11 (also see Table 10A-C) have been valuable for examining latency and host- 
virus interactions and have enabled genes with important roles in viral pathogenesis 
and host responses to be investigated.
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Table 11. Animal models of latency
Reference Animal* S iteb Reactivation factors Features of system
Hill et al., 
1975; 1978.
M Ear Some spontaneous 
reactivation, increased by UV 
light, ice or tape stripping of 
the skin of the ear.
Latent infection established in cervical 
ganglia and DRG. Reactivation 
characterised by erythma or vesicles at 
inoculation site.
Sawtell and 
Thompson, 
1992a.
M eye, FP, 
S
Hyperthermic stress at 43°. Latent infection in lumbosacral DRG and 
TG. Reactivation in only a small 
proportion of neurons.
Fawl and
Roizman,
1993.
M eye Cadmium administration. Only CdS04 and no other 
metallothioneins induced reactivation.
Shimeld et 
al., 1989.
M eye Iontophorosis with 
cyclophosphamide and 
dexamethasone.
Treatment causes ocular shedding of virus 
in 50% of animals.
Cook et al., 
1991a, b; 
Kwon et al., 
1981; Haruta 
et al., 1989.
R eye Iontophorosis as above, also 
with adrenaline.
Small percentage of spontaneous ocular 
shedding and induced shedding with 
treatment. Latent infection in cornea 
cells and TG.
Stanberry et 
al.,
1985a,b; 
1992.
GP IV, IU No treatment required. Self-limiting primary infection. Latent 
infection established in lumbosacral 
DRG. Spontaneous reactivation.
a M=mouse; R=rabbit; GP=guinea pig 
b FP=foot pad; S=snout; IV=intravaginal; IU=intraurethral
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1.10.2. Sites of latency
Goodpasture (1929), suggested that HSV-1 remains in the ganglia in a latent state after 
the local lesion has healed. Later, HSV-1 was isolated from human peripheral sensory 
ganglia (PSG) (Stevens and Cook, 1971), the trigeminal ganglia (TG) and spinal 
ganglia, the autonomic nervous system (Price et al, 1975), the brainstem (Deatly et al, 
1988) and the cerebral hemispheres (Fraser et a l, 1981). The possibility of 
extraneuronal latency has been investigated in experimental animals, and HSV-1 was 
demonstrated in the skin (Clements and Subak-Sharp, 1988), cornea (Abgharis and 
Stulting, 1988) and adrenal medulla (Stevens, 1978). However, disorders caused by 
reactivation usually result from reactivation from nervous tissue.
Following peripheral inoculation of virus, HSV-1 DNA can be detected in the relevant 
PSG. Viral replication at the periphery is not essential for this process, since 
replication-deficient mutants can reach the PSG and establish latent infection in ganglia 
(Steiner et a l, 1990). Once the virus reaches the PSG it can resume replication and 
infect neurons as well as satellite cells in the PSG. Following a full replication cycle in 
PSG neurons, infectious particles can leave the neuron to infect satellite cells within the 
ganglion and proceed by retrograde axonal transport to the central nervous system 
(CNS) where the same pattern of replication takes place. In the CNS the virus can also 
spread transneurally via synapses. After a period of 10-14 days following primary 
infection, no replicating or infectious virus can be detected in the nervous system of the 
infected animal and the virus is deemed to have entered the latent state.
Replication is thought to be initially dependent on the presence of sufficient amounts of 
Vmw65 which enables initiation of the replication cascade. Studies with a mutant, 
m l814, which contains a 12 bp insertion in Vmw65 rendering it unable to form the IE 
transactivation complex and stimulate IE transcription but not impairing the structural 
role of the protein (Ace et al, 1989), suggest that replication occurs in the nucleus only 
when sufficient amounts of Vmw65 are available in the cell body, a process which 
results in cell destruction. The lack of Vmw65 aborts replication at a very early stage 
of infection (Valyi-Nagy et al, 1991 a,b) and enables the infected cell and thus the 
latent HSV-1 genome to survive.
1.10.3. State of the latent genome
The entire genome of HSV-1 has been detected in the ganglia of latently infected mice 
by Southern blotting (Rock and Fraser, 1983, 1985). The latent DNA is maintained as 
a circular molecule or in a concatemeric form (Rock and Fraser, 1983, 1985; Efstathiou
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et al, 1986) and is not integrated into the host genome (Mellerick and Fraser, 1987). 
Partial micrococcal nuclease digestion has demonstrated that latent DNA is associated 
with nucleosomes in a pattern similar to that of the host nuclear chromatin structure 
(Deshmane and Fraser, 1989). It has been suggested that the nucleosomes may be 
necessary for the long term stability of the genome and may have some involvement in 
silencing of the genome during latency.
Estimates of the number of copies of the viral genome per latently infected cell range 
from 0.01-1, but these are probably underestimates. The importance of copy number is 
not known, but it has been suggested that a low number is associated with viral 
inability to initiate replication within the nucleus, whereas a high number may facilitate 
reactivation (Roizman and Sears, 1987; 1990; Fraser et al., 1991). In vitro, a Vmw65 
mutant (Ace et al, 1989) and a Vmw68 mutant (Sears et al., 1985) are both replication- 
deficient, a condition which can be overcome by increasing the moi in cell culture.
1.10.4. Establishment and maintenance of latency
The virus reaches the neuronal cell body by travelling along the axon from the 
periphery or after replication in an adjacent cell. The lytic viral replication cycle will 
eventually shut off host cellular protein synthesis and result in cell death, and so 
latency cannot be established in cells in which the virus has completed a full replication 
cycle (Steiner and Kennedy, 1991). Viral or cellular factors that interfere with viral 
replication will therefore favour the establishment of latency. During transport to the 
nucleus (Lycke et al., 1984; 1988) the amount of Vmw65 that is lost may determine the 
fate of the infection. If sufficient remains, lytic replication and cell destruction will 
occur, but if there are insufficient amounts, the lytic replication cascade will not begin 
and a latent infection will be formed.
Latchman et a l  (1989) suggested that cellular factors have an important role in 
facilitating the establishment of latency. For example, a cellular promoter may 
compete for some limiting factor required for transactivation by Vmw65. The role of 
Vmw65 in the virus lifecycle is to direct the limited amount of Octl in the infected cell 
away from cellular genes and towards TAATGARAT-containing genes, allowing 
transcriptional activation of the EE genes to occur. The failure of EE gene expression in 
neuronal cells is likely to be caused by differences in the nature of cellular transcription 
factors. The factor which has been identified as the lymphocyte- and neuron-specific 
octamer binding protein (Oct2), is present in DRG neurons, the natural site of HSV-1 
latency in vivo (Lillycrop et al, 1991, 1994). Experimentally, raised levels of Oct2 can
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repress the IE promoter by preventing binding of transactivating Octl protein to 
TAATGARAT (Perry et al, 1986), or by virtue of the fact that Oct2 cannot form a 
complex with Vmw65 (Gerster and Roeder, 1988). It is not known which viral 
functions are required for the establishment of latency or if any viral genes are 
expressed at this stage.
Neither the TK gene (Efstathiou et al., 1989; Coen et al, 1989) or the IE proteins 
Vmwl 10, Vmwl75 or Vmw63 (Leib et al, 1989a,b; Clements and Stow, 1989) are 
required for the establishment of latency, but the deficient replication of such mutants 
may render the reactivation inefficient. There are a number of complex viral and 
cellular interactions which likely to be involved in the establishment and maintenance 
of latency, but they are not yet fully understood.
1.10.5. Gene expression during latency
The only region of the genome which is transcribed during latency is located largely 
within Rl (Stevens et al., 1987, 1988) and specifies RNAs which accumulate during 
latency (Rock et al., 1987). The LATs are transcribed in the opposite direction from 
RL2 (encoding Vmwl 10), overlaping the RL2 mRNA at its 3’ end by approximately 
700 bp (see Fig. 12B). The LATs have been shown to consist of several RNA species. 
A large 8 kb RNA, which has been detected in latently infected TG (Zwaagstra et al,
1990), is considered to be the primary transcript from which the other LATs are 
derived (Fig. 12D) (Deatly etal., 1987; 1988). Three collinear LATs of 2, 1.5 and 1.45 
kbp have been detected by Northern blot analysis of RNA isolated from latently 
infected ganglia (Spivack and Fraser, 1987). Only the 2 kbp LAT has been detected 
during viral replication in cell culture and at much lower levels than are present in 
latency (Krause et al, 1988). This LAT is thought to be a stable intron formed by 
splicing of the 8 kbp primary transcript (Farrel et a l, 1991; Devi-Rao et al., 1991), and 
the 1.5 and 1.45 kb LATs are thought to be spliced products from the 2 kb transcript 
(Wagner, 1988b). However, if the 2 kb LAT is an intron then this situation is unusual, 
since introns are not usually further processed and the 6 kb LAT RNA which would 
result from splicing of the 8 kb LAT to remove the 2 kb intron has not been identified.
The LAT promoter (see Fig. 12 C) found upstream of the 5’ end of the 2 kb LAT 
(Batchelor and O’Hare, 1990) controls the entire region transcribed during latency, 
since mutants with lesions within the promoter do not have any detectable LATs 
produced (Steiner et al., 1989). The region contains binding sites including a TATA 
box, CAAT and CREB sites (Batchelor and O’Hare, 1990), and there are potential
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binding sites for Vmwl75 and Vmw65. The activity of the promoter is repressed by 
Vmwl75 but there is little effect by Vmw65 (Batchelor and O’Hare, 1990).
1.10.6. Function of the LATs
The initial hypothesis about the function of the LATs was that that they are antisense 
inhibitors of RL2 (Stevens et al., 1987). Thus, they could inhibit the expression of 
Vmwl 10, shut off viral replication and promote maintenance of latency. This 
hypothesis implied that LAT mutants would replicate better, express higher levels of 
Vmwl 10, fail to establish latent infections or reactivate more efficiently than wt virus. 
LAT mutants, however, are not impaired in their ability to establish and maintain 
latency (Deshmane et al., 1993), replicate normally in vivo and in cell culture, express 
normal levels of Vmwl 10 (Leib et al, 1989b; Steiner et al., 1989) and are able to 
reactivate from latency normally or somewhat less well than wt viruses (Steiner et al., 
1989; Block et al., 1990). Therefore, the role of LATs as antisense RNAs has been 
dismissed.
A second possibility is that the LATs could act via a translation product (see Fig. 12E). 
Two ORFs are located at the 3’ end of the LATs, beyond the proposed intron and 
splicing site of the 2 kb LAT. They have been shown to encode 30 kDa and 12 kDa 
polypeptides by in vitro transcription-translation (Spivack et al., 1991), but these 
proteins have not been detected during HSV-1 replication or latency. In an in vitro 
latency model, an 80 kDa protein from the region including part of ORF 1 was 
identified (Doerig et al., 1991a), but the size is not consistent with the sequence data. 
Also, these ORFs are not conserved between HSV-1 and HSV-2 (McGeoch et a l ,  
1991). It remains to be seen if this or any other protein is expressed during latency in 
vivo.
Thus, the function of the LATs has not yet been determined.
1.10.7. Reactivation of latent infection
Reactivation of HSV-1 and HSV-2 in humans results in cold sores or genital lesions 
respectively, and can be triggered by a number of stimuli including injury to the tissue 
innervated by the neuron harbouring the latent infection, exposure to UV light, or 
certain stress situations (Hill et al., 1975). However, reactivation is not associated with 
significant damage or destruction of latently infected neurons and so must differ from 
the mass cell destruction observed in cell culture during HSV-1 lytic infection. The
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main question posed by the phenomenon of reactivation concerns how replication 
begins in the absence of Vmw65 which normally initiates IE gene expression. It has 
been shown that lack of functional Vmw65 prevents reactivation in cell culture (Ace et 
al., 1989), but explant reactivation of the mutant m l814 from latently infected mouse 
TG occurs similarly to wt (Steiner et al., 1990). It is possible that an increase in the 
number of HSV-1 genomes per latently infected cell overcomes the lack of Vmw65 in 
the same way that the mutant can replicate in cell culture at high moi (Roizman and 
Sears, 1990). The observation that compounds such as HMBA and DMSO can 
enhance the reactivation of HSV-1 (Leib et al., 1989a) and improve the replication of 
m l814 in cell culture (McFarlane et a l, 1992) suggests that they can replace the 
transactivation function of Vmw65. Thus, it is possible that viral or cellular factors act 
similarly.
The LAT promoter contains a cAMP-responsive element, and cAMP has been shown 
to increase reactivation of wt HSV-1 viruses (Leib et al., 1991), indicating that 
reactivation might occur via second messenger signal transduction. In one in vitro 
system, nerve growth factor (NGF) is required to maintain the latent state, and removal 
of the compound results in reactivation (Wilcox and Johnston, 1987, 1988). Also, NGF 
mRNA has been detected in the peripheral sensory ganglia (PSG) of latently infected 
mouse ganglia post explantation, at the same time as reactivation was occurring (Valyi- 
Nagy et al., 1991b). Thus, NGF and cAMP may be implicated in reactivation, but their 
role, if any, requires clarification.
1.10.8. In vitro models
There are two main features required in an in vitro latency system if it is to mimic the 
situation in viva non-integrated viral DNA in an endless conformation and expression 
of the LATs. Many of the systems employed involve infection of cells in culture with 
HSV-1 under unnatural conditions, including, the use of ts mutants at the NPT or 
addition of agents such acyclovir which prevents viral DNA replication and 
cyclohexamide which prevents protein synthesis (Wigdahl et al., 1982; Russell and 
Preston, 1986; Cook and Brown, 1987; Wilcox and Johnson, 1987). Owing to these 
features, results from such systems need to be considered cautiously. None of the in 
vitro systems described in Table 12 mimics the in vivo situation exactly, but the ability 
to reactivate latent genomes simultaneously is useful in characterising the 
establishment, maintenance and reactivation of latency at the molecular level.
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Table 12. In vitro models of latency
R e fe r e n c e s Cell type Inhibitors which 
induce/maintain the 
latent state
Induction of 
r e a c t iv a t io n
Features o f the system
Wilcox and 
Johnson, 
1987; 1988; 
Wilcox et al. , 
1990; Doerig 
et al.,
1991a,b.
Sensory neurons 
from DRG of rats, 
monkeys or 
humans.
Acyclovir. Removal of NGF. 
Activation of 
phosphokinase C or 
cAMP pathways.
100% of neurons reactivate 
and the 2 kb LAT is 
expressed. Structure of latent 
genome is unknown. 
Unconfirmed report of a LAT- 
encoded protein.
Nilheden et al., 
1985 a, b.
C l300 mouse
neuroblastoma
cells.
Treat cells with 
neutralising HSV-1 
antibody.
Superinfection with 
HSV-2.
Genome is maintained in an 
endless state.
Wigdahl et al., 
1982; 1983; 
1984.
Human embryo 
lung fibroblasts 
or rat foetal 
neurons.
(E)-5-(2- 
bromovinyl)-2’- 
deoxyuridine plus 
IFNa, incubation 
at 40.5°.
Remove inhibitor and 
incubate at 37°, or 
superinfect with 
HCMV.
Genome is non-integrated and 
linear. LATs are not 
expressed.
Russell and 
Preston, 1986; 
Harris et al., 
1989.
Human foetal lung 
cells (HFL).
Low moi infection, 
incubation at 42°.
Superinfection with an 
HS V-1 ts mutant or wt 
HCMV.
Genome is non-linear. No 
inhibitors are required.
Harris and 
Preston, 1991.
HFL. Use of the Vmw65 
mutant i«1814 at 
low moi plus AraC 
teatment. Incubate 
at 37° or 42°.
Superinfection with a 
virus expressing 
Vmwl 10.
Genome is non-linear. LATs 
are not expressed.
Jamieson et 
al., 1995; (CM 
Preston and LH 
Robinson, 
unpublished 
data).
HFL. Use of the 
Vmw65/Vmwl 10 
mutant in 1820 at 
high moi, plus 
IFNa and AraC 
treatment.
Superinfection with a 
virus expressing 
Vmwl 10.
Genome is non-linear, and 
associated with nucleosomes. 
LATs are not expressed.
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Despite the fact that the latency systems of Preston and co-workers do not express 
LATs, they do have several advantages over the inhibitor-induced systems. 
Incidentally, the absolute requirement for the expression of LATs in latency has not 
been determined, and it is thought that many latently infected neurons do not express 
LATs (Ramakrishwan, 1994; Mehta et al., 1995). In the first system, the use of high 
temperatures avoided the use of inhibitors, the latent state was stable, a high proportion 
of cells harboured a reactivatable infection, the latent genomes were non-linear and 
Vmwl 10 was the sole requirement for reactivation (Russell and Preston, 1986). Later, 
the use of the Vmw65 mutant ml814 (Ace et a l, 1989) which establishes latency in 
HFL cells (Harris and Preston, 1991) and a mutant (m l820) which has the Vmw65 
insertion and also behaves like a Vmwl 10 mutant in HFL cells have been useful 
models (Jamieson et al., 1995). These represent useful tools in the study of the 
molecular aspects of latency and reactivation without the added complications of host 
responses to infection in vivo.
1.11. AIMS OF THE THESIS
1.11.1 Background 
Genes
HSV-1 UL14, UL15, UL16 and UL17 are part of a block of genes (UL10 to UL19) 
which is conserved among the alpha-, beta- and gammaherpesviruses (Davison, 1993). 
They are expressed as late mRNAs (McGeoch and Schaffer, 1992).
UL15 is the only spliced gene in U l (McGeoch et al., 1988). UL15 homologues in the 
three herpesvirus subfamilies have an equivalent structure with two exons, and a 
variable number of genes (2-4) in the intron (Dolan et al., 1991). In contrast, the 
proposed counterpart in CCV has three exons, and the boundary between the first and 
second exons corresponds precisely to that in other herpesviruses (Davison, 1992). 
Construction of an HSV-1 mutant expressing UL15 without the intron has shown that 
separation of the two exons is not essential for replication of HSV-1 in cell culture 
(Baines and Roizman, 1992b). The effect of the absence of the intron in an animal 
model has not been reported.
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The UL15 protein contains potential ATP-binding motifs (Dolan et al., 1991), and a 
possible function was suggested by Davison (1992) who noted that the UL15 protein 
may be related to a protein encoded by T4 bacteriophage gene 17. This protein is part 
of the phage terminase, or DNA packaging protein complex, and mutations result in the 
arrest of phage production during DNA packaging, leading to an accumulation of 
empty proheads and uncleaved concatemeric DNA (Bhattachorgga and Rao, 1993; 
Powell e ta l, 1990; Carrascose and Kellenberge, 1978).
During the course of this work, Poon and Roizman (1993) described a ts mutant with a 
lesion in UL15. The mutant produced viral DNA at the NPT, but failed to package it 
into capsids. In a subsequent paper, Baines et al. (1994) showed that the UL15 gene 
encodes two proteins (one is a truncated form of the full length UL15 protein, similar to 
the situation with UL26 and UL26.5, see Section 1.8.2). The full length protein is 
necessary for cleavage and packaging of viral DNA. The published data on UL15 are 
therefore consistent with the view that UL15 is a subunit of the herpesvirus terminase.
No mutants have been described for UL14 or UL17, and the roles of the protein 
products of these genes are not known. The status of both genes in cell culture is also 
unknown, although Baines and Roizman (1991) suggested from their inability to obtain 
a mutant that UL17 may be essential.
The function of the UL16 protein is unknown although it has been shown to be non- 
essential in cell culture (Baines and Roizman, 1991). Growth curves of a mutant 
lacking 988 bp of UL16 (1119 bp) indicated that yields of UL16' virus in Vero or BHK 
cells were reduced from those of wt (10- or 3-fold respectively) (Baines and Roizman,
1991).
Cosmids
The manipulation of large fragments of HSV-1 DNA is difficult, but in principle the 
cosmid system should permit easier manipulation and production of mutants. Mutants 
produced using a mutant cosmid set can be isolated in the absence of a background of 
wt virus, and even viruses which have multiple mutations or are at a severe growth 
disadvantage to wt can be isolated. A set of 5 cosmids, comprising cos32, cos24 
(which contains genes UL14-17 in a region which does not overlap adjacent cosmids), 
cos 46 (which contains a proportion of oriL+ molecules), cos51 and cos48, which 
together contain the entire HSV-1 sequence were utilised (see Fig 13) to generate 
frameshift mutations in genes UL14-17 (further details in Section 4.1).
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1.11.2 Aims
The aims of this thesis were firstly to modify an available cosmid set to enable the 
production of mutations in HSV-1 genes UL14 to UL17, and to produce mutant 
cosmids with 4 bp insertions in UL14, UL15 and UL17. The second stage was to 
ascertain whether UL14, UL15 or UL17 are essential by attempting to generate virus 
mutants on non-complementing cell lines, and to produce virus mutants in these genes 
on potential complementing cell lines where necessary. The third stage was to produce 
UL16‘ mutants and characterise their phenotypic features in vitro and in vivo. The last 
stage was to attempt to detect the UL14, UL16 and UL17 proteins.
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2.1. Cells and viruses
Wild type HSV-1 strain \ T  (Brown et al., 1973) and mutants derived therefrom were 
grown in baby hamster kidney clone C l3 (BHK C l3) cells (MacPherson and Stoker, 
1962) or MeWo cells (Bean et al., 1975). A number of other cell lines were used in the 
in vitro analysis of UL16‘ viruses, details are given in Table 17 Section 4.1.
2.2. Cell culture growth media
Components of media and some complete media were produced in house by the media 
department or were supplied by Gibco-BRL.
Eagles A: 0.23 g/1 CaCl2.2H20  
0.23 g/1 M gS04.7H20  
0.1 ml/1 cone HC1
Eagles B: 50% (v/v) salts/plus 
40% (v/v) amino acids/plus 
3.2% (v/v) vitamins
salts/plus: 10.24 g/1 NaCl
0.64 g/1 KC1
0.24 g/1 NaH2P 0 4.2H20
7.2 g/1 glucose
0.00016% (v/v) Fe2(N 03)3
0.468 g/1 L-glutamine
0.016% (v/v) penicillin
0.16 g/1 streptomycin
0.00032% (v/v) amphotericin B (0.025%)
amino acids/plus: 0.84 g/1 arginine mono HC1
0.48 g/1 cystine
0.384 g/1 histidine mono HC1
1.048 g/1 isoleucine
1.048 g/1 leucine
1.462 g/1 lycine mono HC1 
0.66  g/1 phenylalanine 
0.952 g/1 threonine 
0.16 g/1 tryptophan
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0.724 g/1 tyrosine 
0.936 g/1 valine 
0.3 g/1 methionine 
0.07 g/1 inositol 
0.03% (v/v) phenol red 
55 g/1 NaHC03
vitamins: 0.05 g/1 choline chloride
0.05 g/1 folic acid
0.05 g/1 nicotinamide
0.05 g/1 pantothenic acid, Ca salt
0.05 g/1 pyridoxal HC1
0.05 g/1 thiamine HC1
0.005 g/1 riboflavine
ETC 10: 70% (v/v) Eagles A
10% (v/v) Eagles B
10% (v/v) tryptose phosphate
10% (v/v) newborn calf serum (NBCS)
ETF10: As above with NBCS replaced by foetal 
calf serum (FCS)
ETC5:
EC2:
As for ETC 10 but with 5% (v/v) NBCS
85.75% (v/v) Eagles A 
12.25% (v/v) Eagles B 
2% (v/v) NBCS
Methyl cellulose overlay: 39% (v/v) carboxymethylcellulose
1.56% (v/v) tryptose phosphate
3.9% (v/v) NBCS
24.3% (v/v) NaC03 (7.5%)
1.56% (v/v) penicillin/streptomycin 
(10000  IU/ml)
0.8% (v/v) L-glutamine (200mM) 
0.08% (v/v) amphotericin B
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7% (v/v) 10 x Glasgow’s modified 
medium
Emetr: 7:1 (v/v) Eagles AiEagles B lacking
methionine
Emet+: Ernet" containing:
20% (v/v) 7:1 (v/v) Eagles A:Eagles B 
2% (v/v) NBCS
Ecys- : 7:1 (v/v) Eagles A:Eagles B lacking 
cystine
Ecys+ : Ecys" containing:
20% (v/v) 7:1 (v/v) Eagles A:Eagles B 
2% (v/v) NBCS
Dulbecco’s medium: 500 ml Dulbecco’s modified Eagle
medium
9% (v/v) FCS
1% (v/v) penicillin/streptomycin
1% (v/v) L-glutamine
1% (v/v) non-essential amino acids
Cell storage medium: 55.6% (v/v) Eagles A 
7.2% (v/v) Eagles B 
7.2% (v/v) tryptose phosphate 
25% (v/v) FCS 
10% (v/v) glycerol
2.3. Bacterial strains
Escherichia coli (E. coli) XLl-Blue (Stratagene), MAX efficiency D H 5a and DH5a 
FIQ  competent cells were used (Gibco-BRL). The genotype of each is as follows: 
XLl-Blue - recA, endAl, gyrA96, thi-1, hsdR17, supE44, relA l, lac, [F’ proAB, 
lacIqZAM15, TnlOitef)]. DH5oc - F \  cp80d/acZAM15, A(lacZYA-argF), U169, deoR, 
recA 1, end A l, hsdR\l(rK~, n^-), supE44, X', thi-1, gyr A96, relAl. DH5aF’IQ - F’,
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<p80d/<zcZAM15, A(lacZYA-argF), U169, deoR, recA 1, end A l, /zs<iR17(rK-, mK-), 
supE44, X', thi-l, gyr A96, re lA l/F p ro A B +, /«cIqZAM15, z^f::Tn5[Kmr]-
2.4. Bacterial growth media
2YT broth:
L-broth:
L-broth agar:
Top agar:
SOC medium:
TSB:
TSB/DMSO
TSB/glucose:
85 mM NaCl 
1% (w/v) bactopeptone 
1% (w/v) yeast extract
177 mM NaCl 
1% (w/v) bactopeptone
1.5% (w/v) agar in L-broth
0.6% (w/v) bacto-agar in H20
2% (w/v) bactopeptone 
0.5% (w/v) yeast extract 
10 mM NaCl 
25 mM KC1 
10 mM MgC03 
10 mM MgS04 
20 mM glucose
L-broth containing:
10% (w/v) PEG 3350 
10 mM MgCl2 
10 mM MgS04
TSB containing 5% (v/v) DMSO 
TSB containing 20 mM glucose
2.5. Radiochemicals
These were obtained from the Radiochemical Centre, Amersham.
Hexaprimer and nonaprimer kits for radiolabelling DNA probes were obtained from 
Appligene (details of the labelling process is given in Section 3.14).
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2.6. Enzymes
All restriction endonucleases and buffers were obtained from Bethesda Research 
Laboratories (BRL), New England Biolabs or Boehringer Mannheim.
Lysozyme (3 x crystallized, dialysed and lyophilized) and ribonuclease A (type II-A; 
DNAse free) were obtained from Sigma Chemical Co.
Trypsin (modified, sequencing grade) was obtained from Promega or Boehringer 
Mannheim.
2.7. Chemicals
The chemicals used were of analytical grade and most of these were supplied by BDH 
Chemicals or Sigma Chemical Co.
The exceptions were:
Geneticin G-418 sulphate: Gibco BRL.
Ampicillin (Penbritin): Beecham Research.
Ammonium persulphate (APS) and N,N,N\N’-tetramethylethylenediamine (TEMED): 
Bio-Rad Laboratories Ltd.
Sulforhodamine B: Kodak.
Coomassie brilliant blue: Bio Rad Laboratories.
100 mM dGTP, dATP, dTTP, dCTP, 5 mM deaza-dGTP, ddGTP, ddATP, ddTTP, 
ddCTP: Pharmacia.
ECL Western blotting detection reagents: Amersham Life Sciences.
Ecoscint A: National Diagnostics.
En3Hance: DuPont.
2.8. Plasmids
The plasmid vector used to construct p8A and pl4, pl5 and p l7  was pUC19gD/neor, 
which was provided by Dr A Patel. pUC19gDIned  consists of pUC19, the neomycin 
resistance gene driven by the SV40 late promoter and the HSV-1 US6 (gD) promoter 
upstream from two unique restriction sites (Kpnl, Bglll). In some constructs the gD 
promoter was used to drive inserted genes (p i5, Section 4.1.4) in others, inserted genes 
were inserted under the control of their own promoters. Plasmids pGEM-1 and pGEM- 
2 were obtained from Promega and were used for the construction of plasmids to be 
used in transcription and translation assays. Plasmid pMJ511 was produced by Dr A.J. 
Davison and modified by Dr V.G. Preston. The cosmids used are described in Section 
4.1. They are derived from the SuperCosl vector (Stratagene) which contains a 
bacterial origin of replication, dual cos sites, the ampicillin resistance gene for 
prokaryotic selection and the neomycin marker under the control of the SV40 promoter 
for expression in eukaryotic cells.
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2.9. Protein blotting for mass spectrometric analysis
10 x PVDF buffer: 0.5 M Trizma base 
0.5 M glycine
Transfer buffer: 1 x PVDF buffer 
20% (v/v) methanol 
0.01% (w/v) SDS
Matrix: 10 mg/ml a-cyano-4-hydroxycinnamic 
acid in 50% (v/v) acetonitrile plus 
0 .1% (v/v) trifluoroacetic acid
Sulforhodamine stain: 50 mg/1 sulforhodamine
30% (v/v) methanol 
0 .2 % (v/v) acetic acid
Formic acid/ethanol: 1:1 (v/v) formic acid:ethanol
2.10. Protein gels
(i) Single concentration acrylamide/NN’-methylenebisacrylamide gels
Acrylamide solution: 37.5 g acrylamide and 
1 g NN’methylenebisacrylamide 
in 100 ml H ,0
Stacking gel buffer: 0.5 M Tris-HCl pH 6.8
Resolving gel buffer: 1.5 M Tris-HCl pH 8.8
Electrophoresis buffer: 6 g/1 Trizma base 
57.6 g/1 glycine 
0.2% (w/v)SDS
Destain solution: 30% (v/v) methanol 
10% (v/v) acetic acid
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Stain solution: Destain solution containing 0.1% (w/v) 
Coomassie brilliant blue
Boiling buffer: 16% (v/v) stacking buffer 
5% (w/v) SDS 
10% (v/v) glycerol 
0.5 mM dithiothreitol (DTT) 
1% (w/v) bromophenol blue
(ii) Single concentration acrylamide/DATD gels
Acrylamide solution:
Resolving gel buffer
30 g acrylamide and
0.5 g diallyltartardiamide (DATD)
in 100 ml H20
185 g/1 Tris-HCl
4 g/1 SDS
to pH 8.8
Stacking gel buffer: 59 g/1 Tris-HCl 
4 g/1 SDS 
to pH 6.8
Electrophoresis buffer: 63.2 g/1 Tris-HCl 
4 g/1 glycine 
1 gA SDS
Stain solution: 0.25 g/1 Coomassie brilliant blue 
45% methanol 
9% acetic acid
Destain solution: 17% (v/v) acetic acid 
44% (v/v) ethanol
(iii) Gradient acrylamide/NN’-methylenebisacrylamide gels
Electrophoresis buffer: 63.2 gA Tris
4.0 gA glycine
1.0 gA SDS
53
Chapter 2: Materials
Acrylamide solution:
Fix solution: 
Stain solution: 
Destain solution: 
Boiling buffer:
2.11. BHK C13 transfections
HeBS buffer:
HeBS/DMSO:
Optimem medium and lipofectamine for 
were obtained from Gibco BRL.
95 g acrylamide and 
5 g NN’-methylenebisacrylamide 
in 100 ml H20
50% (v/v) methanol 
7% (v/v) acetic acid
0.2% (w/v) Coomassie brilliant blue in 
fix solution
5% (v/v) methanol 
7% (v/v) acetic acid
30% (v/v) stacking gel buffer (Section 
2 .1 0 (ii))
6 % (w/v) SDS 
30% (v/v) glycerol 
15% (v/v) (3-mercaptoethanol 
1 % (w/v) bromophenol blue
8 g/1 NaCl 
0.37 g/1 KC1
0.1 g/1 anhydrous Na2H P04 
1 g/1 D-glucose 
5 g/1 Hepes 
to pH 6.9
20% (v/v) DMSO in HeBS buffer 
transfecting cells by the lipofection method
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2.12. Agarose gel electrophoresis
lOxTBE:
DF dyes:
2.13. Small scale DNA preparation
TE:
GTE:
GTE/lysozyme:
SDS/NaOH:
STET buffer:
STET/lysozyme:
2.14. Southern blotting
20 x SSC:
109 g/1 Tris 
55 g/1 boric acid 
9.3 g/1 EDTA
37.2 g/1 EDTA
100 g/1 Ficoll 400
50% 10 x TBE
1% (w/v) bromophenol blue
10 mM Tris-HCl pH 8 
1 mM EDTA
2.5 mM D-glucose 
6.25 mM Tris-HCl pH 8 
10 mM EDTA
4 mg/ml lysozyme in GTE
1% (v/v) SDS 
5% (v/v) 10M NaOH 
in GTE (prepared fresh)
5% (v/v) Triton X-100 
50 mM EDTA 
0.5 M Tris-HCl pH8 
8% (w/v) sucrose
4 mg/ml lysozyme in STET buffer
174 g/1 NaCl
88.2 g/1 sodium citrate
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50 x Denhardt’s solution: 1% (v/v) Ficoll 4000 
1% (w/v) polyvinylpyrrolidone (PVP) 
1% (w/v) bovine serum albumin 
3 x SSC
Hybridisation buffer: 3 x SSC
5 x Denhardt’s solution 
0.1 g/1 calf thymus DNA 
0.1% (w/v) SDS 
20 mM Tris-HCl pH 7.5
Wash buffer: 2 x SSC
0.1% (w/v) SDS 
20 mM Tris-HCl pH 7.5
Gel soak I: 175 g/1 NaCl
40 g/1 NaOH
Gel soak II: 121.1 gA Tris
35 g/1 NaCl 
to pH 8 with HC1
TCA: 5% (w/v) trichloroacetic acid
Rapid-hyb buffer, used for prehybridisation and hybridisation in some experiments, 
was obtained from Amersham Life Sciences.
2.15. Western blotting
Western blot transfer buffer: 3 g/1 Tris
14.4 gA glycine 
80% (v/v) methanol 
to pH 8.3 with HC1
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Complete PBS:
PBS A/BSA:
PBS A/Tween 20/BSA:
PBS A/Marvel/BSA:
2.16. DNA Sequencing
PEG/NaCl:
40% acrylamide solution: 
Top gel mix:
Bottom gel mix:
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170 mM NaCl 
35 mM KC1
1 mM Na2HP04
2 mM KH2P 0 4
PBS A
6.8 mM CaCl2
4.9 mM MgCl2
0.05% (w/v) BSA in PBS A
0.1% (v/v) Tween 20 
1% (w/v) BSA 
in PBS A
0.05% (w/v) BSA
5% (w/v) Marvel (low fat milk
substitute)
in PBS A
20% (w/v) PEG 6000
2.5 M NaCl
40 g acrylamide
5 g NN’-methylenebisacrylamide 
in 100 ml HzO
460 g/1 urea 
0.5 x TBE
6% (v/v) acrylamide solution
460 g/1 urea
50 g/1 sucrose
50 mg/1 bromophenol blue
2.5 x TBE
6% (v/v) acrylamide solution
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Formamide dyes: 1 g/1 xylene cyanol FF
1 g/1 bromophenol blue 
10 mM EDTA 
in deionised formamide
X-gal:
IPTG:
2 mM dNTPs:
Chase solution:
dNTP/ddNTP solutions: volumes in pi
40mg/ml 5-bromo-4-chloro-3-indoyl p- 
D-galactopyranoside in 
dimethyl formamide
30mg/ml isopropyl 
p-D-thiogalactopyranoside
2 mM each of dGTP, dATP, dTTP, 
dCTP
0.125 mM each of dGTP, dATP, dTTP 
and dCTP
G A T c
TE 2000 1000 2000 2000
0.5 mM 7-deaza- 
dGTP
50 1000 1000 1000
0.5 mM dTTP 1000 1000 50 1000
0.5 mM dCTP 1000 1000 1000 50
5 mM ddGTP 20 - _
5 mM ddATP 2 _
5 mM ddTTP - 50
5 mM ddCTP - - 7
2.16. Other buffers
Low pH citrate buffer: 0.4 M citric acid
0.1MKC1 
0.135 M NaCl 
to pH 3 with HC1
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5 x ligase buffer:
Ficoll gradient solutions:
Cell lysis buffer:
Stripping buffer: 
PBS/calf:
PBS A/SDS:
Versene:
Trypsin:
Tris-saline:
Trypsin/versene:
3 M Tris-HCl pH 7.5 
30 mM MgCl2 
30 mM DTT 
1.45% (w/v) PEG 6000
5% (w/v) Ficoll in Eagles A 
plus Eagles B without phenol red; 
15% (w/v) Ficoll in Eagles A 
plus Eagles B without phenol red
0.6% (w/v) SDS 
10 mM Tris-HCl pH 7.5 
1 mM EDTA 
5 mg/1 protease
1% (v/v) NP40 in PBS A
14% (v/v) NBCS in PBS A
1% (w/v) SDS in PBS A
0.6 mM EDTA 
0 .0002% (w/v) phenol red 
in PBS A
0.25% (w/v) trypsin dissolved in Tris- 
saline
140 mM NaCl 
30 mM KC1 
280mM Na2HPO4 
25 mM Tris-HCl pH 8 
1 mg/ml glucose 
0.1 mg/ml streptomycin 
100 units/ml penicillin 
0.0015% (w/v) phenol red
1:1 (v/v) trypsin:versene
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2.17. Immune precipitation
Zweig’s buffer:
RIPA buffer:
0.1 M Tris-HCl pH 8
10% (v/v) glycerol
0.5% (v/v) NP40
0.5% (w/v) sodium deoxycholate
0.2 mM phenylmethylsulphonyl
fluoride
1% (v/v) NP40
1% (w/v) sodium deoxycholate 
0.1% (w/v) SDS 
Im M D TT 
in PBS A
2.18. HSV-1 DNA preparation
RSB: 10 mM Tris-HCl pH 7.4
lOmMKCl 
15 mM MgCl2
RSB/NP40: 0.5% (v/v) NP40 in RSB
NTE: 10 mM Tris-HCl pH 7.4
100 mM NaCl 
1 mM EDTA
2.19. Miscellaneous
The following items were used in addition to standard laboratory materials and 
equipment:
Spin-X centrifugation filter tubes: Costar.
Sephaglas BandPrep kits: Pharmacia LKB Biotechnology.
Hybond-N nylon membrane: Amersham Life Sciences.
Immobilon-P polyvinylidene difluoride microporous membrane: Millipore 
Corporation.
TnT™ SP6 and T7 coupled reticulate lysate system: Promega.
Kodak X-OMAT XS-1 and duplicating film: Kodak.
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Antibodies potentially directed against the UL16 and UL17 proteins were supplied by 
Charles Cunningham.
Electroporator II and electroporation cuvettes 0.1 cm: Invitrogen.
3MM chromatography paper: Whatman.
UV Stratalinker 1800: Stratagene.
61
Chapter 3
Methods
Chapter 3: Methods
3.1. Cell culture
BHK C13 cells and MeWo cells were grown in ETC10 or Dulbecco’s medium at 37° in a 
humidified atmosphere comprising 95% (v/v) air and 5% (v/v) C 02. The cells were 
harvested from plastic roller bottles by pouring off the medium and washing the 
monolayer with 20 ml versene. They were then washed twice with 20 ml trypsin/versene 
to remove the monolayer and resuspended in fresh medium at a concentration of 
approximately 107 cells/ml. For experimental use, the cells were incubated in 24 x 5 mm 
or 6 x 35 mm well tissue culture plates as required.
3.2. Virus stocks
BHK C13 cells were grown in roller bottles until 90% confluent in Dulbecco's medium, 
and then infected. The medium was replaced with 50 ml of Dulbecco's medium, and the 
appropriate virus dilution was added in 500 |il of Dulbecco's medium. The roller bottles 
were gassed with C 02 to 5% (v/v) and returned to 37°. The infected cells were incubated 
at 37° and harvested when the cpe was maximal (usually 2-4 days pi). Infected cells 
were shaken into the medium and pelleted by centrifugation at 2000 rpm using a Sorvall 
RC-5B refrigerated Superspeed centrifuge for 5 min. The supernatant was decanted and 
the cell pellet was resuspended in 1-2 ml of complete PBS, to give the cell-associated 
virus stock. The supernatant was centrifuged again at 12,000 rpm for 1 h and the pellet 
was resuspended in 1-2 ml of complete PBS to give the cell-released virus stock. Both 
stocks were disrupted in a bath ultrasonicator at 4°, frozen on dry ice and stored at -70°. 
Virus stocks were titrated before use.
3.3. Titration of virus stocks
Virus stocks were titrated at 37° on 80-90% confluent monolayers of BHK C13 cells on 
35 mm 6-well trays in Dulbecco’s medium. Aliquots of 200 fil of virus dilutions 
(usually 10‘3 to 10‘8) were added to drained monolayers and the plates were returned to 
the incubator for 1 h before being overlayed with 3 ml methyl cellulose overlay. After 2- 
4 days the overlay was removed and the plates were stained with Giemsa stain for 30 min 
at room temperature. The plaques were counted under a dissection microscope and the 
virus titre established.
3.4. Picking plaques
Plaques were picked using sterile 20 jul pipette tips, placed into 1 ml of Dulbecco’s 
medium, sonicated and stored at -70°.
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3.5. Particle counts
Equal volumes of the virus stock, latex beads (at a known concentration) and stain (1% 
phosphotungstic acid pH 7.0) were mixed and adsorbed onto a parlodion-coated copper 
grid. Excess liquid was drained off and the numbers of virus particles and latex beads 
present in the field of view of the electron microscope were counted. The concentration 
of the virus particles was calculated by comparison with the number of latex beads. The 
particle counts were carried out by Mr J. Aitken.
3.6. Virus absorption
(a) At 4°
90% confluent BHK C13 cells in 35 mm 6-well plates were precooled to 4° for 30-60 
min, infected with 200 pfu virus/plate in 500 pi of Dulbecco's medium and maintained at 
4°. Non-adsorbed virus was removed by washing the monolayers twice with PBS A at 
0, 15, 30, 45, 60, 90, 120 or 240 min pi. Plates were overlayed with 3 ml methyl 
cellulose overlay, incubated at 37° for 2-3 days and then stained with Giemsa stain by 
removing the overlay, replacing it with stain for 30 min at RT, washing the plate with 
water and air drying. The number of plaques on each plate was counted and the number 
at each time point was calculated as a percentage of the virus adsorbed at 240 min. The 
percentage of virus bound at each time point was calculated as the mean of the plaque 
count from three plates.
(b) At 37°
The experiment was carried out as described above except that the cells were maintained 
at 37° for times of 0, 5, 10, 15, 20, 30, 45, 60, 90 and 120 min pi.
3.7. Virus penetration
90% confluent BHK C13 cells in 35 mm 6-well plates were precooled to 4° and infected 
with 200 pfu virus/plate in 500 pi of Dulbecco's medium. Virus was adsorbed at 4° for 
10 min and non-adsorbed virus was removed by washing twice with 2 ml of cold PBS 
A. Low pH citrate buffer was added to three wells of one 6 well plate and PBS A was 
added to the other three. The plate was incubated at 4° for 5 min before being washed 
twice with 2 ml of PBS A and overlayed with methyl cellulose overlay and placed at 37° 
C. The low pH citrate buffer wash removes unpenetrated and unbound virus and the 
PBS A wash removes unbound virus only. The remaining plates were taken to a 37°C 
room, overlayed with preheated Dulbecco's medium at 37° and incubated at 37° for 5, 
10, 15, 20, 30, 45 or 60 min. The medium was then replaced by 1 ml of low pH citrate
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buffer or PBS A. After 5 min at 37°, the plates were washed twice with PBS A, 
overlayed with methyl cellulose overlay and incubated at 37° for 2 days. The plates were 
stained with Giemsa stain and plaques were counted. The percentage of virus bound at 
each time point represents the mean of the plaque count from three plates and was 
calculated as a percentage of the virus that penetrated at the same time point when the 
cells were washed with PBS A.
3.8. One-step growth curve
Confluent monolayers of BHK C13 cells on 35 mm 6-well plates were infected at a moi 
of 5 pfu/cell in Dulbecco’s medium and incubated at 37° for 1 h. The cells were washed 
once with low pH citric acid buffer, twice with PBS A, and overlayed with 2 ml 
Dulbecco's medium. The zero time point sample was harvested immediately after 
washing and further samples were harvested at 3, 6, 9, 12, 16, 20, 24, and 36 h pi by 
scraping the cells into the medium with a rubber policeman. The samples were sonicated 
using a waterbath and titrated using confluent BHK C13 cells as described previously in 
Section 3.3. The virus yield at each time point was calculated in pfu/ml.
3.9. Multi-step growth curve
This was carried out as described for the one-step growth curve (Section 3.8), except that 
BHK C13 cells were infected at 0.01 pfu/cell in Dulbecco’s medium and harvested at 0, 
6, 12, 24, 36, 48, 60, 72 and 96 h pi.
3.10. Radiolabelling of virus particles
Confluent roller bottles of MeWo or BHK C l3 cells were infected with the appropriate 
virus in Dulbecco’s medium at low moi for 12-24 h. The monolayers were washed in 
low methionine medium (Emet+) and then incubated in this medium for 4 h at 37°. [35S]- 
methionine was then added (500 pCi/roller bottle) in 20-40 ml Emet+ and incubation was 
continued for 3-4 days. Virions and L-particIes were prepared, resuspended in 100-200 
jil of Dulbecco's medium and stored at -70° (see Section 3.18).
3.11. Radiolabelling infected cells
(a) Long term labelling
35 mm 6-well plates of 80-90% confluent BHK C l3 cells were infected with virus in 
Dulbecco’s medium at 2.5 x 107pfu/plate at 37° for 1 h. The plates were washed twice
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with Emet+ or Ecys+ medium and then maintained in 1 ml of the appropriate medium. At 
4 h pi, 50 pCi of [35S]-methionine or [35S]-cystine was added directly to the plate. At 
20-24 h pi, the sample was harvested by washing twice in PBS A, adding 250 pi of 
boiling solution and heating the plate at 80° for 5 min. The lysed cells were transferred 
to a vial, heated at 100° for 5 min and stored at -70°.
(b) Pulse labelling
35 mm 6-well plates of 80-90% confluent BHK C13 cells were washed with Emet+ or 
Ecys+ medium and incubated in 2 ml of the appropriate medium for 1 h at 37°. Cells 
were infected with virus diluted in the appropriate medium at 2.5 x 107pfu/plate for 1 h at 
37°, washed and maintained in Emet+ or Ecys+ medium. At appropriate times the 
monolayers were washed in Emef or Ecys', 50 pCi of [35S]-methionine or [35S]-cystine 
were added and the incubation continued at 37° for 2 h. The cells were washed twice in 
PBS A and lysed by the addition of 250 pi of boiling solution. The labelling times were 
0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-10 h, 10-12 h, in addition to 4-24 h long term labelling.
The harvested samples were electrophoresed on a 5-12.5% gradient polyacrylamide gel 
and a 12% single concentration gel (see Section 3.16). The gels were fixed for 1 h, 
destained for a minimum of 1.5 h with three changes of destain buffer, treated with 
En3Hance, dried for 1.5 h at 80°C on a gel drier, and autoradiographed at -70°.
3.12. Binding of virus to cells
[35S]-methionine labelled virions were prepared as described previously (Section 3.11). 
They were titrated on BHK C13 cells, the radioactivity was counted and particle counts 
were obtained. Confluent monolayers of BHK C13 cells were infected with 
approximately 100,000 particles/cell (approximately 10-100,000 cpm) in 200 pi of 
Dulbecco’s medium. Infected cells were maintained at 37° for 0, 5, 10, 15, 20, 30, 45, 
60, 90 or 120 min, then the supernatant was transferred into a scintillation vial for 
counting. The monolayers were washed three times with 1 ml PBS A, the washes were 
collected together and 300 pi from the 3 ml final volume were prepared for scintillation 
counting. 200 pi of PBS A/1% SDS was added to the monolayers for 5 min and the 
lysed cells were scraped into a vial for scintillation counting. 4 ml of Ecoscint A was 
added to each vial and the radioactivity of the samples was counted in a scintillation 
counter for 4 min, using a program for detecting 35S. The percentage binding of viral 
particles was determined by the equation: (a/a+b+lOc) x 100, where a= radioactivity of 
cells, b= radioactivity of supernatant and c= radioactivity of the washes.
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3.13. Infected cell DNA
Confluent monolayers of BHK C13 cells in 24-well trays were infected with virus 
diluted in 500 pi of Dulbecco’s medium for 1 h at 37°. The virus aliquot was replaced 
by 1 ml of medium and the trays were incubated at 37° until complete cpe was observed. 
400 pi of cell lysis buffer was added and the cells were incubated at 37° for 1-4 h. The 
lysed cells were transferred to a vial containing 30 (il of 5 M NaCl and extracted with 400 
pi of phenolichloroform (see Section 3.23). The DNA was ethanol precipitated by 
mixing the DNA sample with two volumes of ethanol and incubating at -20° for up to 1 
h, then centrifuged at 12,000 rpm for 10 min and resuspended in 40 pi 5 pg/ml RNase A 
(see Section 3.23).
3.14. Southern blotting
(a) Labelling of probe
A hexa- or nona-primer kit from Amersham was used to label and purify probes. 
Usually 1 pg of plasmid DNA containing the appropriate HSV-1 fragment to be used as a 
probe was denatured at 100° for 10 min, quenched on ice for 5 min and then centrifuged 
briefly at 12,000 rpm. 4 pi of nonaprimer, 1 pi each of dATP, dTTP, dCTP and 5 pi of 
[32P]-dGTP were added to the vial. 1 pi of this mixture was spotted onto two Whatman 
disc filters (A and B), then 1 pi of the Klenow fragment of E. coli DNA polymerase I 
was added and the vial incubated at 37° for 1 h. After incubation, 1 pi was spotted onto 
a third filter (C). To purify the probe, 60 pi of absorb solution and 2 pi of resin were 
added and the mixture was vortexed and centrifuged briefly. The pellet was resuspended 
in 100 pi of wash buffer, centrifuged at 12,000 rpm briefly and resuspended in 100 pi of 
elute solution. The vial was placed at 65° for 5 min and then centrifuged at 12,000 rpm 
briefly. The supernatant was heated at 100° for 2 min and then stored at -20°. 50 pi of 
purified probe was used for each membrane hybridisation.
The filters (A, B and C) were used to estimate the percentage incorporation of the probe. 
Filters B and C were washed three times for 5 min in cold 0.5% trichloroacetic acid then 
twice in ethanol. Filter A was not washed. Dried filters were placed in vials containing 5 
ml Ecoscint A and counted in a scintillation counter. The percentage incorporation was 
calculated from the equation [(C-B) / A] x 100. Usually 75-95% incorporation was 
obtained.
(b) Transfer of DNA
DNA samples were electrophoresed on an agarose gel and denatured by two 20 min 
washes in gel soak I, followed by two 20 min washes in gel soak II at RT. Hybond-N
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membrane was cut to size (approximately 10.5 x 13.5 cm) and soaked in 20 x SSC 
before use. The gel was placed on a platform with filter paper bridging a reservoir of 20 
x SSC buffer. The membrane was placed on top and care was taken to remove air 
bubbles. Filters and paper towels which were cut to the correct size (approximately 9.5 x
12.5 cm) were placed on top and then a weight was added. Blotting occurred at room 
temperature overnight. The membrane was removed, dried at RT for 15 min and UV 
cross linked using a UY Stratalinker 1800.
(c) Hybridisation
The membrane was wrapped in a nylon sheet and placed into a hybridisation bottle in 50 
ml of hybridisation buffer. The membrane was incubated in a hybridisation oven at 65° 
for 3-4 h and then the probe was added (50|il, see Section 3.14(a)). Incubation was 
continued overnight at 65°, then the membrane was washed with 50 ml of blot wash 
buffer. The membrane was rinsed with blot wash buffer and then incubated at 60° with 
blot wash buffer a further six times for 15 min each. The membrane was soaked in 25% 
(v/v) cold blot wash buffer, air dried and placed in a plastic bag for autoradiography at 
RT or -70°.
3.15. Blotting by centrifugation and rapid hybridisation
Samples were electrophoresed using a small agarose gel kit, and the gels were treated in 
the same way as described in Section 3.14b, except for the inclusion of an initial 5 min 
wash step using 0.2 M HC1. The gel and membrane were placed together in a sandwich 
of 3MM filter paper and centrifuged at 1000 rpm for 1 h. The membrane was air dried, 
UV cross-linked and pre-hybridised in a bottle containing 15 ml of Rapid-hyb buffer at 
65° for 15 to 60 min. The probe was added and hydridisation continued at 65° for a 
further 2 h. The membrane was washed four times for 10 min with blot wash at 65°, 
rinsed in 50% (v/v) cold blot wash buffer, air dried and autoradiographed.
3.16. Polyacrylamide gel electrophoresis 
Single concentration gels
(a) Stocks of acrylamide/NN’-methylenebisacrylamide were prepared and dialysed using 
Amberlite beads. Polymerisation was initiated by addition of 1.125ml of 1.5% (w/v) 
APS and 108 |il of TEMED per 45 ml of resolving gel solution and 1.4 ml of APS and 
48 pi of TEMED per 20 ml of stacking gel.
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(b) Single concentration 30% (v/v) acrylamide/0.5% (v/v) DATD gels were also used. 
Polymerisation was initiated by addition of 240 jil of 10% (v/v) APS and 35 |il of 
TEMED per 40 ml of resolving gel solution and 100 (il of APS and 10 (il of TEMED per 
15 ml of stacking gel solution.
The resolving gel solution was poured between two well-washed glass plates separated 
by 1.5 mm spacers and sealed with Teflon tape. Butan-2-ol was layered on top of the 
resolving gel solution until it polymerised, then removed prior to adding the stacking gel 
solution, into which was placed a Teflon well-forming comb. Before electrophoresis, 
protein samples were boiled for 5 min in boiling solution to denature them and applied to 
the gel which was electrophoresed overnight at 10 mA at RT.
Gradient gels
From a stock of acrylamide/NN’-methylenebisacrylamide a 30% stock of acrylamide 
solution containing 19:1 acrylamide/NN’-methylenebisacrylamide was made. From this 
stock, a 5% acrylamide solution was polymerised by the addition of 450 fxl of 10% (v/v) 
APS and 30 |xl of TEMED per 72 ml and a 12.5% (v/v) solution was polymerised using 
198 |il of 10% (v/v) APS and 30 \l\ of TEMED per 72 ml.
The gel was poured using a gradient mixer between two well-washed glass plates 
separated by 1.5 mm spacers and sealed with tubing. Butan-2-ol was layered on top of 
the gel solution until the latter polymerised and was replaced by a 5% (v/v) acrylamide 
stacking gel, into which was placed a Teflon well-forming comb. The samples were 
electrophoresed at 10 mA overnight at RT.
3.17. Staining gels with Coomassie brilliant blue
Following electrophoresis, proteins were fixed for 30 min in fix solution and then stained 
in the appropriate stain solution. This was followed by destaining in the appropriate 
destain solution for at least 1 h or (usually) overnight.
3.18. Preparation of virions and L-particles
Ten roller bottles of BHK C l3 or MeWo cells were infected at a low moi with the 
appropriate virus diluted in Dulbecco’s medium. After incubation at 37° for 3-4 days 
(BHK C13 cells) or at 31 °C for 4-5 days (MeWo cells), the infected cells were shaken 
off into the medium and centrifuged at 2000 rpm for 5 min. The supernatant was 
decanted and centrifuged at 12,000 rpm for 2 h. The pellet was resuspended in 1-2 ml
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complete PBS and carefully layered on top of a 5-15% (w/v) Ficoll gradient. The 
gradient was centrifuged in a Sorvall ultracentrifuge (Du Pont) at 12,000 rpm for 2 h at 
4°. Virions and L-particles were removed from the gradient via needle puncture, diluted 
to 30 ml in complete PBS and pelleted by centrifugation at 20,000 rpm for at least 40 
min. The pellets were carefully resuspended in 100 pi of complete PBS, frozen on dry 
ice and stored at -70°.
3.19. Fractionation of virions and L-particles
Five pi of 10% NP40 in PBS A was added to 45pi of a virion or L-particle preparation 
and incubated on ice for 20 mins, mixing occasionally. The sample was centrifuged at
12,000 rpm for 10 min at 4°. The supernatant containing the envelope fraction was 
transferred to a fresh vial. The capsid-tegument pellet was resuspended in 500 pi of 1% 
NP40 in PBS A, sonicated and pelleted by centrifugation at 12,000 rpm for 10 min at 
4°, and the pellet resuspended in 50 pi of complete PBS. To each sample of the 
envelope and capsid-tegument fraction, an equal volume of boiling solution was added, 
and the samples were incubated at 100° for 5 min, frozen on dry ice and stored at -70°.
3.20. Blotting polyacrylamide gels for mass spectrometric analysis
The electrophoresed gel was cut to size and soaked in transfer buffer for at least 5 min. 
The membrane was prepared by soaking in methanol and then in transfer buffer for 5 
min. The membrane was applied to the gel and they were sandwiched between two filter 
papers and electroblotted at 100 V for 1 h at RT. The membrane was removed, washed 
extensively in distilled water and dried in vacuo overnight. The membrane was stained 
with sulforhodamine solution for 1 min, washed in water and air dried.
3.21. Mass spectrometric analysis of virion proteins
A photograph of the stained membrane was taken using a photo-imager (Appligene). 
Appropriate bans were excised from the membrane and placed into 0.5 ml tubes, 3 pi of 
trypsin (sequencing grade) in 50 mM ammonium bicarbonate containing 1% (w/v) n- 
octyl p-D-glucopyranoside (Sigma) was added and the tubes were incubated at RT 
overnight. 6 pi formic acid:ethanol (1:1 v/v) was added for 1 h at RT to elute the 
peptides, then 0.5 pi of each sample was placed onto the mass spectrometer loading strip 
and air dried. 0.5pl of matrix solution containing insulin B chain as a size marker was 
added to each sample and air dried before insertion into the mass spectrometer (Finnigan 
MAT Lasermat). The sample was subjected to laser desorption mass spectrometric
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analysis (Pappin et al., 1993, 1994), producing a mass spectrum characteristic of the 
protein analysed. The protein was identified using the Massmap software (Finnigan 
MAT), where the peptide profile produced is compared to the theoretical tryptic peptide 
profiles of proteins stored in a database.
3.22. Transformation of bacterial cells with plasmid or cosmid DNA
(a) Heat shock of E. coli DH5a cells
10 pi of competent DH5a cells were added to pre-cooled 15 ml Falcon tubes, 1-2 pi of 
ligated DNA (usually cosmid DNA) was then added. Tubes were maintained on ice for 
30 min, placed at 42° for 45 sec and transferred to ice for 2 min. 300 pi of SOC medium 
was added to each sample and the tubes were shaken at 37° for 1 h. Transformed cells 
were spread onto L-broth agar plates containing 100 pg/ml ampicillin, and incubated at 
37° overnight.
(b) DMSO shock of E. coli XL-1 ceils
A single colony of XL-1 cells from a streaked L-broth agar plate was added to 10 ml of 
2YT broth and shaken at 37° overnight. 100-200 pi from this culture was added to 10 
ml of 2YT broth and shaken at 37° for 3 h (until the optical density of the culture at 540 
nm was 0.3). The culture was centrifuged at 2000 rpm for 10 min and the pellet was 
resuspended in 1 ml of TSB/DMSO and maintained on ice for 10 min. 100 pi of these 
cells was added to precooled 15 ml Falcon tubes, 1-4 pi of ligated DNA was added and 
the mixture was incubated on ice for 20 min. Each tube then received 300 pi of 
TSB/glucose or SOC medium and was shaken at 37° for 1 h. The samples were spread 
onto L-broth agar plates containing 100 pg/ml ampicillin and incubated at 37° overnight.
(c) Electroporation
Competent XL-1 cells were produced from an overnight culture of XL-1 cells grown in 
10 ml 2YT. One 1 of 2YT was inoculated with the overnight culture and incubated for 3- 
4 h at 37°. The cells were pelleted by centrifugation at 2000 rpm for 15 min and 
resuspended in distilled water. This procedure was repeated four times to remove 
impurities which could affect the electroporation procedure. Ligated DNA samples were 
added to 50 pi of these cells and the mixture was placed into a 0.1 cm electroporation 
cuvette. The electroporator was used according to the manufacturer’s instructions. The 
sample was pulsed once, 400 pi of SOC medium was added to remove the sample and 
this was added to a 15 ml Falcon tube containing a further 800 pi of SOC medium and 
shaken at 37° for 1 h. Each sample was spread onto three L-broth agar plates containing 
100 pg/ml ampicillin and incubated at 37° overnight.
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3.23. Small scale preparation of DNA
(a) Alkaline lysis
Following transformation of bacteria, colonies which grew on L-broth agar plates 
containing 100 pg/ml ampicillin were picked using sterile cocktail sticks into 10 ml 2YT 
broth containing 100 pg/ml ampicillin and 10 mM magnesium sulphate and shaken at 37° 
overnight. 1.5 ml of each culture was decanted into a 1.5 ml tube and centrifuged at
12.000 rpm for 3 min. The supernatant was discarded and the pellet was resuspended in 
100 jil of GTE/lysozyme and incubated at RT for 10 min. 200 jllI of SDS/NaOH was 
added, the tube mixed and placed on ice for 10 min. 150 pi of 3 M potassium acetate 
was added, the vial mixed and returned to ice for 10 min. The sample was centrifuged at
12.000 rpm for 10 min and the supernatant decanted into a fresh tube to which was 
added 400 jllI of phenol/chloroform. The tube was mixed and centrifuged at 12,000 rpm 
for 5 min. The aqueous phase was removed into a fresh 1.5 ml tube to which was added 
20 jil of 3 M sodium acetate pH 3 and 800 pi of ethanol. The tube was mixed and placed 
at -20° for 20 min before being centrifuged at 12,000 rpm for 10 min to pellet the 
precipitated DNA. The supernatant was removed and the pellet washed with 70% (v/v) 
ethanol before being lyophilised for 3 min. The pellet was resuspended in 50 pi 5 pg/ml 
RNase A (DNAse free).
(b) STET lysis
The bacterial pellet obtained from an overnight culture as in (a) was resuspended in 
100 pi of STET/lysozyme in a 1.5 ml tube and placed in a heat block at 100° for 75 sec. 
The tube was then centrifuged at 12,000 rpm for 10 min, and the supernatant was 
transferred to a fresh tube containing 400 pi of 0.3 M sodium acetate pH 3 and mixed 
with 800 pi ethanol. The DNA was precipitated at -20° for 1 h, pelleted by 
centrifugation at 12,000 rpm for 10 min and then resuspended in 50 pi 5pg/ml RNaseA.
3.24. Producing glycerol stocks of cosmids or plasmids
Bacterial stocks were prepared from 10 ml overnight cultures grown at 37° in L-broth or 
2YT broth. 1.5 ml was decanted into a plastic storage vial and centrifuged at 12,000 rpm 
for 3 min. The pellet was resuspended in 500 pi of sterile bactopeptone before adding 
500 pi of sterile 80% (v/v) glycerol. The stocks were frozen on dry ice and stored at 
-20° or -70°.
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3.25. Restriction endonuclease digestion
Digestion of DNA using restriction enzymes was carried out according to the 
manufacturer’s instructions.
3.26. Partial digestion of cosmids in the presence of ethidium bromide
Cos24 was linearised at Aspl\%  sites in the presence of ethidium bromide to yield full 
length linear molecules and then treated with bacteriophage T4 DNA polymerase in the 
presence of the four deoxynucleoside triphosphates to produce blunt ends. After ligation 
this should result in the insertion of 4 bp into the Aspl\%  site, converting it from 
GGTACC to GGTACGTACC and thus introducing a shift in the translational reading 
frame from that point onwards. Optimal conditions for linearization were obtained by 
carrying out digestions of cos24 at a constant enzyme concentration in the presence of 
different concentrations of EtBr. The EtBr was removed by phenol:chloroform 
extraction and ethanol precipitation (see Section 3.23). Cleaved ends of partially digested 
cos24 were converted to blunt ends, electrophoresed through an agarose gel and 
extracted from the gel by electroelution (see Section 3.29a). The DNA was extracted 
with phenolxhloroform, ethanol precipitated and resuspended in 50 jil of H20 . The 
linearised cosmid was checked by agarose gel electrophoresis, ligated and transfected 
into E.coli MAX efficiency DH5a cells. Resulting cosmids were screened for the loss 
of an A sp llS  site and the gain of a novel SnaBl site. SnaBl cuts at the sequence 
TACGTA, which is generated when the 4 bp insertion occurs.
3.27. Production of blunt ends and ligation of cosmid or plasmid DNA
DNA fragments were treated with T4 DNA polymerase (3 units) in the presence of the 
four deoxynucleoside triphosphates (2mM) in 10 x React A buffer for 1 h at 37° to 
produce blunt ended DNA. The ligation mixture contained the DNA, 1 unit of T4 DNA 
ligase, 4 |xl of 5 x ligase buffer, 2 jil of lOmM ATP and was made up to a final volume 
of 20 |il with water. The mixture was incubated at 16° overnight.
3.28. Agarose gel electrophoresis
100 ml of 0.8% (w/v) agarose was dissolved in 1 x TBE by boiling, then cooled at RT 
for 15 min before being poured into a taped gel plate (15 cm x 10 cm) containing a Teflon 
well-forming comb. When the gel was set, the tape was removed and the gel was placed 
into a horizontal gel electrophoresis apparatus containing 1 x TBE in the buffer tanks.
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DNA samples were mixed with 0.25 volume of DF dyes before being loaded into the 
wells and electrophoresed at 25 V overnight or 75 V for 4-5 h.
For some experiments, a mini-horizontal gel apparatus was used (Anachem). A gel 
comprising 50 ml of 0.8% (w/v) agarose in 1 x TBE was cast in the apparatus, where it 
was electrophoresed for 2 h at 50 V.
In both cases the samples were stained with 0.5 (ig/ml EtBr in 100 ml of 1 x TBE for 30 
min at RT, and visualised by exposure to UV light. For analytical gels, short wave UV 
light was used, and for preparative purposes long wave UV light was used. The gels 
were photographed using a photo-imager system (Appligene).
In most cases, a HindUl digest of bacteriophage DNA was electrophoresed on the same 
agarose gel as a molecular weight marker, occasionally, a wt plasmid, cosmid or virus of 
known structure was electrophoresed alongside the samples as a control and doubled as 
an appropriate molecular weight marker.
3.29. Purification of restriction fragments from agarose gels
(a) Electroelution
Restriction fragments were separated electrophoretically on agarose gels and visualised 
under long wave UV light. Bands of interest were excised in the minimum volume of 
agarose using a sterile scalpel. Each slice was placed with 500 jil TBE into dialysis 
tubing which had previously been boiled in 1 x TBE. The tubing was sealed, making 
sure all air bubbles had been removed and the DNA was electroeluted in a horizontal gel 
kit at 100 V for 4 h. The polarity of the current was then reversed for 45 sec and the 1 x 
TBE containing the DNA was transferred into a sterile 1.5 ml tube. The solution was 
extracted with phenol:chloroform and ethanol precipitated (see Section 3.23), 
resuspended in H20  and stored at -20°.
(b) Sephaglas
The fragment of interest was excised and transferred into a preweighed 1.5 ml tube in 
order to determine its weight. The DNA was eluted according to the manufacturer’s 
instructions, and recovery was assessed by agarose gel electrophoresis.
(c) Spin-X tubes
The fragment of interest was excised, placed into a Spin-X tube and centrifuged at
12,000 rpm for 5 min at 4°. An equal volume of 0.3 M sodium acetate pH 3 was added 
to the sample and the tube was centrifuged again at 12,000 rpm for 5 min at 4°. One
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twentieth of the volume remaining after centrifugation of 3 M sodium acetate and 2 
volumes of ethanol were added to the tube. The DNA was precipitated at -20° for 1 h 
and pelleted by centrifugation at 12,000 rpm for 20 min. The DNA was washed with 
70% (v/v) ethanol, dried, resuspended in H20  and stored at -20°.
3.30. Transfection of BHK C13 cells 
Regenerating virus
Cosmids were digested with Pac I to excise the HSV-1 DNA inserts, and equimolar 
amounts of the inserts representing the entire HSV-1 genome were mixed together and 
transfected into cells as follows.
(i) Calcium phosphate precipitation and DMSO shock
Samples of the cosmids in the set were prepared as described in Section 3.23 and mixed 
in approximately equal volumes. The mixture was precipitated with 87 pi of HeBS, 7 pi 
CaCl2 and 2 pi of calf thymus DNA, and incubated at room temperature for 30 min, 
before being added to 80-90% confluent monolayers of BHK C l3 cells on 35mm 6-well 
plates. The plates were incubated at 37° for 30 min, 3 ml of Dulbecco’s medium was 
added and incubation was continued for a further 3.5 h at 37°. One ml of 20% (v/v) 
DMSO in HeBS buffer was added to the cells for 3 min 45 sec at RT then the DMSO 
solution was removed and replaced with 5 ml of methyl cellulose overlay. Plates were 
maintained at 37° for 4-5 days until plaques were observed.
(ii) Lipofection
Cosmid DNA was added to a tube containing 100 pi of Optimem medium. A mixture of 
10 pi lipofectamine and 100 pi of Optimem medium was added and the mixture was 
allowed to stand at RT for 30 min to allow DNA-liposome complexes to form. 500 pi of 
Optimem medium was added and the final mixture was applied to 50-70% confluent 
monolayers of BHK C l3 cells which had been prewashed with Optimem medium. The 
cells were incubated at 37° for 5 h before 3-5 ml of Dulbecco’s medium containing 20% 
(v/v) NBCS was added. The cells were maintained in a 37° incubator overnight and then 
the medium was replaced with methyl cellulose overlay. The monolayers were incubated 
at 37° for 3-5 days until plaques were observed.
Constructing complementing cell lines
Plasmids were transfected into BHK C13 cells by either of the methods described above, 
except that the transfected cells were overlayed with Dulbecco’s medium rather than 
methyl cellulose overlay. When the cells were fully confluent, they were removed from 
the plates by a trypsin/versene wash and each well was diluted into 18 ml of Dulbecco’s
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medium containing neomycin (G418) (400 |ig/ml) and divided between the 6 wells of a 
35 mm 6-well plate. Transformed cells were identified by their ability to grow in 
neomycin-containing medium.
3.31. Determination of differences in plaque area
Photographs of Giemsa-stained infected cell monolayers were taken using a camera- 
mounted microscope. Photographic prints were obtained for 30-100 different plaques 
for each virus and the plaques were cut out and weighed. Relative plaque area was 
determined by relating weight directly to plaque area.
3.32. Effect of interferon
Interferon-sensitive HFL cells were grown until 80% confluent in 35 mm 6-well plates. 
The medium was removed and replaced with 2ml of Dulbecco’s medium containing 1000 
U/ml interferon, or medium lacking interferon. The plates were incubated at 37° 
overnight, then the cells were washed twice with medium and infected with virus diluted 
in Dulbecco’s medium at 5 pfu/cell for 1 h at 37°. The virus inoculum was removed and 
the cells were overlayed with methyl cellulose overlay and maintained at 37° for 24-48 h. 
The cells were then scraped into 2 ml of Dulbecco’s medium, and the virus yield 
determined by titration on BHK C l3 cells.
3.33. HSV-1 DNA preparation
Five roller bottles of BHK C13 cells were infected with virus in Dulbecco’s medium at a 
moi of 0.001 pfu/cell and incubated at 37° until cpe was complete. Cells were shaken 
into the medium and pelleted by centrifugation at 2000 rpm for 10 min. The supernatant 
was retained on ice while the cells were resuspended in 10 ml RSB/0.5% NP40 and 
incubated on ice for 10 min. Nuclei were pelleted by centrifugation at 1000 rpm for 5 
min. The supernatant was retained and the pellet re-extracted with RSB/0.5% NP40. 
The cytoplasmic supernatants and the supernatant from the infected cell culture were 
combined and centrifuged at 12,000 rpm for 2 h to pellet the virus, which was 
resuspended by sonication in 8 ml of NTE. To lyse the virus, EDTA (5%) and SDS 
(5%) were added and the mixture incubated for 5 min on ice followed by 5 min at 37°. 
Viral DNA was extracted twice with phenol:chloroform and once with chloroform by 
gently mixing equal volumes and incubating at RT for 5 min followed by 5 min on ice. 
Each extraction was centrifuged at 2000 rpm for 10 min, and the fluid upper aqueous 
layer was dialysed against 0.1 x SSC at RT overnight. The recovered DNA was stored 
at -70°.
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3.34. In vitro transcription and translation
pGEMl and pGEM2, which have T7 and SP6 promoters in different orientations 
separated by a multiple cloning site, were linearised at the Smal site within the multiple 
cloning site region and incubated with calf intestinal phosphatase according to the 
manufacturer’s instructions. A UL16-containing DNA fragment (29717 bp to 31213 bp 
in the HSV-1 sequence) was obtained from Kpnl q by digestion with Bsu36l and BssSl 
in the appropriate buffers. The fragment was extracted from an agarose gel by the 
Sephaglas method (Section 3.29). The fragment was blunt-ended with the Klenow 
fragment of E. coli DNA polymerase I, ligated into the pGEM plasmids, and transformed 
into XL-1 cells. Ampicillin-resistant colonies were grown and plasmid DNA was 
prepared, digested, and electrophoresed to obtain clones containing the fragment in each 
orientation.
Using the Promega TNT coupled reticulocyte lysate system, a standard in vitro assay was 
set up according to the manufacturer’s instructions. In most experiments, 0.5 p,g of 
purified plasmid was used per 25 |il reaction containing 12.5 |xl of TNT lysate, 2 p,l of 
[35S]-methionine or [35S]-cystine and 0.5 jil of TNT reaction buffer, 0.5 |il of amino acid 
mixture lacking methionine or cystine, 0.5 jil of RNase inhibitor and 0.5 |il of the TNT 
T7 or SP6 RNA polymerase. Reactions were incubated at 30° for 90 min, and an aliquot 
was transferred to a tube containing boiling solution. The mixture was boiled for 5 min 
and subjected to SDS/PAGE.
3.35. Immune precipitation
Confluent monolayers of BHK C13 cells in 50 mm plates were infected at 5 pfu/cell in 
Dulbecco’s medium. The medium was replaced by 3 ml of medium containing 50 |iCi of 
[35S]-methionine or [35S]-cystine from 8-12 h pi or 4-24 h pi. The monolayers were 
washed with PBS A, air dried and stored at -70°. After thawing, the cells were lysed by 
the addition of 1 ml of Zweig’s buffer or RIPA buffer. After incubating at RT for 1-2 
min, the lysed cells were transferred into a 1.5 ml tube and incubated on ice for 1 h, then 
centrifuged at 12,000 rpm for 5 min. The supernatant was transferred to a fresh tube.
50 jllI of serum was added to 200 jil of the extract produced above, and the mixture was 
placed on ice overnight. Protein A-Sepharose was prepared by mixing 1 g of protein A- 
sepharose with 4 ml of RIPA buffer or Zweig’s buffer until resuspended, then 
centrifuging at 1000 rpm for 5 min. This process was repeated three times, then the 
protein A-Sepharose was resuspended in 1 ml of the appropriate buffer. 60 |il of protein 
A-Sepharose beads was added to these samples and incubation was continued on ice for
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30 min with occasional mixing. The samples were centrifuged at 7000 rpm for 1 min, 
and the pellet was washed with 1 ml of Zweig’s buffer or RIPA buffer and resuspended 
in the appropriate buffer. The pellet was washed thus four times and the beads were 
finally resuspended in 60 |il of boiling mix and boiled for 5 min. 40 (il of each sample 
was electrophoresed on a 12% polyacrylamide gel. The gel was fixed for lh in fix 
solution, destained three times for 30 min in destain solution, soaked for lh in 
En3Hance, washed in H20  for 15 min and dried on a gel drier at 80° for 1.5 h. The gel 
was then exposed to photographic film.
3.36. Western blotting
Protein samples were electrophoresed on a single concentration polyacrylamide gel and 
electroblotted in Western blotting transfer buffer to a Hybond ECL membrane. The 
membrane was washed twice for 30 min in PBS A containing 0.05% (w/v) BSA and 5% 
(w/v) Marvel (low fat milk substitute). This was followed by two 15 min washes in 
PBS A containing 0.05% (w/v) BSA. The antibody produced against the protein under 
investigation was diluted as appropriate in PBS A/Tween 20/1% (w/v) BSA, added to the 
membrane and incubated at room temperature for 2-3 h. The membrane was subjected to 
two more 15 min washes in PBS A containing 0.05% (w/v) BSA prior to the addition of 
1:1000 dilution of protein A conjugated to horseradish peroxidase and incubated at RT 
for 1-2 h. A further two 15 min washes in PBS A containing 0.05% (w/v) BSA were 
followed by a 1 min incubation in a 1:1 mixture of reagent 1 and 2 from the ECL western 
blotting detection kit, which causes a light emitting reaction. The treated membrane was 
then placed in a plastic bag, taking care to remove air bubbles, and exposed to 
photographic film for an appropriate time (1 sec-1 min).
3.37. Analysis of viral growth in vivo
Intracranial (IC) and footpad (FP) injections (Project Licence No. PPL/60/01357) were 
carried out by Dr. A. MacLean (under Animal Licence No. PIL/60/5294).
(a) Neurovirulence
Three week old BALB/c mice were anaesthetised using halothane and given intracranial 
injections into the central region of the left cerebral hemisphere. Individual virus stocks 
were injected at doses of 102 to 105 pfu/mouse in 25 p,l in PBS/calf (three or four mice 
were inoculated with each virus dilution). Stocks were titrated on the day of the 
inoculation to ensure that the correct dose had been administered. The mice were
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monitored twice daily for 14 days post inoculation for signs of illness or death. The 
LD50 for each virus was calculated according to the formula of Reed and Muench (1938).
In order to determine the genotype of replicating viruses, the brains of three-week old 
BALB/c mice that had been infected with 107 pfu/mouse were removed at 5 or 7 days 
post inoculation and homogenized in 1 ml PBS/calf. The progeny virus was titrated on 
BHK C13 cell monolayers. The stability of viral genotypes were examined by probing 
infected cell DNA after Southern blotting (see Section 3.14).
(b) Latency
Four week old B ALB/c mice were inoculated in the right rear footpad with virus stocks at 
doses of 104to 107 pfu/mouse in 25 jllI of PBS/calf. Following inoculation, virus stocks 
were titrated to ensure that the correct dose had been administered. After 6 weeks, all 
surviving mice were killed and dissected, and the nine ipsilateral dorsal root ganglia 
supplying the lower limb of each mouse were separately cultured in ETF10 in microtitre 
plates. They were screened every second day for the presence of infectious virus by 
transferring the culture supernatant to BHK C13 cell monolayers. The cells were 
incubated for 2 days at 37° and examined for the presence of plaques or cpe. Plaques 
were picked at various stages of reactivation and viral phenotypes examined by probing 
infected cell DNA following Southern blotting (see Section 3.14).
3.38. DNA sequencing
The ends of cos46 were sequenced to confirm that the it overlapped with the cosmids 
adjacent to it in the set. Also, mutated cosmids were sequenced to confirm the precise 
nature of the mutations introduced.
(a) DNA preparation and ligation
Bacteriophage M13 mpl9 RFII DNA was digested sequentially with Smal then EcoRl in 
the appropriate buffers. Cosmid DNA (2 jig) was digested with Smal (Smal cuts HSV-1 
DNA frequently but does not cut the cosmid vector). The digested DNAs were 
electrophoresed on an agarose gel and the appropriate fragments were recovered from the 
agarose using the Sephaglass method (Section 3.29). The DNA fragments were then 
digested with EcoRl (which cuts in at each end of the cosmid vector), extracted with 
phenolxhloroform, ethanol precipitated and resuspended in 50 jxl of HzO (see Section 
3.23). Ligations were set up containing 1 |ig of M13 DNA, 5 |ig of cosmid DNA, 1 x 
ligation buffer, 10 mM ATP and 1 unit of T4 DNA ligase. Two control ligations were
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also set up, both without the cosmid DNA and one also without ligase. Ligations were 
incubated at 16°C overnight and then frozen at -20°.
(b) Transformation of E. coli
200 jllI of an overnight culture of XL-1 cells was added to 10 ml of 2YT broth and 
shaken at 37° for 2 h. The cells were pelleted by centrifugation at 2000 rpm for 5 min, 
resuspended in 1 ml of TSB/DMSO and incubated on ice for 10 min. 100 pi of cells and 
5 pi of a 1:5 dilution of the ligations were added to precooled 15 ml Falcon tubes and 
incubated on ice for 15 min. The mixture was placed at 42° for 2 min before adding 3 ml 
of melted top agar solution (at 42°) containing 96 pi of 4% Xgal, 160 pi of 30 mg/ml 
IPTG and 1.6 ml of the original overnight bacterial culture. The mixture was poured 
onto L-broth agar plates, and the plates incubated inverted at 37° overnight.
(c) Preparation of DNA templates
1 ml of an overnight culture of XL1 cells was added to 100 ml of 2YT broth and 1.2 ml 
was aliquoted into each well of a 24 well plate. Clear plaques were transferred to the 
wells using sterile cocktail sticks and the plates were incubated in a shaking benchtop 
incubator at 37° for 6 h. 1 ml of culture was transferred to a 1.5 ml tube and centrifuged 
at 12,000 rpm for 5 min to pellet the bacteria. The supernatant was transferred to a fresh 
tube, mixed with 120 pi PEG/NaCl and incubated at 4° overnight. The bacteriophage 
was pelleted by centrifugation at 12,000 rpm for 5 min and resuspended in 100 pi TE 
and 50 pi of phenol/TE by vortexing. After 1 h at RT the tube was vortexed again and 
centrifuged at 12,000 rpm for 2 min. The supernatant was transferred to a fresh tube and 
mixed with 20 pi of sodium acetate and 250 pi of ethanol. After incubation at -20° 
overnight, the DNA was pelleted by centrifugation at 12,000 rpm for 10 min at RT, 
washed with 70% (v/v) ethanol and lyophilised. The pellets were resuspended in 30 pi 
of TE and stored at -20°.
(d) DNA sequencing reactions
2 pi of each template was added to a 96 well microtitre plate, followed by 10 pi of 
annealing mix. The plate was vortexed briefly and incubated at 37° for 30 min. 2 pi of 
each annealed template was dispensed into 4 wells of a 96 well microtitre plate. 2 pi of 
[35S]-G, -A, -T or -C mixture plus Klenow was aliquoted onto the side of one well each. 
The plate was covered, centrifuged briefly in a tabletop centrifuge (Sorvall RT6000B) 
and placed at 37° for 10 min. 2 pi of chase solution was added to the sides of each well, 
the plate was centrifuged briefly and incubated at 37° for 10 min. The plates were stored 
at -20°.
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(e) Gel electrophoresis
Clean siliconised sequencing gel plates were assembled into a sandwich using sealing 
tape, with two large foldback clips on each side positioned over the spacers. 60 ml of 
top gel mix and 12 ml of bottom gel mix were aliquoted into separate beakers, to which 
120 jil and 24 }il of APS, respectively, was added. The same volumes of TEMED were 
added and the solutions mixed. 12 ml of polymerising top gel mix was taken up into a 
25 ml pipette, followed by all of the polymerising bottom gel mix, allowing a few 
bubbles to disturb the interface. This mixture was dispensed into the plate sandwich 
followed by the remaining top gel mix. The sandwich was then placed almost 
horizontally and two narrow well sharkstooth combs were placed adjacently into the top 
5 mm of the gel, with the teeth uppermost. The gel was allowed to set for 15-30 min, the 
tape was removed from the bottom of the plates and the sandwich was placed into a 
sequencing apparatus in which the electrophoresis tanks were filled with 0.5 x TBE. The 
combs were removed and the wells washed with 0.5 x TBE using a syringe. The combs 
were replaced with the teeth touching the top of the gel. 2 jllI of formamide-dyes was 
added to each well of the microtitre plate containing the sequencing reactions. The trays 
were vortexed briefly, then placed into a boiling water bath for 1 min and chilled on ice. 
2 jil of each sample was loaded for each template, (in the order G, A, T and C) and the 
gel was electrophoresed at 60 W until the bromophenol blue dye reached the bottom of 
the gel (approximately 2.5 h). The plates were separated and the plate containing the gel 
was fixed with 3-4 10 min washes of 10% acetic acid in a fume hood. The fixed gel was 
transferred to 3MM paper, covered with clingfilm, dried for 45 min at 80° on a gel drier 
and autoradiographed.
80
Chapter 4
Results
Chapter 4: Results
4.1. COSMIDS CONTAINING MUTATIONS IN UL14, UL15 AND 
UL17
4.1.1. Status of or/L in the cosmid set
Cunningham and Davison (1993) developed a cosmid-based system of mutagenesis for 
producing mutations in HSV-1 genes. Of the three cosmid sets generated, one, 
comprising five cosmid clones (cos32, cos24, cos71, cos51, cos48), which together 
contain the coding sequence of the entire HSV-1 genome (Fig. 13), was initially used in 
this study with the aim of producing frameshift mutants in HSV-1 genes UL14 to UL17. 
Cos24 contains genes UL14-UL17 in a region which does not overlap with adjacent 
cosmids, and thus mutants can in principle be generated in these genes without 
generating wt vims. UL14 is a small gene which is orientated in the opposite direction to 
UL15. UL15 is the only spliced gene in UL and contains UL16 and UL17 entirely in the 
intron on the opposing strand (see Fig. 13b).
Cunningham and Davison (1993) found that oriL is readily lost from cosmids. This is 
consistent with earlier work showing that orii is unstable in plasmids (Weller et al., 
1985; Hardwicke and Schaffer, 1995). Cunningham and Davison (1993) found that 
cosmids containing the oriL region had either lost oriL entirely and were thus orii or were 
composed of a mixture of orii and orii cosmids, with the former in the minority. They 
also noted that orii vims was invariably produced from cosmids that are predominantly 
orii, presumably because of the ability of the minority of orii molecules to replicate and 
predominate in the viral progeny. Cunningham and Davison (1993) noted that cos71 is 
completely orii, and therefore it was necessary at the initiation of this work to replace 
cos71 by a cosmid containing an orii population. A candidate cosmid (cos46) from the 
library was investigated.
The status of oriL in cos46 was checked by probing Kpnl digests with a plasmid 
containing Kpnl v, which contains the oriL spanning region (although this fragment itself 
lacks the complete orii). Cos 14, from another cosmid set, which contains o r ii  
molecules, and an orii derivative of cos 14 were used as controls. Fig. 14 shows that 
four different cos46 preparations were orii.
Restriction endonuclease (RE) analysis showed that cos46 overlaps the flanking cosmid, 
cos51. The restriction fragment pattern of cos46 following digestion with EcoRl 
confirmed that it overlapped cos51 since both contain the EcoRl L fragment. The ends of 
the cos46 insert were sequenced to define precisely the extent of overlap with both 
adjacent cosmids. Cos46 was digested with Smal plus EcoRl, the ends excised from an 
agarose gel and inserted into Smal plus EcoRl digested M13mpl9. The ends of the
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Fig. 13. Location of cosmid inserts with respect to the HSV-1 genome
a Locations of cosmid inserts are indicated by open bars and their precise locations in the HSV-1 
sequence are given in bp. The position of the orii region is denoted by a vertical line in cos71 and 
cos46 and the area containing UL14-UL17 is shaded in cos24.
b Detailed representation of the position of UL14-UL17. The shaded boxes represent protein coding 
sequences, horizontal lines indicate mRNA and the arrows indicate direction. The nucleotide positions 
in the HSV-1 sequence of the end of the UL13 and the beginning of the UL18 coding regions are given in 
bp.
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Fig. 14. Status of orii  in cos46
An autoradiograph of a Southern blot in which Kpnl fragments from four different preparations of cos46 
and two varients of cos14 (one consisting entirely of orii- molecules (-) and the other containing a 
majority of orii and a minority of orii+ molecules (+)) were transferred from a 0.8% (w/v) agarose 
gel and probed with a plasmid containing Kpnl v, which contains the orii region. Fragments 
representing the full length (v; 1933 bp) and deleted (Av; approximately 1800 bp) forms of Kpnl v are 
indicated. The more intense bands near the top of the autoradiograph are due to hybridisation of 
vector sequences, and the less intense bands near the top of the autoradiograph are due to partial 
digestion of the cos46 samples.
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Fig. 15. Status of ori\_ in wt and reconstructed viruses
An autoradiograph of a Southern blot in which infected cell DNA was digested with (a) Kpnl or (b) 
BamHI plus BstEl, and electrophoresed through (a) a 0.8% agarose or (b) a 5% polyacrylamide gel, 
transferred to a nitrocellulose membrane and probed with a plasmid containing Kpnl v. The positions 
of Kpnl v (full length) and A v  (deleted) are shown in (a) and the locations of or/|_+ and orii ~ 
fragments are shown in (b). The o r i i '  virus was prepared by cosmid recombination and provided 
by C. Cunningham.
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cos46 insert were found to be located at 39233 and 77851 bp in the HSV-1 DNA 
sequence and therefore, cos46 overlaps cos24 by 5363 bp and cos51 by 3761 bp (see 
Fig. 13).
4.1.2. Regeneration of wt virus
The five cosmids (cos32, cos24, cos46, cos51, cos48) were digested with P ad  to excise 
the intact inserts, since Pad does not cleave HSV-1 DNA. Approximately equimolar 
amounts of digested cosmids were mixed together (they were quantified by comparison 
with DNAs of known concentration (obtained commercially) by agarose gel 
electrophoresis) and transfected into BHK C l3 cells and plaques were picked at 2-4 days 
post transfection. Small viral stocks were made from each of the picked plaques, and 
infected cell DNA was prepared. Kpnl or BamUl plus BstEl digests were probed with a 
plasmid containing Kpnl v (Fig. 15). All of the five picked plaques were found to be 
orii .
4.1.3. Construction of mutant cosmids
Aspl IS, which cuts (at the sequence G’GTACC) seven times in the cos24 insert but not 
in the vector, was used to produce frameshift mutations. Fig. 16 shows Kpnl profiles of 
the five parental cosmids. Kpnl recognises the same site as A spl 18 but cleaves 
differently (at GGTAC’C).
Optimal conditions for linearising cos24 with Aspl IS were established with respect to 
enzyme dilution and EtBr concentration. Linearised cos24 DNA was extracted from 
agarose gels by electroelution, treated with T4 DNA polymerase in the presence of the 
four dNTPs to produce flush ends and ligated. This results in a 4 bp insertion 
(GGTACGTACC), which alters the reading frame of the gene from that point onwards, 
and creates a new SnaBl site (GGTACGTACC) in place of the lost A spl IS (Kpnl) site. 
Fig. 17 shows a map of the fragments obtained following digestion of cos24 with Kpnl 
or SnaBl.
After transfection, cosmids were obtained with insertions in UL6 , UL7, UL14, UL15 or 
UL17. Each mutation was detected by screening for loss of the appropriate Kpnl 
(Aspl 18) site and gain of a new SnaBl site (Fig. 18). Thus, for example, the mutation 
in UL14 results in fusion of Kpnl q (3819 bp) and f (10837 bp), giving rise to a novel
14.6 kbp fragment. The creation of a novel SnaBl site generates fragments of 6062 bp 
and 228 bp (electrophoresed from the bottom of the agarose gel) from the parental 6.29 
kbp fragment. The UL6 , UL7, UL14 and UL15 mutations were confirmed by Kpnl and 
SnaBl RE analysis. The UL17 mutation was confirmed by Kpnl digestion, but the
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Fig. 16. Kpnl restriction profiles of parental cosm ids
An EtBr-stained 0.8% (w/v) agarose gel of Kpnl digests of the five cosmids. HSV-1 Kpnl fragments 
generated from cos24 are shown; b* contains part of Kpnl b and b’ plus the cosmid vector (see Fig. 
17). M is a HindlW digest of bacteriophage lambda DNA used as size markers.
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Fig. 17. Kpn  I (Asp  718) and SnaBl s ites  in cos24
(a) Fragments produced by digestion of cos24 with K p n  I or /Asp718 are shown as shaded rectangle 
The name and size in bp of each fragment is given. The positions of the seven restriction sites in tf 
HSV-1 sequence are given in bp and denoted by arrows. The horizontal lines at the end of the frag 
represent vector sequences, which lack Kpnl  sites.
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sizes of the two fragments are given in bp. The position of the restriction sites in the HSV-1 sequenc 
given in bp and denoted by arrows. The horizontal lines at the end of fragments indicate vector 
sequences, which lack S n a B l  sites.
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Fig. 18. Identification of mutant cosm ids by RE analysis
EtBr-stained gels of cosmids with 4 bp insertions at sites in UL14, UL15, UL17, UL6 and UL7 (denoted 
14", 15", 17", 6‘ , 7") were screened for the loss of a Kpnl site and gain of a SnaBl site. Cos24 was 
used as a control and the HSV-1 Kpnl fragments are indicated (b* = part of Kpnl b plus b' and the 
cosmid vector). Digestion of 15" with SnaBl produced a partial SnaBl digest. M is a Hindlll digest of 
bacteriophage lambda DNA used as size markers.
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Fig. 19. The structure of plasmid p8A, containing UL14-UL18
a RE map of p8A for Kpnl, Sail, BamHI and C/al. Fragment sizes are given in bp.
b An EtBr-stained gel of pUC19gD/neo<' linearised with Sph\ (p) or p8A digested with Kpnl, Sa/I, BamHI 
or C/al. M is a Hind\\\ digest of bacteriophage lambda as size markers.
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anticipated 4 bp insertion may not have take place since a novel SnaBl site was not 
detected.
An attempt was made to generate additional mutant cosmids using Kpnl and A/w44I. 
Kpnl recognises the same site as Aspl IS but cleaves to leave a 3’ 4 bp overhang, so that 
mutated cosmids would contain a 4 bp deletion. A/w44I cleaves at G’TGCAC, present 
in UL14, UL15, UL16 and UL17, and thus mutated cosmids would contain a 4 bp 
insertion. However, mutant cosmids were not obtained using these enzymes. Since in 
some experiments at least 200 colonies were screened in order to obtain a single mutant 
cosmid, and cosmids with insertions in UL14, UL15 and UL17 had already been 
produced using A sp l IS, work with these two enzymes was not pursued. In addition, 
two UL16' mutant viruses had already been produced in the laboratory by C. 
Cunningham using a different cosmid set.
4.1.4. Candidate complementing cell lines
At the beginning of this work little was known about the nature of UL14-UL17. Poon 
and Roizman (1991) had shown that a UL16’ deletion mutant was viable in cell culture, 
and also suggested that UL17 is an essential gene because they were unable to produce a 
UL17‘ mutant. Given the possibility that UL14, UL15 and UL17 might be essential, cell 
lines potentially expressing these genes were constructed.
a. Cos24 cell line
A candidate complementing cell line, produced by transfecting cos24 into BHK C13 cells 
was provided by C. Cunningham. The cosmid vector contains the neomycin resistance 
gene and the resulting cell line was neomycin (G418) resistant. This cell line has the 
potential to express UL1 to UL21, and has been shown to complement UL9' and UL12' 
mutants but not UL6 ' or UL8‘ mutants. (C. Cunningham and A.J. Davison, personal 
communication).
b. 8A cell line
As an initial step, an 8.6 kbp Sphl fragment from cos24 containing the entire coding 
sequences of UL14 to UL18 was inserted into the BglII site in pUC19gD/ne</ to give 
plasmid p8A (Fig. 19A). pUC19gD/«e<?r consists of pUC19, the neomycin resistance 
gene under the control of the SV40 promoter and the HSV-1 US6 (gD) promoter (which 
may be used to drive the inserted genes if their own promoter is absent) upstream from 
two unique restriction sites (Bglll and Kpnl), and was provided by Dr A. Patel. The 
structure of p8A was assessed by RE analysis with Kpnl, Sail, BamHI or Clal. This 
analysis confirmed that p8A contains the expected insert, since the RE profiles shown in
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Fig. 19B are as predicted in Fig. 19A. p8A was transfected into BHK C l3 cells by 
lipofection and 98 neomycin-resistant cell lines were isolated from single colonies.
c. p14, p15 and p17 cell lines
Cell lines p i4, pl5 and p i7 were produced using plasmids containing UL14, UL15 or 
UL17 individually.
BglII fragments containing UL14 or UL17 were inserted into pUC19gDIned  under their 
own promoters. The UL15 coding region (lacking the intron) was isolated from a 
modified form of pMJ511 and inserted into pUC19gD/«eor under control of the US6 
(gD) promoter. pMJ511 is a vaccinia virus transfer vector containing the fused exons of 
UL15 under the control of a vaccinia promoter, and was constructed from a genomic 
clone by Dr A.J. Davison. A novel BglU site was inserted at the 5’ end of the coding 
region by Dr V.G. Preston to give the modified form of pMJ511. The structures of 
plasmids containing UL14 (p i4), UL15 (pi5) or UL17 (pl7) were confirmed by RE 
analysis (Figs. 20 and 21).
BHK C l3 cells were transfected with pl4 (orientation 1), p i5 (orientation 2) or p l7  
(orientation 1) by calcium phosphate precipitation and DMSO treatment. Six neomycin- 
resistant cell lines were isolated using p i4, 15 with pl5 and two with pl7.
4.1.5. Generation of viruses
a. Cos24 cell line
The cos24 cell line and BHK C l3 cells were transfected with the UL14, UL15 and UL17 
mutant cosmid sets in a number of experiments. Viral plaques were obtained only from 
the UL14 set. Plaques were picked and small viral stocks were produced. Kpnl digests 
of infected cell DNA were probed with plasmids containing Kpnl q or f, and the results 
showed that all progeny were wt in that they produced Kpnl q and f and not the fused 
fragment (Fig. 22). Reversion of the lesion introduced into UL14 indicates that the 
mutant is severely disabled or not viable in BHK C13 cells and that the cos24 cell line 
does not complement the mutation.
b. 8A cell line
Fifteen cell lines were transfected with the three mutant cosmid sets. Four cell lines 
produced virus after transfection with the UL14, UL15 and UL17 mutant cosmid sets. 
Plaques were picked and small viral stocks produced on the 8A cell line originally tested. 
Tfpnl-digested infected cell DNA was probed with plasmids containing Kpnl q or w . 
Fig. 23 shows that only wt progeny were produced in that they contained Kpnl q and w
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a RE map of p14 and p17 for Kpn\. Fragment sizes are given in bp.
b  Representative pannels of a single EtBr-stained gel of p14 and p17 digested with Kpn I are spliced 
together. Plasmids contain the UL14 or UL17 fragment in both orientations (1 or 2). Cos24 digested with 
Kpnl, linearised pUC19gD/neorvector (p -4.5 kbp) and a Hind\\\ digest of bacteriophage lambda DNA (M) 
were used as size markers.
pl)C19gD/neor
- 4 .5  k
K p n l-----
UL 15(11)
1585 bp 911 bp
Kpnl Kpnl
or
Kpnl
UL 15(11)
I ►
911 bp 1585 bp
Kpnl Kpnl
b
Fig. 21. The structure of p15
a RE map of p15 for Kpnl. Fragment sizes are given in bp. I and II indicate the two exons of UL15.
b An EtBr-stained gel of p15 digested with Kpnl. Plasmids containing the UL15 fragment in both 
orientations (1 or 2) are shown. Linearised pUC19gD/neorvector (p -4.5 kbp) and a HindlW digest of 
bacteriophage lambda DNA (M) were used as size markers.
BHK C13 i r 24 cell line-
co s
possible mutants 
UL14 ------- " ----------  UL14
10837 bp 
Kpnl f
3819  bp 
Kpnl q
Fig. 22. Genotype of virus generated from the UL14" cosm id  se t
An autoradiograph of a Southern blot in which infected cell DNA produced from wt, cos wt {wt HSV-1 
produced from the parental cosmid set), and possible UL14 mutants picked from BHK C13 cells or the 
cos24 cell line was digested with Kpnl, transferred from a 0.8% (w/v) agarose gel and probed with 
plasmids containing Kpnl q and f. The positions and sizes in bp of these fragments is shown. 
Apparently faster migrating forms of Kpnl f in some lanes are due to a loading artifact.
Possible mutants
Kpn I q 3819 bp
Kpnl w 1743 bp
Fig. 23. G enotype of virus generated from one p8A cell line
An autoradiograph of a Southern blot in which infected cell DNA was digested with Kpnl and 
transferred from a 0.8% (w/v) agarose gel to a membrane which was probed with plasmids 
containing Kpnl q and w. The position and size of these fragments are shown.
cosw/1 UL14 UL15
wt  UL7" Possible UL7 mutant viruses
Kpn\ y + f 
12357 bp
Kpnl y 
1520 bp
Fig. 24. G enotype of virus generated from the UL7“ cosm id se t
An autoradiograph of a Southern blot in which infected cell DNA was digested with Kpnl, transferred 
from a 0.8% (w/v) agarose gel and probed with a plasmid containing Kpnl y. The UL7‘ lane 
contains a mutated cosmid and illustrates the mutant banding pattern due to fusion of two fragments. 
The size and position of detected fragments are shown. The faint bands at the same level as the 
UL7' band may be due to non-specific hybridisation.
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and not the fused fragment. Reversion to wt showed that disruption of UL14, UL15 or 
UL17 is severely detrimental or lethal to viral growth and that the cell lines tested were 
not able to complement the defects.
c. p14, p15 and p17 cell lines
All of the cell lines were screened using the appropriate mutant cosmid sets and at least 
10 plaques were picked from each for preparation of small viral stocks. Infected cell 
DNA was digested with Kpnl and probed with a plasmid containing the appropriate Kpnl 
fragment. Only wt plaques were produced (data not shown), indicating that the cell lines 
were not able to complement the defects and confirming the severely detrimental effects 
of mutations in UL14, UL15 or UL17.
4.1.6. Generation of virus from the mutant UL7 cosmid set
In addition to the cosmids with mutations in UL14, UL15 and UL17, a mutant cosmid 
with a 4 bp insertion in UL7 was made (see Section 4.1.3). The status of UL7 in cell 
culture is unknown. The mutation is located in a region of the cos24 which overlaps 
cos32 and thus wt and mutant virus can be produced following transfection of the mutant 
cosmid set. A cell line that complements UL6' and UL8' mutants and which therefore 
may express UL7 was provided by Dr A. Patel. Transfection of this cell line and BHK 
C13 cells with the UL7' cosmid set resulted in approximately equal numbers of plaques. 
Probing of infected cell DNA with a plasmid containing Kpnl y showed that all of the 
plaques picked from the candidate complementing cell line were wt in that they contained 
Kpnl y and not the larger fused fragment (Fig. 24). Plaques picked from BHK C l3 cells 
were also found to be wt (data not shown). This indicates that the cell line does not 
complement the mutation and that the UL7' mutant is severely disabled or not viable.
4.1.7. Mass spectrometric analysis and identification of proteins
Proteins whose predicted sequences are present in databases may be identified by newly 
developed techniques involving mass spectrometry of electroblotted proteins digested 
with proteases (e.g. trypsin), and computer-aided comparison of the observed peptide 
masses with the masses predicted from theoretical cleavage of protein sequences in a 
database.
The protein products of the EHV-1 counterparts of UL16 and UL17 have been identified 
in small amounts in the EHV-1 tegument using this technique (A.J. Davison, personal 
communication). Thus, an attempt was made to identify the UL16 and UL17 proteins in 
HSV-1 virions. Attempts to identify the UL16 protein are described in Section 4.2.3.
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Virions L-particles
wt UL47- wt UL47-
E V CT CT V E E LP CT CT LP E
UL46
(a, b )   UL47
UL49
UL18
UL26 (N)
Fig. 25. Identification of proteins using m ass spectrom etric analysis
A coomassie blue stained gel of virions and L-particles from wt virus and a UL47" mutant. Bands a 
(upper) and b (lower) (□ ) were identified in the UL47' virus samples and a number of lower 
molecular weight bands were identified, including band c (*). These three proteins were analysed 
by laser desorption mass spectrometry (see Figs. 26 and 27). Known HSV-1 virion proteins are 
shown in bold type on the left. V=virions, LP=L-particles, E=envelope fraction, CT=capsid/tegument 
fraction.
Chapter 4: Results
The UL17 protein (predicted mass 74584.1 Da) was expected to comigrate with the 
UL47 protein (predicted mass 73818.7 Da) on polyacrylamide gels. UL47 is a major 
component of virions, so a UL47‘ virus was utilised so that minor proteins that might 
comigrate with the UL47 protein could be analysed. The UL47' virus used contained a 4 
bp insertion at the Kpnl site at position 103010 bp in the the HSV-1 sequence and was 
produced by C. Cunningham. In Fig. 25, two bands (a and b) are evident in the region 
of the Coomassie blue-stained gel which usually would be obscured by the UL47 
protein. These bands were isolated from a stained membrane, digested with trypsin and 
subjected to laser desorption mass spectrometric analysis. It was not possible to 
distinguish between the two bands during excision and so they were analysed together. 
Fig. 26a shows a typical mass spectrum obtained from analysis of bands a + b. The 
peaks are small and the background is high, as is typical of minor proteins. The values of 
all credible peaks were entered into the Massmap search program, which compares them 
with the profiles of proteins whose sequences are present in a database (Genbank). Fig. 
26b shows the proteins identified from the results obtained in Fig. 26a. From the 
thousands of proteins searched, UL46 and UL17 were identified as the best two 
matches. Fig 26c shows the masses which are unique to each protein or which are 
shared by both. UL17 and UL46 share four peptide masses, but each has enough unique 
masses to indicate its presence in this region. The UL46 protein (predicted mass 
78246.3 Da) normally migrates with a greater apparant mass by SDS-PAGE (see Fig. 
25), and the minor form detected in bands a + b may be an alternatively processed form.
In Fig 25, a number of faint bands are also visible in the 20-40 kDa region of the stained 
gel. Analysis of band c (as described above) indicated the presence of the UL14 protein 
in conjunction with other proteins. Fig. 27a shows the mass spectrum obtained. 
Analysis of these peptide peaks indicated the presence of UL14 and UL49 (Fig. 27b). 
Fig. 27c shows the peptide peaks unique to each protein.
Since the proteins analysed were present in small amounts, it was difficult to produce 
enough material to analyse and so identification has been made at the limits of detection. 
However, various rounds of Massmap analysis from a number of different experiments 
indicate that the UL17 and the UL14 proteins are present in small amounts in HSV-1 
virions.
4.1.8. Assessment of an antibody potentially identifying the UL17 protein
A p-galactosidase fusion protein rabbit antiserum potentially directed against the UL17 
protein (residues 458 to 531) was produced by C. Cunningham but had not been 
evaluated, and so was used as a way of identifying the UL17 protein in Western blots.
86
Fig. 26. Mass spectrometric analysis of proteins a and b which comigrate 
with UL47
a A mass spectrum generated from analysis of bands a and b (see Fig. 25). All of the masses 
represent the protonated forms. The 3496.9 peak is the insulin B chain marker used to calibrate the 
spectrum.
b The Massmap program was used to identify the proteins by comparison of credible peaks from a 
with those of proteins stored in a database (Genbank). The search mass uncertainty was ±3 .3  Da and 
the search mass range 70-80000 Da. The results identified HSV-1 proteins UL17 and UL46 as the 
two best matches.
c The masses unique to each protein are shown: UL17 (4), UL46 (7) and those which the two proteins 
have in common (4).
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Fig. 27. Mass spectrometric analysis of protein c
a A mass spectrum generated from analysis of band c (see Fig. 25). All of the masses represent the 
protonated forms. The 3496.9 peak is the insulin B chain marker used to calibrate the spectrum.
b The Massmap program was used to identify the proteins by comparison of credible peaks from a 
with those of proteins stored in a database (Genbank). The search mass uncertainty was ± 3  Da and 
the search mass range 20-40000 Da. The results identified HSV-1 proteins UL14 and UL49.
c The peaks unique to each protein are shown: UL14 (4) and UL49 (4).
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Pre-immune and immune sera reacted similarly with several virion proteins from wt or 
the UL47' mutant, despite carrying out reactions under a range of conditions (data not 
shown). The antiserum also failed to identify a convincing candidate protein in infected 
cells. These results imply that the antisera does not contain antibodies against UL17.
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4.2. CHARACTERISATION OF UL16" MUTANTS
4.2.1. UL16‘ MUTANTS
The cosmid system does not lend itself readily to generating revertants since there is no 
general basis on which to identify them. An alternative approach is to generate a number 
of independent mutants with lesions in the target gene in order to resolve potential 
problems associated with spontaneous secondary mutations. Therefore, during this 
work six UL16' mutants were analysed. Having produced the mutants, it was found that 
revertants could be isolated on the basis of plaque size (see Section 4.2.2.1).
4.2.1.1. Production of mutants
Two UL16' mutants (la  and lb) which have a 4 bp insertion at the BgUl site 
(A’GATCT) at position 31096 bp were produced from two independently derived mutant 
cosmids by C. Cunningham using a different cosmid set from that described in Section 
4.1 (set C in Cunningham and Davison, 1993). C. Cunningham also provided cosmids 
with a 16 bp insertion containing stop codons in all reading frames 
(GATCTAATCTAGATTA) proportedly inserted at each of the three Sau3Al (‘GATC) 
sites in UL16, and a further four UL16* viruses were produced from these. During the 
course of this work, therefore, six mutants with insertions in UL16 were produced: la  
and lb first (generated by C. Cunningham), followed by mutants lc, Id, 2a and 3a 
(generated in the course of this work). Also, two independent wt viruses were derived 
from the parental cosmid set (cosvvtfl and coswr2). The locations of the mutations are 
summarised in Table 13 and Fig. 28.
4.2.1.2. Mutant genotypes
Infected cell DNA from mutants la and lb was digested with Kpnl plus BglQ. and the 
infected cell DNA of mutants lc, Id, 2a and 3a with Xbal plus EcoRL. Southern blots 
were probed with a plasmid containing Kpnl q. Fig. 29 shows the results for la  and lb . 
Wt virus exhibits bands of 2041 bp and 1351 bp; an additional 426 bp fragment would 
have electrophoresed from the bottom of the gel. The mutants exhibit the 2041 bp 
fragment plus a novel 1777 bp fragment resulting from fusion of the 1351 and 426 bp 
fragments. The results in Fig. 30 confirm the genotypes of the other UL16' viruses. Wt 
virus exhibits one large band of 15252 bp. The insertion of the oligonucleotide creates a 
novel Xbal site which causes the cleavage of the 15252 bp fragment into two smaller 
fragments.
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Table 13. UL16- mutants
Viruses Insertion at position Type of insertion p ro S a q ^ r.re ^ d u e s ).
coswM none none - w t 373 (full length)
coswf2 none none - w t 373 (full length)
1a 31096 bp 4 bp 84(18)
1b 31096 bp 4 bp 84(18)
1c 31096 bp Cl
_
Q
C
O 66 (0)
1d 31096 bp 16 bp 66 (0)
2a 30671 bp 16 bp 208 (0)
3a 30181 bp 16 bp 371 (0)
The number in parenthesis indicates the additional residues produced after the insertion.
31293  bp
-------►
UL16
31096 bp 
1a, 1b, 1c, 1 d
▼
30671 bp 
2a
30174  bp
30181 bp 
3a
Fig. 28. Positions of insertion mutations in UL16
The e n dso fthe  UL16 coding sequence are qiven with respect to the HSV-1 DNA sequence and the 
direction of transcription is shown by a horizontal arrow (Table 13 contains further details).
Mutant cosmids lc, Id, 2a and 3a were also sequenced to confirm the sites into which 
the oligonucleotide had been inserted, by ligating an XbaVHaelll digest of the cosmid 
with Xba\JHae\\\ digested Ml3mp 19 (see Section 3.38). As an example, Fig. 31 shows 
the sequence of the mutation in 2a, and confirms that the insertion occurred at 30671 bp 
in the HSV-1 sequence.
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Kpn\ q
28628 bP^TTTTI: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : rT:T::T:: : : IT:I: : : : : : : : : : : : : : :  32447 bpi : : : : : : : : ; * * ; : : : : : : : : : : : : : : : : : : : : : :  • :
2041 bp 426bp 1351 bp
Bgl\\ sites 
30669 bp 31096 bp
▲
Loss of site following 4 bp insertion 
to yield
2041 bp 1777 bp
cos wt 
1 2
Fig. 29. G enotypes of UL16" mutants 1a and 1b
A A map of the 3819 bp Kpnl q fragment is shown as a shaded rectangle. The two BglW sites are 
denoted by vertical lines and the sizes of fragments generated following BglW digestion are given. 
After insertion of 4 bp at 31096 bp, the BglW site is lost, resulting in the generation of a novel fragment. 
Not drawn to scale.
B An autoradiograph of a Southern blot in which infected cell DNA was digested with Kpnl plus BglW 
and probed with a plasmid containing Kpnl q. The sizes of the fragments detected are shown.
A Kpnl q 28628-32447 bp
3a
2a
31081 bp
30671 bp
lc and Id ■<
30197 bp
860 +
►  14392 bp
1335 + 
13917 bp
1745+ 
13507 bp
UL16-
B
Also a 16745bp 
EcoRI fragment
15252 bP 
13507 bp 
13917 bp 
14392 bp
1745 bp 
1335 bp
860 bp
c o s
wt2 1c 1 d 3a 2a
c o s
wf\ wt
Fig. 30. Genotypes of UL16" mutants 1c, 1d, 2a and 3a
A A map of the 15252 bp EcoRllXbal fragment (hatched rectangle) which contains UL16 (shaded rectangle). The 
Sau3AI sites into which the oligonucleotide was inserted are denoted by vertical lines. Insertion results in the gain 
of a novel Xbal site. The sizes of the two predicted novel fragments following digestion with EcoRI plus Xbal are 
given on the right. The region covered by the Kpnl q probe is shown by a shaded rectangle. As well as binding to 
these fragments, the probe also binds to an HSV-1 16745 bp EcoRI fragment, the right end of which is denoted by 
an open box.
B An autoradiograph of a Southern blot in which infected cell DNA was digested with Xbal plus EcoRI and probed 
with a plasmid containing Kpnl q. The sizes of the resulting bands are given in bp.
G A T C  C T A G
..GTCGCTGTCCATCCCAGCAGTAGATCTAATCTAGATTAGATCTGGCCGCTGGGGAGGTGCCACCA..
I
Fig. 31. Confirmation of the lesion in mutant 2a by sequencing
An autoradiograph of a sequencing gel in which the position of the insertion of an oligonucleotide into the 
Sau  3AI site at position 30671 bp within gene UL16 is confirmed. The sequence from the 
autoradiograph corresponds to the expected sequence shown below the figure. The novel Xbal site 
generated is underlined.
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4.2.2. IN  V ITRO  ANALYSIS OF UL16' MUTANTS
Mutants la and lb were constructed prior to the commencement of this work and were 
used in all of the experiments. Additional mutants were used in selected experiments. 
HSV-1 wt and cosvvrl or coswr2 were used as wt controls.
4 .2 .2 .1 . P laqu e area
In initial virus titrations on BHK C13 cells it became obvious that the mutants la and lb 
had a smaller plaque size than the wt viruses. In an experiment designed to allow 
statistical comparisons of this aspect of the mutant and wt viruses, plaque area was 
measured by photographing Giemsa-stained infected cell monolayers, cutting out the 
plaques from prints and weighing them. Mutant virus plaque size was 14-19% (la) and 
24-35% (lb) that of wt plaques on BHK C13 cells, a hamster fibroblastoid cell line 
(Table 14 a and Fig. 32A). CosvvH plaques were the same size as wt (80-102%). The 
viruses were also titrated on MeWo cells, a human fibroblastoid cell line, and mutants 
produced plaques 31-64% (la  and lb) the size of wt (Table 14b).
Table 14. Relative plaque areas 
(a) BHKC13
Virus
Expt 1a
No of plaques 
examined
2 days pi
% ° f w t-
plaque area*
Expt 2b
No of plaques 
examined
2 days pi
% of 
plaque area
No of plaques 
examined
rlauc ni■ uays pi. ;.*
coswM 60 80 ±15 54 102 ±20 31 87 ±12
1a 111 15 ±6 87 14 ±5 52 19 ±6
1b 107 25 ±7 82 24 ±8 46 35 ±10
a = 69 wt plaques examined (100%±9) b = 39 wt plaques examined (100%±15) c = 35 wt plaques examined 
(100% ±12) d = ±SD
(b) MeWo
Expt 1a 2 days pi Expt 2b 2 days pi Expt 3C U Idays ph
Virus
*
No of plaques 
examined
%-ofwr
plaque aread
No of plaques • » examined
% of wt■ iplaque area
No of plaques r . n , 
examined plaque area
coswM 48 99 ±15 54 60 ±10 40 124 ±20
1a 45 64 ±10 72 31 ±9 51 46 ±10
1b 52 61 ±8 49 31 ±7 46 64 ±12
a = 45 wt plaques examined (100%±18) b = 48 wt plaques examined (100%±10) c = 41 wt plaques examined 
(100% ±15) d = ±SD
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The effect of the UL16 mutation seems to be more marked on BHK C l3 cells. The 
difference in the plaque size between the two mutants was not significantly different.
The previous three experiments were independent, but they were carried out within a few 
days of each other. Therefore, the experiment was repeated at a later date and extended 
to include additional mutants and c o s w t 2. The results (Table 15 and Fig. 32B) show that 
mutants la-d (which are mutated at the same site) have similarly sized plaques on BHK 
C13 cells (20-27% the size of wt). The two coswf viruses and mutant 3a (which is 
missing only the last 2 residues of the UL16 protein) had plaques the same size as wt. 
Mutant 2a gave plaques that were only 4% the size of wt.
Table 15. Relative plaque areas on BHK C13 cells
Expt 4a 2 Days pi
Virus No of plaques 
examined
% of wt plaque 
area ±SD
coswH 30 109 ±18
cos i/i/f2 44 92 ±14
1a 32 26 ±8
1b 39 25 ±5
1c 68 20 ±6
1d 53 27 ±7
2a 132 4 ±2
3a 37 97 ±12
3 = 40 wt plaques examined (100%±14)
These results indicate that the last two residues of UL16 are dispensible for formation of 
plaques of wt size, and suggest that the larger portion of the UL16 protein produced by 
2a may interfere with the normal function of the protein to a greater extent than the 
portion of the protein produced by mutants la-d. The possibility that 2a contains another 
mutation which is contributing to plaque size is considered unlikely (see below).
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Fig. 32. Differences in plaque size
Photographs were taken of Giemsa-stained plaques at 2 d pi in two separate experiments, A and B. Typical 
plaques are shown, (a) wt, (b) cosw/1, (c) 1a, (d) 1b, (e) 3a, (f) 2a. See Tables 14 and 15 for details.
2041 bp 
1777  bp
1351 bp
Revertants
i
U L1 6 -
Wt 1b 1 2 3 4 5 6 7 8 9 10 11 12
Fig. 33. S tatus of recovered virus after co-transfection of UL16“ 1b DNA and a 
plasm id containing wt UL16
An autoradiograph of a Southern blot in which infected cell DNA prepared from large plaques (1-12) 
were digested with Kpnl, transferred to a membrane and probed with a plasmid containing Kpnl q.
The UL16' 1b lane shows the mutant banding pattern from fusion of two fragments (see Fig. 29 for 
details). The sizes of the detected fragments are given in bp.
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Revertants or rescuants (1 b rev and 2a rev) were produced from mutants 1 b and 2a to 
confirm the relationship between loss of the intact UL16 protein and small plaque size, 
and for use in in vivo analysis (see Section 4.2.4.1.).
Mutant lb DNA was cotransfected into BHK C l3 cells with plasmid p i, which contains 
UL16 in its entirety, linearised with Sphl (see Section 4.2.4.1). Revertant or rescuant 
(large) plaques were present at a higher proportion than would be expected from a 
plasmid recombination experiment, suggesting that a proportion had arisen by 
intramolecular recombination within the 4 bp direct repeat at the site of the lesion. Large 
plaques were picked, and KpnVBglW digested infected cell DNA was produced and 
probed with a plasmid containing Kpnl q. All recovered viruses were wt (Fig. 33). 
Revertants or rescuants were also obtained from mutant 2a (data not shown).
Examination of the plaque size of revertants and mutants was carried out as described 
previously. Revertants from mutants lb and 2a produced plaques the same size as wt, 
while the original mutants produced small plaques as before (Table 16). These results 
indicate that the mutations in UL16 are directly linked to plaque size.
Table 16. Relative plaque areas on BHK cells.
Expt 5a 2 days pi
Virus No of plaques 
examined
% of wt plaque 
area ±SD
coswfl 40 107 ±10
1b 79 34 ±9
2a 95 7 ±3
1b rev 36 97 ±12
2a rev 42 101 ±18
a = 35 wt plaques examined (100%±9)
4.2.2.2. Growth characteristics
The growth characteristics of the mutants under conditions of high or low moi were 
investigated, since the smaller plaque size of the mutants could be due to a slower growth 
rate or to a lower yield of infectious virus. BHK C 13 cells were infected with mutant 1 a, 
mutant lb, cosvvH or wt virus at high (10 pfu/cell) or low (0.01 pfu/cell) moi and yields 
were calculated during the period 0-36 h pi for high moi and 0-96 h pi for low moi. The
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cells were scraped into 2 ml of medium, sonicated and titrated on BHK C13 cells. The 
results (Fig. 34a and b) show that mutants la and lb grew to about 20-30% of the final 
titre of the two wt viruses in both high and low multiplicity infections. It is of interest 
that the mutants show a delay in the initiation of growth, this corresponds to the results 
obtained from EM analysis (Section4.2.2.5).
In a second experiment, BHK C13 cells were infected with each of the mutants and w t  
viruses at low moi. Fig. 35 shows that mutants la-d grew to about 20-30% of the final 
titre of the two wt viruses. The growth curve of mutant 3a was similar to that of wt, 
whereas mutant 2a was about 15,000-fold reduced in yield. The growth characteristics 
correlate with the plaque area results: mutants la-d were impaired, mutant 3a was 
indistinguishable from wt virus and mutant 2a was severely impaired.
4.2.2.3. Growth on different cell lines
Mutants la and lb, cosvvrl and wt were tested in a single experiment for their ability to 
grow on cell lines other than BHK C13 and MeWo. The cell lines tested are shown in 
Table 17a. Cells on 35mm 6-well plates were infected with virus (1 x 104 pfu/plate), 
incubated at 37° for 3 days, scraped into the medium, sonicated and titrated on BHK C13 
cells. The virus yields are shown in Table 17b.
Table 17. Growth on different cell lines
(a) Cell types investigated
Cell line Type Reference
HeLa Human epithelial Scherer et a/., 1953
HFL/2002 Human fibroblastoid Breul etai, 1980
BSC-1 Monkey epithelial Hopps et al., 1963
CV1 Monkey fibroblastoid Kit etai, 1965
MDCK Canine epithelial Madin and Darby, 1958
BHKC13 Hamster fibroblastoid McPherson and Stoker, 1962
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Fig. 34. High and low multiplicity growth curves of wt  and mutant viruses
(a) BHK C13 cells were infected with virus at 10 pfu/cell and maintained at 37°C  for time points of 0- 
36h pi, or (b) BHK C13 cells were infected with vims at 0.01 pfu/cell and maintained at 37°C  for a 
period of 0-96h pi. Vims yield was titrated on BHK C13 cells. The standard deviation is shown as an 
appropriately coloured bar above and below the value at each time point.
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Virus Final titre (96h pi) ±SD
wt 4.0 ± 0.03 x I09
cosvr'/1 6.8 ± 0.017 x I09
la 1.3 ± 0.3 x I09
lb 2.1 ±0.051 xlO9
cosw/2 5.4 ± 0.13 xlO9
lc 1.8 ± 0.088 x 109
Id 7.4 ± 0.029 x I08
3a 3.6 ± 0.2 x 109
2a 2.3 ± 0.26 xlO5
Fig. 35. Low multiplicity growth curve of wt  and mutant viruses
BHK C13 cells were infected with virus at 0.01 pfu/cell and maintained at 37°C  for periods of 0-96 h pi. 
Virus was titrated on BHK C13 cells for 2-3 days before the plates were stained and the plaques 
counted. The table shows the titre at the last time point ±standarddeviation.
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(b) Yield of virus
-
Titre of w t Titre of coswtl Titre of 1a Titre of 1b
HeLa 5x106 7.5x10s (150)a 7x105 (14) 6.5x105 (13)
HFL/2002 1 x109 1x109 (100) 7.2x107 (7) 8.7x107 (9)
BSC-1 1.8x10s 3x10® (166) 3.5x107 (19) 2.4x107 (13)
CV1 —k X o o
o
1.4x108 (100) 2.7x107 (19) 1.9x107 (14)
MDCK 5.5x10s 5.5x10® (100) 4x10s (7) 2.5x10s (5)
BHKC13 5x107 9x107 (180) 8x106 (16) 8.4x10s (17)
a = The number in parenthesis is the yield as a percentage o f  the wr yield
These results show that the mutants grew on four of the cell lines to about 13-19% of wt. 
Yields were somewhat lower on HFL and MDCK cells (5-9%).
4.2.2.4. Particle:pfu ratio
Mutant la, mutant lb, cosvvfl and wt virus were harvested late in infection (2-3 d pi) 
from single roller bottle stocks of infected BHK C13 cells. Cell-released particles were 
counted by Mr J. Aitken and virus yields were titrated on BHK C13 cells. In the first 
experiment, the particle:pfu ratio of the wt viruses was found to be within the normal 
range observed for wt HSV-1, while those of the mutants was 30-37 (la) or 8-10 (lb) 
times greater. In a second experiment, the wt ratio was lower but still within expected wt 
values, whereas the mutant values were 4-5 fold higher (Table 18).
Table 18. Particle:pfu ratio
----------- ----------- 1
Experiinent 1
r—
Exper
coswtl
ment 2
r —
pfu 1.4x1010 2x10 10 2.4x108 1.1 x109 3.2x10 10 2.1x10 11 8.2x109 6.6x109
oc 2.5x10 11 2.9x1011 1.3x10 11 1.6x10 11 2x10 11 1.5x1011 2 x 1 0 11 2x10 11
ratio 17.8 14.5 541 145 6 7 24 30
4.2.2.5. EM analysis
The ability of the mutants to produce the normal range of viral particles was investigated 
by EM. BHK C13 cells were infected with mutant la, mutant lb, coswtl or wt virus at 
high moi and fixed at 9 or 16 h pi. The mutants produced all three types of capsid in
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normal ratios (data not shown). It was noted, however, that mutant-infected cells 
contained fewer virions. The results in Section 4.2.2.4, however, indicate that the 
mutants produced the same number of particles, although the number of infectious 
particles was less. This may be explained by the different samples used (CR virus for 
particle counts and CA virus for EM) and the times in infection when the samples were 
examined (2 days pi for particle counts and 9-16 h pi for EM). The mutants may be 
slower to produce viral particles initially but reach wt levels later in infection.
4.2.2.6. Temperature sensitivity
A single experiment was carried out to investigate the ability of the mutants to grow at 
different temperatures. BHK C13 cells were infected at 10 pfu/cell with mutant la, 
mutant lb, coswtl and wt virus at 31°, 37° or 39.5° for 16 h and then titrated on BHK 
C l3 cells at 37°. The results in Table 19 show that the titre of mutants la and lb was 12- 
25 fold less than wt at 37°, 4-10 fold less at 31° and 5-fold less than wt  at 39.5°, and 
indicate that the mutants are no more temperature sensitive than wt.
Table 19. Viral yields at three different temperatures on BHK C13 cells
Virus 31° 37° 39.5°
w t 1.4x108 2.8x108 1.7x107
coswtl 7.8x107 1.5x108 8.6x106
1a 1.3x107 1.2x107 1.7x106
1b 2x107 1.1x107 3.1x106
4.2.2.7. Efficiency of adsorption and penetration
Experiments were carried out to ascertain whether the mutants are able to adsorb to and 
penetrate cells as efficiently as wt. Mutants la and lb, cosvvrl and wt were allowed to 
adsorb to cells at 4° for 30-60 min, or at 37° for 0-120 min, then non-adsorbed virus was 
removed by washing the cells with PBS A. Infected cells were incubated at 37° for 2-3 
days pi before staining and counting plaques.
To investigate penetration, vims was adsorbed for 10 min at 4° and unbound vims was 
removed by washing with PBS A. Cells were maintained at 37° for a period of 5-60 min 
and washed with PBS A to remove unbound vims or with a low pH buffer to remove 
non-penetrated and unbound vims. Infected cells were incubated at 37° for 2 days before 
staining and counting plaques.
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The adsorption results are shown in Fig. 36a and b and the penetration results in Fig. 37. 
Adsorption o f the mutants appears to be as efficient as wt and penetration is slightly 
reduced from wt.
4.2.2.8. Binding of virus to cells
Confluent BHK C13 cells were infected with radiolabelled virions and maintained at 37° 
for periods of 0-2 h. The percentage of virus bound to the cells at each time point was 
calculated using the equation described in Section 3.12. These results indicate that there 
may be a very slight impairm ent of the ability of mutant lb  to bind to cells (Fig. 38).
4.2.2.9. Effect of interferon treatment on virus yield
Su et al. (1993) mapped a region o f the HSV-1 genome conferring resistance to 
interferon a  and (3 (IFN) to UL14, UL15 and UL16. Therefore, the U L16 m utants were 
exam ined to see whether they are more sensitive to IFN than wt. IFN -sensitive H FL 
cells were pretreated overnight with lU/ml IFN-ot, washed twice with medium and then 
infected at 5 pfu/cell. Untreated HFL cells were also infected as controls. At 24 h pi the 
cells were scraped into 2 ml o f medium and viral yields determined by titration on 
untreated BHK C l 3 cells (Table 20).
Table 20. Virus yields from cells pretreated with interferon
Virus Expt 1 Expt 2
Untreated IFN-
treated
%0f
untreated
Untreated IFN-
treated
% of 
untreated
wt 2x1010 6x109 30 1.4x1010 1x101° 71
coswtl 4.2x1010 3x1010 71 3x1010 1.6x1010 53
coswt2 4.5x1010 1.1 x1010 24 2.4x1010 1.4x1010 58
1a 9.2x109 2.3x109 25 8.1x109 8x109 99
1b 3x10 9 2.8x109 93 4.8x109 3.1x109 65
1c 1.6x10 10 9.2x109 58 2.9x109 1.7x109 59
1d 2.6x109 6.8x108 26 4.4x109 3.7x109 84
2a 2.7x107 4.6x106 17 2.3x107 1 x107 43
3a 2.7x10 10 2x109 7 1x101° 8.4x109 84
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Fig. 36. Virus adsorption
BHK C13 cells were infected at 200 pfu/plate at 4° for 10 min then non-adsorbed virus was removed. 
The plates were maintained (a) at 4° or (b) 37°, then the cells were washed at various time points to 
remove non-adsorbed virus. The cells were maintained in medium for 2-3 days, then the plates were 
stained and plaques counted. The standard deviation is shown as an appropriately coloured bar above 
and below the value at each time point. It must be noted that in some cases the SD bar is found behind 
another bar or value marker and cannot therefore be clearly observed.
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Fig. 37. Virus penetration
BHK C13 cells were infected at 200 pfu/plate at 4°C for 10 min then non-adsorbed virus was 
removed. The cells were incubated at 37°C and then washed at various time points with either PBS A 
or low pH buffer. The cells were incubated for 2-3 days, then the monolayers were stained and 
plaques counted. The standard deviation is shown as an appropriately coloured bar above and below 
the value at each time point.
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Fig. 38. Binding of virus to cells
BHK C13 cells were infected with 105 particles/cell and 104-105 cpm of [35S]-methionone-labelled 
virions. At various time points, the supernatant was removed, and the cells were washed and 
scraped into medium. Radioactivity in these samples was counted in a scintillation counter and the 
results expressed as percentage binding. The standard deviation is shown as an appropriately 
coloured bar above and below the value at each time point.
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The yield of wt virus on treated cells was expected to be reduced to 10-50 % of the 
untreated value, depending on the amount of interferon used and the cell type used 
(Munoz and Carrasco, 1984; DeStasio and Taylor, 1990; Chatteijee et al., 1995). 
Therefore if the mutation of gene UL16 caused a significant difference in interferon 
resistance, the mutants would fail to replicate on interferon treated cells. Results from 
these experiments indicate that there is substantial variation in the reduction in yield 
caused by IFN treatment and that UL16 does not play a role in conferring interferon 
resistance.
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4.2.3. IDENTIFICATION OF THE UL16 PROTEIN
Several techniques were employed in an attempt to identify the UL16 protein, which has 
a predicted mass of 40444.2 Da, and is produced late in infection.
4.2.3.1. Western blotting and Immune precipitation
Two P-galactosidase fusion protein rabbit antisera potentially directed against the UL16 
protein (residues 309 to 373) were available in the laboratory, but had not been tested 
previously, so an attempt was made to identify the UL16 protein using these antisera.
Mutant lb and wt virions were fractionated into envelope and capsid/tegument fractions, 
which were electrophoresed, blotted and then incubated with a potential UL16 antibody 
(16Ab/l) (1/200 dilution of stock). No significant difference was observed between the 
results obtained using pre-immune and immune sera (Fig. 39A). A second UL16 
antibody (16Ab/2) (1/200 dilution of stock) also failed to identify a convincing candidate 
protein in infected cells (Fig. 39B). Various conditions of Western blotting were 
assessed in order to reduce non-specific binding, including longer washing periods, 
more frequent washes and increased amounts of detergent in the wash buffer, but these 
did not significantly improve the results. These antibodies may not recognise the UL16 
protein, or may not be sensitive enough to detect the protein if it is made in small 
amounts.
TheUL16 antisera were also used in immune precipitation reactions utilizing extracts of 
infected BHK C l3 cells pulse labelled with [35S]-methionine or [35S]-cystine for periods 
of 2 h to 12 h pi or throughout infection (4-24 h pi). Attempts to detect a specific 
reaction yielded no obvious difference between mutant and wt (data not shown). The 
extraction and reaction buffers were varied in an attempt to improve the results but this 
was of no benefit.
In summary, use of antisera potentially recognising the UL16 gene product did not lead 
to identification of the protein.
4.2.3.2. Pulse labelled infected cells
BHK C13 cells were infected with virus and labelled with [35S]-methionine for 2 or 4 h 
intervals up to 12 h pi or throughout infection (4-24 h pi). Analysis of electrophoretically 
separated proteins revealed differences in the banding pattern between the la  and lb 
mutants and coswtfl and wt virus (band a; 42 kDa) (Fig. 40). Close examination 
revealed that mutant la  and coswtfl share a band in common and mutant lb  and wt virus 
share a band in common which is lower in mobility. This difference was consistently
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Fig 39. Western blot of wt and UL16" virions and virus infected cells
An autoradiograph of a Western blot in which virion fractions (A) or infected cell extracts (B) were 
electrophoresed on a 9% acrylamide gel, electroblotted onto a membrane and incubated with a 
candidate UL16 antibody (UL16Ab/1 or 2) or pre-immune serum. PI is pre-immune serum, w t l s w t  
virus, 16 is UL16" virus, V=virions, LP=L-particles, c/t=capsid/tegument fraction, e=envelope 
fraction. Size markers were not included on the acrylamide gels.
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Fig. 40. Candidate UL16 protein in wt, coswfl, mutant 1a and 1b infected 
cells (labelled with [35S]-methionine)
An autoradiograph of a 12% polyacrylamide gel in which pulse labelled infected cells were subjected 
to SDS-PAGE. The region of the gel containing the 4-24 h labelled cells is shown. The bands 
refered to in the text ( a -4 2  kDa and b -4 0  kDa) are indicated on the right. Actin is denoted by an 
arrow and molecular weights are given on the left in kDa. M is mock infected.
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observed. On the same autoradiograph, another difference in the same area was 
observed: a band appeared to be present in both wt samples but not the mutants (band b; 
40 kDa) (Fig. 40). This band represents a candidate UL16 protein. Further attempts to 
resolve this region of the gel were made using acrylamide/DATD gels, but failed to 
provide additional information (data not shown).
4.2.3.3. In vitro transciption and translation
The UL16 protein was produced in vitro in order to help identify the protein in 
radiolabelled extracts of infected cells.
Kpnl q was digested with Bsu36l and BssSI to excise the fragment containing UL16 and 
457 bp at the 5’ end and 134 bp at the 3’ end (29717-31427 bp in the HSV-1 sequence). 
This fragment was cloned in both orientations into the Smal site of pGEMl and pGEM2 
under control of the T7 and SP6 promoters, giving rise to four UL16-containing 
plasmids: pi (UL16 inserted into pGEMl under control of the T7 promoter), p2 
(pGEMl/sp6), p3 (pGEM2/T7) and p4 (pGEM2/sp6). The plasmids were transcribed 
and translated in vitro and the resulting proteins, labelled with [35S]-methionine or [35S]- 
cystine, were subjected to SDS-PAGE. Fig. 41 and 42 show that the UL16 protein was 
produced from all four plasmids (approximately 39 kDa). In both cases the UL16 
protein was produced in greater amounts from the T7 promoter. The UL10 protein was 
produced as a control for the the procedure. A plasmid containing UL20 was also used 
but it did not produce a protein.
In order to confirm that the 39 kDa protein is the product of UL16, p i was cleaved 
within the UL16 sequence. Digestion with BamHl and Clal results in cleavage of the 3’ 
terminal 395 bp of UL16 (tl), and digestion with Pstl removes the 3’ terminal 197 bp of 
UL16 (t2). Fig. 43 shows that a truncated UL16 protein was not detected using the 
template cleaved with BamHl and Clal (tl) (the protein would have electrophoresed from 
the bottom of the gel). Digestion with Pstl (t2) produced two bands, one of 39 kDa and 
one of approximately 35 kDa. The production of both the wt protein and truncated 
protein was due to partial digestion. Controls for the procedure were as described above.
The UL16 protein produced in vitro (39 kDa) does not correspond in mobility to any 
viral protein detected in methionine- or cystine-labelled infected cells, including the 
candidate UL16 protein identified in Section 4.2.3.2, which has a lower mobility (band 
b; 40 kDa) (see Fig. 41 and 42). This may be due to differences in modification between 
the viral UL16 protein and the protein produced in vitro from E. coli.
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Fig. 41. In vitro transcription and translation of plasmids containing UL16 
(labelled with [35S]-methionine)
An autoradiograph of a 12% polyacrylamide gel in which [35S]-methionine labelled proteins were 
separated. The products of plasmids p1, p2, p3, p4 (see text for details) pfc), UL10 (O ) and luciferase 
(□ )  are indicated. [35S]-methionone and [35S]-cystine labelled infected cells were used as markers. 
The candidate UL16 protein (b; 40 kDa) is shown by an arrow on the left. Actin and UL49 proteins 
are denoted by arrows and molecular weights are given in kDa on the left.
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Fig. 42. In v i t r o  transcription and translation of plasmids containing UL16 
(labelled with psS]-cystine)
An autoradiograph of a 12% polyacrylamide gel in which [35S]-cystine lalelled samples were 
separated. The products of plasmids p1, p2, p3, p4 (see text for details) (^ ) ,  UL10 (O) and 
luciferase (□ ) are shown. [35S]-methionone and cystine labelled infected cells were used as 
markers. The candidate UL16 protein (b; 40 kDa) is identified in the methionine labelled sample by an 
arrow. The actin and UL49 proteins are denoted by arrows and molecular weights are given in kDa 
on the left.
4 —  A ctin  
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Fig. 43. Confirmation of the in vitro transcription and translation product of 
plasmid p1 by truncation of the gene
An autoradiograph of a 12% polyacrylamide gel in which [35S]-cystine labelled samples were 
separated. Plasmid p1 was either uncut (U), linearised (L) or digested with BamH\ICIa\ (t1) or Psfl 
(t2). UL10 and UL20 were expressed from the T7 promotor as controls. The products of plasmids 
p1 truncation t2 ( • )  and control UL10 (O) are shown. p5S]-methionone and cystine labelled 
infected cells were run as markers. The candidate UL16 protein (b; 40 kDa) is denoted by an arrow 
on the right. The actin and UL49 proteins are denoted by arrows and molecular weights are given in 
kDa on the right.
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It was noted that neither the candidate band (band b; 40 kDa) nor any other protein in the 
same region was prominent in the cystine-labelled infected cell extracts (see Figs. 41 and 
42). Since the predicted UL16 protein contains 20 cysteine residues in the coding 
sequence and only three methionine residues, it was expected that the UL16 protein 
should be relatively easier to identify in [35S]-cystine labelled cells.
Taking into account the relative intensities of actin (which contains 17 methionine 
residues and six cysteine residues) and the UL49 protein (which contains four 
methionine residues and two cysteine residues) in [35S]-methionine and [35S]-cystine 
labelled infected cell extracts (see Figs. 41 and 42; Met and Cys marker tracks), results 
indicate that neither the candidate band nor other bands in this region of the gel exhibit 
relative intensities consistant with their identity as the UL16 protein.
In summary, failure to identify the UL16 protein indicates that it may be a very minor 
protein, may comigrate with a more abundant protein, or may be processed such that it 
migrates to a different region of the gel.
4.2.3.4. Mass spectrometric analysis
On Coomassie-blue stained polyacrylamide gels, there was no obvious difference 
between the protein profiles of mutant lb and wt virions (data not shown). However, 
since the protein encoded by the UL16 counterpart was identified in the virions of EHV-1 
virus by mass spectrometric analysis (43kDa) (AJ. Davison, personal communication) 
(see Section 4.1.7), a number of faint protein bands in the 40 kDa region were subjected 
to laser desorption mass spectrometry during analysis of the UL17 and UL14 proteins 
(details in Section 4.1.7.), but the UL16 protein was not identified despite extensive 
analysis (data not shown).
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4.2 .4 . IN  V IVO  ANALYSIS OF UL16' MUTANTS
UL16 is not essential for virus growth in cell culture, although mutants la-d yielded 
approximately five to ten fold less virus than wt and have a smaller plaque size compared 
to wt. Since a number of genes which are non-essential in cell culture have been shown 
to have vital roles in vivo (see Section 1.9 for details), cosvv/1 and the UL16' mutants 
were tested for their pathogenicity and ability to replicate and establish and reactivate 
from latent infection in vivo using the mouse model.
4.2 .4 .1 . N eu roviru len ce
Two experiments were carried out at different times in which cosvvrl, UL16' mutants and 
revertants were injected into mice intracerebrally (IC). The inoculations were performed 
by Dr A. MacLean. The virus stocks were titrated on the day of use to confirm the 
amount of virus injected. Mice were injected with a range of doses and their clinical state 
was monitored for 14 days pi. LD50 values were calculated by the formula of Reed and 
Muench (1938), and the detailed results are given in Tables 21 and 22, and summarised 
Table 23.
Table 21. Fate of IC injected mice - experiment 1
. . .  . . . .  Virus/titre mouse 1 mouse 2 mouse 3
.
mouse 4 _mouse 5 Total LDS.
coswM 102 Ka 4d Sb S S .C 1/4 5x102
coswM 103 K5d s K5d S . 3/4
1a 102 S s S s _ 0/4 >3.16x105*
1a 103 S s S s s 0/5
1a 104 S s S s - 0/4
1a 105 S s S s - 0/4
1b 102 S s S s . 0/4 7x103
1b 103 S s S s s 0/5
1b 104 K5d K5d K7d s - 3/4
1b 105 K5d K5d K5d s - 3/4
a K illed on day stated pi. 
b Survived. 
c N ot done.
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Table 22. Fate of IC injected mice - experiment 2
Virus mouse 1 mouse 2 mouse 3 mouse 4 Total LD50
coswfUO2 Dd 8d D8d Sb S 2/4 102
coswfUO3 Ka 8d D8d K8d K8d 4/4
1a 103 S S S S 0/4 105
1a 104 S S S S 0/4
1a 105 K 3d K 3d S S 2/4
1b 102 S S S S 0/4 5x104
1b 103 K8d S S S 1/4
1b 104 K8d K8d K8d S 3/4
1d 102 S S S S 0/4 7x104
1d 103 K6d S S S 1/4
1d 104 K5d K5d S S 2/4
1b rev 102 K4d K4d K4d K4d 4/4 <6x101
1 b rev 103 K3d K 3d K4d K4d 4/4
a Killed on days stated pi. 
b Survived. 
d Died on date stated.
Table 23. Summary of LDS0 values from two experiments
Virus Expt 1 - LD50 Expt 2 ■ LD50
coswtf 5 x 102 102
1a >3.16 x105 105
1b 7 x 103 5 x 104
1d . a 7 x 104
1b rev - <6 x 101
a Not done.
It is evident that there is substantial variation between the two experiments, probably due 
to the age and state of health of the animals. This is discussed further in Chapter 5.
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In each of the experiments coswri produced an LD50 value within the wt range as defined 
by MacLean et al. (1991) (Dr A. MacLean, personal communication). Mutants la  and 
lb, which should be genetically identical, appeared in experiment 1 to be attenuated to 
different extents (103 and 101 fold respectively). However, this difference was not 
repeated in experiment 2; mutants la  and lb were attenuated to a similar degree (5 x 102 - 
and 103 fold respectively). These results firmly support the conclusion that mutants la 
and lb are attenuated, but experimental factors may be too variable to support the 
conclusion that they are attenuated to different degrees. Mutant Id, which has a different 
insertion at the same site as in la  and lb (see Fig. 28), was attenuated to a degree similar 
to la  and lb (7 x 102) in experiment 2. A revertant of lb (lb  rev) was virulent in 
experiment 2, and this indicates that the attenuation of the mutants is due to the UL16 
mutation.
The genotype of virus replicating in the brains of mice inoculated with mutant lb was 
tested. Vims was recovered by homogenising the brains and titrating the homogenate on 
BHK C13 cells. Small viral stocks were made and probing of Kpnl/B gill digests of 
infected cell DNA with a plasmid containing Kpnl q showed that all of the recovered 
viruses were mutant (Fig. 44). The presence of the 4 bp insertion in lb should result in 
the generation of a novel Clal site (AGATCGATCT), and probing of BamHl/Clal 
digested infected cell DNA with a plasmid containing Kpnl q confirmed the presence of 
this site (Fig. 45).
These experiments show that cosvvH and revertant lb are as virulent as wt and that 
UL16* mutants with a lesion at position 31096 bp exhibit significantly reduced 
neurovirulence, although they can replicate in the brain.
4.2.4.2. Latency
The ability of the cosvvH and mutants la and lb to establish and be reactivated from 
latency was examined by inoculation of 4 week old B ALB/c mice by a peripheral route, 
the footpad (FP). In accordance with the observation that inoculation of HSV-1 by the 
peripheral route results in a high LD50 (MacLean et al., 1991; McKie et al., 1994; Dr A. 
MacLean, personal communication), the LD50 of the mutants la  and lb and coswrl were 
high. The mutants exhibited higher LD50 values than wt, but, the difference was not 
accurately quantified (Table 24).
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Fig. 44. Virus recovered from the brains of mice infected with mutant 1b
A Map showing the RE profile of 1b mutants following digestion with KpnllBglW (not drawn to scale).
B An autoradiograph of a Southern blot in which KpnllBglW digested infected cell DNA was 
transferred from a 0.8% (w/v) agarose gel and probed with a plasmid containing Kpnl q. The sizes of 
detected fragments are shown.
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Fig 45. Confirmation of a novel C/al site in mutant 1b
A Map of the RE profile of ivfand 1b mutant following digestion with C/al/BamHl (not drawn to 
scale). The position of the sites and the UL16 coding region are shown. Kpnl q is shown above the 
figure.
B An autoradiograph of a Southern blot in which Bam  Hl/C/al digested infected cell DNA was 
transferred from a 0.8% (w/v) agarose gel and probed with a plasmid containing Kpnl q. The sizes 
of detected bands are shown.
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Fig. 46. Reactivation of viruses from latency
Mice were injected with virus into the footpad, ganglia were removed at six weeks pi and cultured for 
16 days. The rate of reactivation is expressed as the percentage of total ganglia tested at each 
concentration of virus.
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Table 24. Fate of FP injected mice
Virus
.
mouse 1 mouse 2 . mouse'3 mouse 4 l d 5o
c o s w fl 104 Sb S S S 0/4 7x106
coswM 105 s Ka 10d S s 1/4
coswM 106 s S s s 0/4
coswM 107 K 10d K9d s . c 2/3
1a 104 S S s . 0/3 >3.16x107
1a 105 S S s s 0/4
1a 106 S S s s 0/4
1a 107 S S s s 0/4
1b 104 S S s . 0/3 >3.16x107
1b 105 S S s s 0/4
1b 106 S S s s 0/4
1b 107 S S s s 0/4
a Killed on day stated pi. 
h Survived. 
c N ot done.
Reactivation of virus was investigated by removing ganglia from infected mice at 6 
weeks pi and culturing them in ETF10 for up to 21 days. Virus reactivated from all of 
the coswrl ganglia tested by 6 d post explantation. Mutants la and lb reactivated more 
slowly than coswrl but reached 90-95 % reactivation by day 16 (Fig. 46). A selection of 
• reactivated plaques were picked at 12 d post explantation, infected cell DNA was 
produced, and Kpnl/BgHI digests were probed with a plasmid containing Kpnl q. All of 
the recovered viruses from mutant la or lb infected mice were wt except for one which 
was a mixture of mutant and wt (Fig. 47).
This experiment was repeated using all of the UL16' mutants and an additional coswr 
virus. Cosw/1 reactivated much more slowly than previously, and did not reach 100% 
reactivation. Coswf2 reactivated less well and only reached 59% reactivation by day 20, 
a value still within the normal range for a wt virus (MacLean et al., 1991b; Dr A. 
Maclean, personal communication). The six mutants reactivated very slowly and only 
10-38 % of ganglia had reactivated after 20 days (Fig. 48).
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Fig. 47. Genotypes of reactivated viruses from ganglia of mice infected 
with UL16- 1a or 1b
An autoradiograph of a Southern blot in which Kpn\IBgl\\ digested infected cell DNA was probed with 
a plasmid containing Kpnl q. Infected cell DNA was produced from plaques picked at 12 days post 
explantation. The positions of detected fragments are shown (see Fig. 44 for additional details).
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Fig. 48. Reactivation of viruses from latency.
Mice were injected with virus into the footpad, and ganglia were removed at six weeks pi and cultured 
for 21 days. The rate of reactivation is expressed as the percentage of total ganglia tested.
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Infected cell DNA was made from a selection of reactivated viral plaques picked at 4-6 d 
post explantation, digested with the appropriate enzymes and probed with a plasmid 
containing Kpnl q. Fig. 49 shows that reactivated viruses from mutants lb, lc, Id, 2a, 
and 3a were wt. The virus recovered from mice infected with mutant la was mutant. 
The genotypes of la plaques picked later during reactivation (day 10-12) proved to be wt 
(2 plaques), mutant (1 plaque) and a mixture of wt and mutant (1 plaque) (Fig. 50). 
Thus, as reactivation progressed, wt virus was recovered from la-infected ganglia.
These results suggest that the mutants establish and reactivate from latency less efficiently 
than wt and that there is a strong selection pressure in favour of wt virus arising by 
reversion.
♦
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Fig. 49. Genotype of virus reactivated from ganglia of mice infected with 
UL16" mutants
An autoradiograph of a Southern blot in which X b a llE c o R l (1) or K pn \IB g l\\ (2) digested infected cell 
DNA was probed with a plasmid containing K p n l q. Virus was recovered at 4-6 days post 
explantation. The position of the detected fragments are shown (see Figs. 29 and 30 for details).
Fig. 50. Genotype of reactivated virus from the ganglia of mice infected with 
UL16" 1a mutant
An autoradiograph of a Southern blot in which K pn \IB gl\\ digested infected cell DNA was probed with 
a plasmid containing Kpnl q. Virus was recovered at 10-12 days (1) or 4-6 days (2) post 
explantation. The position of the detected fragments are shown (see Fig. 29 for details).
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5.1. Background
HSV-1 UL14, UL15, UL16 and UL17 are part of a block of genes (ULIO to UL19) 
which is conserved among the alpha-, beta- and gammaherpesviruses (Davison, 1993). 
They are expressed as late mRNAs (McGeoch and Schaffer, 1992).
UL15 is the only spliced gene in U l (McGeoch et al, 1988). UL15 homologues in the 
three herpesvims subfamilies have an equivalent structure with two exons, and a variable 
number of genes (2-4) in the intron (Dolan et al., 1991). In contrast, the proposed 
counterpart in CCV has three exons, and the boundary between the first and second 
exons corresponds precisely to that in other herpesviruses (Davison, 1992). 
Construction of an HSV-1 mutant expressing UL15 without the intron has shown that 
separation of the two exons is not essential for replication of HSV-1 in cell culture 
(Baines and Roizman, 1992b). The effect of the absence of the intron in an animal model 
has not been reported.
The UL15 protein contains potential ATP-binding motifs (Dolan et a l, 1991), and a 
possible function was suggested by Davison (1992) who noted that the UL15 protein 
may be related to a protein encoded by T4 bacteriophage gene 17. This protein is part of 
the phage terminase, or DNA packaging protein complex, and mutations result in the 
arrest of phage production during DNA packaging, leading to an accumulation of empty 
proheads and uncleaved concatemeric DNA (Bhattachorgga and Rao, 1993; Powell et al, 
1990; Carrascose and Kellenberge, 1978).
During the course of this work, Poon and Roizman (1993) described a ts mutant with a 
lesion in UL15. The mutant produced viral DNA at the NPT, but failed to package it into 
capsids. In a subsequent paper, Baines et al. (1994) showed that the UL15 gene encodes 
two proteins (one is a truncated form of the full length UL15 protein, similar to the 
situation with UL26 and UL26.5, see Section 1.8.2). The full length protein is 
necessary for cleavage and packaging of viral DNA. The published data on UL15 are 
therefore consistent with the view that UL15 is a subunit of the herpesvirus terminase.
No mutants have been described for UL14 or UL17, and the roles of the protein products 
of these genes are not known. The status of both genes in cell culture is also unknown, 
although Baines and Roizman (1991) suggested from their inability to obtain a mutant 
that UL17 may be essential.
The function of the UL16 protein is unknown although it has been shown to be non- 
essential in cell culture (Baines and Roizman, 1991). Growth curves of a mutant lacking
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988 bp of UL16 (1119 bp) indicated that yields of UL16* virus in Vero or BHK cells 
were reduced from those of wt (10- or 3-fold respectively) (Baines and Roizman, 1991).
An alignment of the predicted amino acid sequence of the UL16 protein with counterparts 
in other herpesviruses is shown in Fig. 51. Of the 20 cysteine residues in HSV-1 UL16, 
6 are conserved in all three subfamilies and a seventh (in parentheses in Fig. 51) is 
conserved in all but HSV-2 where it is replaced by a glycine. Indeed, two thirds of the 
total conserved residues are cysteines, and are likely to have an important role, possibly 
in forming intra- or inter-molecular disulphide bonds.
5.2. Cosmid-based mutagenesis of UL14, UL15 and UL17
The manipulation of large fragments of HSV-1 DNA is difficult, but in principle the 
cosmid system should permit easier manipulation and production of mutants. Mutants 
produced using a mutant cosmid set can be isolated in the absence of a background of wt 
virus, and even viruses which have multiple mutations or are at a severe growth 
disadvantage to wt can be isolated. However, Cunningham and Davison (1993) reported 
that transfections with mutant cosmids containing 4 bp insertions resulted in the 
generation of revertants (wt progeny) on non-complementing cell lines when the mutation 
was in an essential gene, owing to recombination events occuring during generation of 
the virus. This aspect of the cosmid system in fact provides a positive indication of the 
importance of target genes to growth in cell culture: a failed transfection yields no 
plaques, mutation of a non-essential gene yields only mutants and mutation of an 
essential gene yields only wt viruses. Also, genes which are neither completely essential 
or non-essential but disruption of which confers a severe growth disadvantage will 
produce mutants and a background of revertant virus (wt). In other systems, particularly 
those utilising plasmid recombination, failure to obtain a mutant has been taken as an 
indication of the essential nature of the target gene, whereas this may actually have been 
due to inefficient transfection. Another major advantage of the cosmid system is the 
ability to introduce minimal lesions, for example, the insertion or deletion of only a few 
bp, so that adjacent genes are less likely to be disrupted than they are in mutants in which 
sizeable insertions or deletions are made.
Despite the potential advantages of the cosmid system, there are still a number of 
difficulties. Manipulation of large fragments of DNA derived from cosmids is not easy, 
and obtaining optimal conditions for linearisation of the cos24 in the presence of EtBr 
proved to be critical in the experiments: if conditions were not correct large deletions or 
wt cosmids predominated. Also, transformation of bacterial cells with the cosmids
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Fig 51. Alignment of the amino acid sequence of the HSV-1 UL16 protein 
and its counterparts in the three herpesvirus subfamilies
The alignment was produced using the Pileup program from Genetics Computer Group (1994). 
Padding characters are indicated by dots. Residues conserved between the three subfamilies and, 
non-conserved residues are given in the CON line. The 20 cysteine residues in the HSV-1 sequence 
are denoted by asterisks. HSV-1 (UL16) (McGeoch e ta l . ,  1985,1986, 1988), D.J. McGeoch kindly 
provided the HSV-2 sequence (UL16): it should be noted that this sequence begins with a leucine 
(CTG) rather than a methionine (ATG) codon, EHV-1 (gene 46) (Telford e t  at., 1992), EHV-4 (gene 46) 
(kindly provided by E. Telford and A.J. Davison), BHV-1 (UL16) (Vlcek e ta l . ,  1995), VZV (gene 44) 
(Davison and Scott, 1986), HCMV (UL94) (Chee e ta l . ,  1990), HHV-6 (U65) (Gompels e ta l . ,  1995), 
EBV ((BGLF2) Baer et al., 1984), HVS (ORF33) (Albrecht e t  al., 1992), EHV-2 (ORF33) (Telford e t  al., 
1995), HHV8 (ORF33) (Moore e t  al., 1996). An error in the published HHV-8 sequence by which the 
insertion of an additional residue causes a frameshift was noted. The putative corrected sequence is 
underlined.
H S V -1  M A Q LG PR RPLAPPG PPGTLPRPDSRAG ARGTRDRVDDLG TDVDSIARIVNSVFVW RW RADERLKIFRCLTVLTEPLCQVALP  
H S V -2  LAQRALW RPQATPGPPGAAAPPGHRGAPPDARAP. . D PG P E ADL VAR IA N S  V FVWRWRG DE RL K I FRCLTVLTEPLCQVALP  
E H V -1  M M AA A SD SCLSLW EG SA SSPNR Q LTPEAV N CLTEALTED V AV LR LIR SDPRV K IFM AV SVLTPRLA R FA PP
E H V -4  M A A D L N SY SSIW E G SSL SPN R Q L T IE A A N C L T E A L T E D IA V L R L IR SD PR V K IFM A V SV L T PR L A R FA PP
B H V -1  MAEDPAAAGALLARALTEELGCLHLVRTDSRVKIYVAVATLGRLLARLVSP
V ZV  M ELQ R IFPLY TA TG A A RK LTPEA VQ RLCD ALTLDM G LW K SILTDPRV K IM R STAFITLRIA PFIPL
HCMV MAWRSGLCETDSRTLKQFLQEECMWKLVGKSRKH. R E Y R A V A C R S T IF S P E . . .
H H V -6  M A IST  FSIGDLGYLRNFLQNECNW FRICKKT F Y . R EY R SV A T SSPT  F S L N . . .
EBV M ASAANSSREQLRKFLNK ECLW VLSDASTPQM KVYTATTAVSAVY.. .V P Q
HVS M D D FRN KL RN FLNN EC LWVKNVACT S FT KVY CAT TAVS P F F K P . I S P
E H V -2  M A SG G V GG TRELFRQ FLNKECIW K KSPNSSPYLK IYVATTAISPVFKPDVGG
H H V -8  M ASRRRKLRNFLNK ECIW TVNPM SGDHIKVFNACTSISPVYDPELVT
CON -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
H S V -1  N PD .PG R A L FC E IF L Y L T R PK A L R L PP N T F FA L FFF N R E R R Y C A IV H L R SV T H P L T PL L C T L T FA R IR A A T P PE E T PD PT T E Q  
H S V -2  D PD .PER A L FC E IFL Y L T R PK A L R L PSN T FFA IFFFN R E R R Y C A T V H L R SV T H PR T PL L C T L A FG H L E A A SPPE E T PD PA A E Q  
E H V -1  PPKLTHTAKCAVIMIYLTRPKALALQPKQFHM LVT FNKASVY SL W R V K T K P FPVGTQRFRAVFQDPE F IG L P S D IP D P A A E N  
E H V -4  QSK LTH TA K C AV IM IYLTR PK ALA LQ PK Q FH V LVTFSK SSV YSLV M R V K TK PFPISPQ R FC G V FQ D PEPIG LPSD VPNPA TEN  
B H V -1  ED ASPG AA . . VRVTLYITRPRSLELPPRH FHVLVLFGG AVARACVAGVRTRALVPGSTRVRAVFRDAVAVPAPADLPDPSAEV  
V ZV Q T D T T N IA . V W ATIY ITR PR Q M NLPPK TFH V IV l'JFN YEV SYA IvIT A T L R IY P V E N ID H V F G A T F K N P IA Y P L P T SIP D P R A D P
HCMV . . D D S S . . C IL C Q L L L L Y . R D G  E W IIC FC C N G R Y Q G H Y G V N H V H R R R R R IC H LPTLY Q LSFG G PLG PA SID FLPSF.S
H H V -6  . . N K P K K F C M H C E IV IF K .R SE  EFM FSLAVNGIHFGQFLTGKM KFNKKAVPEGLYYYILELGS. IT P ID L G F IP R Y N S
EBV IA G P P K T Y . M NVTLIVLKPKKK PTYVTVYINGTLATVARPEVLFTKAVQGPH SLTLM YFGVFSDAVGEAVPVEIRGNP
HVS Q G V P D K H Y .IN V T L IIL K P K K S  H PY IT V Y IN D L A V D C C ST E IL Q V K PV PC SH . F S L IY F G P L . . . IA P P H N V Q IP A N L
E H V -2  RGRPGSAHAINVTALFM KPKGR R T C A A FY V N G L L L E A C V P E V IFT K W PG V L G L FL IY F G PFA E . . . P R R P F P IP T E P
H H V -8  . SYALSVPAY N VSV AILLH K V M  GPCVAVG IN G EM IM YW SQ C V SV R PV PG R D G M A LIYFG Q F. . . L E E A S G L R F P Y IA
CON ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
H S V -1  .....................................................................LAEEPW GELDGAYLVPAKTPPEPGACCALGPGAW W HLPSGQIYCW AM DSDLGSLCPPGSR
H S V -2  .....................................................................LADEPVAHELDGAYLVPTDTAPESGACCALGPGAWWHLPGGRIYCWAMDDDLGSLCPPGSR
E H V -1  .....................................................................IPTEINDRLDVSNFATPAQPPKDKYDCCVLAPGVW W SNANKAIYFLQMDVALLALCPAGW K
E H V -4  .....................................................................IPTEINDRLDVSNFATQTQPPKDKYDCCVLAPGVWWYKAQKAIYFLQMDEALLALCPAGWK
B H V -1  .................................................................... VPPAPAEHVDPFAFTAFARPPRDAADCFQLAPGVWWSYADRRLYLVQMDEALLALCPAGWR
VZV .................................................................... TPADLTPTPNLSNYLQPPRLPKNPYACKVISPGVW W SDERRRLYVLAM EPNLIGLCPAGW H
HCMV QVTSSM TCDGITPDVIYEVCM LVPQDEAKRILVKGHGAM DLTCQKAVTLGGAGAW LLPRPEGYTLFFYILCYDLFTSCGNRCD
H H V -6  DCVTNMRC. . V TPEV IY EN C SIV C PE EA N R LTV K G SG D N K LT PLGGCGAWCLKNGGDLYIYTFALAYDLFLTCYDKST
EBV W T C . , . T D . LTTA H V FTTSTA VK TVEE......................... L Q D IT P SE IIP L G R G G A W Y _____ AEGALYMFFVNMDMLMCCPNMPT
HVS SIK A S K K S H . L T K N Q V IF T S K V IH P E R L ..........................PD G Y K S A SL IG . . .ACAW Y--------- SEG A IFQ H FLSTDY M SLC PA FK E
E H V -2  A ISA PQ N V Q LLN RM EM LD TST H IALSD L.........................GEAVAGRE FTSV G K L. VWW______DGEAFFFYYLSM EYM M CCPTISE
H H V -8  PPPSREH VPDLTRQELVHTS Q W R R G  D L ..........................TN CTM GLEFRNVNPF.VW L______GGGSVWLLFLGVDYMAFCPGVDG
CON --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------C ------------
H S V -1  ARHLGWLLARIT . N H PG G C E SC A PPP. H ID S A N A L . . W LSSW TESCPCVAPCLW AKM AQCTLAVQGDASLCPLLFGHPVDT . 
H S V -2  ARHLGW LLSRIT . DP PGGGGACAPTA. H ID S A N A L . . WRAP AVAE AC PC VAP CMWS NMAQRT LAVRG DAS LCQLLFG HPVDA. 
E H V -1  A R G L G IIL G R L L . NHQEGCATCRFTE. H SD P L N A T . . ADSVATPESCLCWAPCLWRKAHQRELTVEGDRYLFRVLFMDAVER. 
E H V -4  A R G L G IIL G R L L .N H Q E G C S T C R F T E .H S D P L N A T .. ADSVAT PE S CLCWAPCLWRKSRQRE L KVEGDRYL FRVL FMDAVER. 
B H V -1  SRSLG GVLGRLL. SH PG G C A A C T A K W .H ID A L N A A .. PE PG AC . DVCPCAAPCLWKKARRQDVPVAGDSSL FRVLFT DAVAR. 
VZV A R IL G S V L N R L L . SHADG CDECNH RV.HVGALYAL. . PHVTNHAEGCVCWAPCMWRKAGQRELKVEVDIGATQVLFVDVTTC. 
HCMV IPSM TRLM AAATACG QAGCSFCTDHEG HVDPTGNYVGCTPDM ..G RCLCYVPC.. G P M T Q S L IH .. . NEEPA TFFC ESDD A K Y  
H H V -6  F P SL A K IIF D M IA C E S E  DCVFCKDHNKHVSQAGQIVGCVSNQ. . E T C F C Y T S C .. K K K M A N .IN .. . N P E L IS L L C D Q E IN K . 
EBV FPSLTH FINLLTRCDNG ECVTCYG AG AH VNILRG W TEDDSPGTSG TCPCLLPC. . TALNN DYVPITGHRALLGLM FKPE DAP F 
HVS F P SL SR IL SL L T R C D D L SC V PC Y G E K IH V N C Q SG Y T D SD C D G K SN SC P C IT SC . . TA LK K D IV PITG H R N L LSLLFD A TIQ H N  
E H V -2  H TTLSR FITLLTQ C D DR G C V PC H G R K IH A N VA G G YTD PG SD G V STTC LCTLSC .. AALEKELVPVTKNKSLLSLM FGPMTYQQ  
H H V -8 M PSLARVAALLTRCDHPDCVH CH GLRGHVNVFRG YCSAQ SPGLSNICPCIKSC. . G T . GNGVTRVTG NRNFLGLLFDPIVQSR
H S V -1  . V T L L Q A PR R P C IT D R L Q E W G G R .C G A D N . IPPT SA G W R L C V FSSY ISR L FA T SC PT V A R A V A R A SSSD PE
H S V -2  . V IL R Q A T R R P R IT A H L H E V W G R . D G A ESV IR PTSAG W RLC V LSSY TSRLFATSC PA VA R AV A RA SSSD YK
E H V -1  . V R L T G L R R SPK IT A N L A .D L W G I. GPH G Q Q IPV NN A G W K LV A LDA D ISR LIVC G C Y ALR Y IC PPTNSK H Q PSSPD EYA
E H V -4  . VRLTGLRRS P K IT A D L A D L W G I. G SH G Q Q IPV N SAGW K LVALDANISKLIVCGCYSLRYLCPSTDCKTQ QLSTSEDA
B H V -1  . VRILGSRRRPRITGALPELLAGV.GPRGEAVPVNGAGW QLRVM DDDVTRLLASSCRAM RSCAAARGSPW G
VZV . I R I T S T . K N PR IT A N L G D V IA G T . N A SG LSV PV N SSG W Q LYM FG ETLSR AIING CG LLQ R ICFPETQ R LSG EPEPTTT
HCMV LCAVGSKTAAQVTLGDGLDYHIGVKDSEGRWLPVKTDVWDLVKVEEPVSRMIVCSCPVLKNLVH
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H H V -8 V T A L .. K ITSH PTPTH V EN V LTG V LD .D G TLV PSV Q G TW VLLRM SDYFSRLLIYECKKLKALGLRSY
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occurs at a low efficiency. As an indication of the experimental difficulties, in one 
experiment 200 colonies were screened in order to obtain a single mutant cosmid.
Having obtained cosmids with a 4 bp insertion in UL6 , UL7, UL14, UL15 and UL17, 
attempts were made to produce mutant viruses by cotransfection of cosmid sets into 
BHK C13 cells. As described before, it was anticipated that, although only mutated 
DNA was transfected into cells, wt progeny would be produced if the mutant was 
severely disabled. Indeed, transfection of BHK C l3 cells with mutant cosmid sets 
produced wt virus. The results obtained indicate that UL7, UL14, UL15 and UL17 are 
important for viral replication in cell culture, since only wt progeny was produced.
Candidate complementing cell lines which would facilitate growth of mutants with 
lesions in essential genes were produced by three different strategies. These were 
generated using either cos24 (containing genes UL1 to UL21), a fragment containing 
genes UL14 to UL18, or fragments containing UL14, UL15 or UL17 individually. 
Overall, 122 candidate cell lines were produced, and 40 were screened by transfection 
with the appropriate mutant cosmid sets. All of the progeny generated from these cell 
lines were wt. This indicates that the cell lines tested did not complement the defects. It 
could be that there was a low copy number of expressing plasmids per cell, such that 
only a small amount of protein was produced, not sufficient amounts to complement the 
defect, or that part of the plasmid may have been lost from the cells. It would have been 
beneficial to check for the presence of HSV-1 DNA by PCR in the possible 
complementing cell lines before transfecting them with the mutant cosmids sets, 
especially given the large number of cell lines.
Recently, a cell line expressing the UL15 protein was obtained by C. Cunningham from 
Dr J. Baines (Cornell University, New York) and used to generate several UL15‘ 
mutants. These mutants synthesise but do not cleave or package viral DNA. The 
availability of UL15’ mutants will facilitate screening of the remainder of the cell lines 
produced during this work.
The UL15 expressing cell line (which may also express UL14) and the parental rabbit 
skin cell line have been tested for the ability to support the growth of virus generated 
from cosmids containing a UL14' mutation (C. Cunningham, personal communication). 
The UL14’ virus produced extremely small plaques on both cell lines, suggesting that 
UL14 is not an essential gene but that mutants are severely disabled and that UL14’ virus 
is not complemented by the UL15 expressing cell line. The mutant can be isolated from
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these cells because monolayers survive in culture for extensive periods, whereas BHK 
C13 monolayers do not survive long enough to support the growth of the mutant.
It is now known that UL15 is an essential gene which requires a complementing cell line 
for isolation of mutants. Although UL14 is not essential, mutants are severely disabled 
and require cell lines which survive for long periods in cell culture for the isolation of 
mutants. UL17' viruses have not been isolated from any cell lines tested so far 
(including rabbit skin cells) and is probably essential. The situation with UL14 indicates 
that although some genes are strictly essential or non-essential in cell culture, some fall 
into neither category in that mutants affect growth properties in cell culture. For 
example, a UL51* mutant does not spread efficiently on confluent Vero cells but can 
spread, form plaques and destroy subconfluent cultures infected shortly after passage 
(Barker and Roizman, 1990). Also, Goldstein and Weller (1988) found that a UL39' 
mutant was more severely compromised in serum starved cells and suggested that UL39 
is required in non-dividing cells. As another example, a UL20' mutant grows on human 
tk' cells but fails to produce plaques on Vero cells (Baines etal., 1991).
5.3. Identification of proteins
Antibodies potentially recognising the UL17 or UL16 proteins were available in the 
laboratory and were used in Western blotting and immune precipitation experiments 
under a range of conditions. None reacted with convincing candidate proteins in infected 
cells or in virions.
Since the counterparts of the HSV-1 UL16 and UL17 proteins have been identified as 
minor components of EHV-1 virions (A.J. Davison, personal communication), mass 
spectrometric analysis of HSV-1 virions was carried out. Use of a UL47‘ virus revealed 
at least two faint bands usually obscured by this major tegument protein on 
polyacrylamide gels. The data suggested that these bands contain the UL17 and UL46 
proteins. The use of a mutant lacking UL47 and UL46 may facilitate the conclusive 
identification of UL17 as a virion component. During the mass spectrometric work, 
analysis of a minor virion protein in the 20-40 kDa region revealed evidence for the 
presence of the UL14 protein plus the UL49 protein. The UL16 protein was not 
identified, despite extensive mass spectrometric analysis of virion proteins, and no 
difference was observed between the protein profiles of wt and UL16' virus on 
polyacrylamide gels.
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Results from various rounds of Massmap analysis from a number of different 
experiments imply that UL17 and UL14 are virion components, but they are present in 
minor amounts and the analysis was carried out at the limits of detection. Confirmation of 
these proteins could be obtained by the use of appropriate antibodies.
Experiments involving pulse labelling of infected cells revealed differences between wt 
and mutants, and indicated a candidate UL16 protein. The UL16 protein produced in 
vitro did not correspond in mobility to a protein in infected cells labelled with [35S]- 
cysteine or [35S]-methionine, including the candidate protein which migrated a little more 
slowly. It is possible that the UL16 protein is modified differently during virus infection 
than in the in vitro system used, which utilised E.coli extracts. However, the presence of 
20 cystine residues and only three methionine residues in the UL16 protein implies that 
the UL16 protein should be relatively more prominent in cystine-labelled cells than in 
methionine labelled cells. None of the proteins migrating in the vicinity of the candidate 
protein, including the candidate protein itself, exhibited labelling properties supporting its 
identity as the UL16 protein. Thus, the UL16 protein was not convincingly identified, 
suggesting that it is minor or comigrates with a major protein encoded by a different 
gene.
Since the completion of this work Dr J. Baines used an antibody to identify the UL16 
protein as a virion component which comigrates with the UL49 protein (a major tegument 
protein) and is produced late in infection (personal communication). In future work, use 
of a UL49' mutant (if viable) may be of benefit in identifying the UL16 protein using 
mass spectrometric analysis. Recently, Wing et al. (1996) reported that the counterpart 
of UL16 in HCMV (UL94) encodes a capsid- or tegument-associated virion protein that 
is expressed with true late kinetics, by the use of a monoclonal antibody.
5.4. In vitro characterisation of UL16' virus
Six UL16' viruses (la-d, 2a and 3a), two revertants (lb  rev and 2a rev), wt viruses 
derived from the parental cosmid set (coswfl and 2) and wt HSV-1 were used in in vitro 
experiments.
The production of three to five-fold less infectious virus by mutants la-d on BHK C13 
cells at high and low moi is consistent with the results of Baines and Roizman (1991), 
who reported a ten-fold reduction in the yield of a UL16 deletion mutant on Vero cells 
and a three-fold reduction on BHK C13 cells. Mutant 2a was 15,000-fold reduced in 
yield compared with wt, while mutant 3a, which contains all but the last two codons of
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UL16, was indistinguishable from wt. Mutants la  and lb grew to about 13-19% of the 
titre of wt on four cell lines, confirming that the yield reduction is not specific to BHK 
C13 cells. The yield was somewhat less (5-9%) on two other cell lines. The extremely 
low yield of 2a is surprising, since the tmncated protein contains a larger portion of the 
UL16 protein (208 residues of the 373 residue full length protein) than mutants la-d (66 
residues). It is possible that the truncated protein interferes with the normal function of
UL16 or that the mutant has a secondary mutation.
Consistent with reduced viral yields, most UL16' mutants produced smaller plaques than 
wt virus on BHK C13 cells. Mutants la-d produced plaques which were 20-27% the 
size of wt plaques, 2a was 4% the size of wt while 3a was the same size as wt. On 
MeWo cells, la and lb plaques were 50 % the size of wt plaques. The small plaque size 
was shown to be linked to the mutations introduced into UL16 by the analysis of several 
distinct mutants with lesions at the same site and by the use of revertants, which 
produced plaques of wt size.
Particle counts (Section 4.2.2.4) showed that cells infected with mutants la  and lb 
released a similar number of particles to wt, but that fewer were infectious (i.e. they 
displayed a high particle:pfu ratio). The mutants appeared to be slower to produce 
virions early in infection (Section 4.2.2.5) but produced as many particles as wt virus 
later in infection. This is consistent with the growth curves where the mutants are slower 
to initiate growth at the first stages of infection.
Mutants la and lb did not bind to cells as well as wt, which may explain the small
plaques and lag in growth, but were able to adsorb and penetrate cells as efficiently as wt 
(no significant differance) and are not significantly temperature sensitive or cell type- 
specific. There was no evidence that UL16 is involved in inducing IFN resistance, 
despite the report by Su et al. (1993) who mapped a region of the HSV-1 genome 
conferring IFN resistance to UL14, UL15 and UL16. It should be noted that the work 
of Su et al. (1993) involved the use of intertypic recombinants between HSV-1 and 
HSV-2, and thus it is possible that the effect they observed was due to secondary 
mutations. Also, it is possible that IFN resistance may be multifactorial (i.e. other genes 
may be involved).
Although UL16 is non-essential for virus growth in cell culture, the mutants yield less 
infectious virus and produce smaller plaques than wt. HSV-1 mutants with a small 
plaque phenotype have been described, including, the Vmw65 mutant /nl814 (Ace et al., 
1989), which has a high particle to pfu ratio and is avirulent but can establish and
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reactivate from latency, an RL1‘ mutant which produces smaller plaques on BHK C l3 
cells and is avirulent (Brown et al., 1994), and a UL39" mutant which yields 4-5 fold 
less virus and is avirulent (Goldstein and Weller, 1988c).
The function of the UL16 protein is unknown. Mutants produce the same number of 
virus particles as wt but fewer are infectious, they yield less infectious virus and produce 
smaller plaques. It is possible that the UL16 protein is involved at a number of stages in 
the replicative cycle. It may act early in infection since although mutants are able to 
adsorb as efficiently as wt virus, they bind and penetrate cells slightly less well. It may 
also have a role in the later stages of infection during the formation of the mature virions, 
since the UL16 protein has been identified as a virion component (Dr J. Baines).
5.5. In vivo characterisation of UL16' virus
There is considerable interest in the use of mutants to identify virulence factors. 
However, there are inherent difficulties in interpreting results from animal models since 
variation may occur due to differences in the age and general state of health of the 
animals, factors which may influence host immune responses. There are several 
important criteria which should be met when analysing mutants in animal models. These 
include the use of independent mutants and revertants, repetition of experiments, and the 
determination of the genotype of viruses replicating or reactivated from ganglia.
5.5.1. Neurovirulence
A number of workers have linked small plaque size to avimlence (see above), and some 
genes which have been shown to be non-essential in cell culture are important in 
neurovirulence and latency in vivo (see Table 12 for details).
In neurovirulence experiments, coswt\ was as virulent as wt virus, and a firm indication 
was obtained that mutants with a lesion at position 31096 bp in UL16 have reduced 
neuro virulence. This has been directly linked to the mutation in UL16 by the use of a 
revertant which is as virulent as coswrl. Genotypic analysis revealed that, although they 
were less virulent, mutants were able to replicate in the brains of mice.
In a pilot experiment mutants la and lb were found to be less virulent that wt but to 
different extents (1000- and 10-fold less than wt respectively). Since these mutants have 
a 4 bp insertion at the same site in UL16 it was expected that they would behave in a 
similar manner. In a second experiment, however, this difference was not observed and
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the mutants (la, lb, Id) were all attenuated to a similar extent (500-1000-fold), 
indicating that there was a degree of variation in these experiments. The variation may 
have been due to factors such as the age and general health of the animal, variation in the 
inoculation proceedure and the conditions in which the animals are maintained. Also, the 
scoring of disease, which influences when animals are killed, is subjective.
5.5.2. Latency
Mutants la-d, 2a and 3a and lb established and reactivated from latency less efficiently 
than wt virus following FP injection and explantation and cocultivation of ganglia.
In an initial experiment, all of the wt viruses reactivated by 6 days post explantation. 
Mutants la and lb reactivated much more slowly than wt but reached 90-95% 
reactivation. The genotypes of a selection of reactivated viruses picked at a late stage of 
reactivation (10-12 days) were determined, and all but one were found to be revertants to 
wt. The other was a mixture of mutant and revertant virus. These results suggest that 
UL16 has a role in efficient establishment of or reactivation from latency.
In a second experiment all of the mutants were tested. Coswfl and coswt2 reactivated 
within accepted levels for wt and all of the mutants reactivated slowly and reached a 
lower final level of reactivation. The genotypes of reactivating viruses arising early 
during reactivation (4-6 days) were wt except for mutant la. Plaques from la at later 
stages of reactivation (10-12 days) were found to consist of revertants (2 plaques), 
mutant (1 plaque) and a mixture of revertant and mutant (1 plaque). These results suggest 
that although mutant la  is able to establish latent infections and reactivate, it does so at a 
lower efficiency than wt. The slower kinetics of reactivation of the UL16’ mutants 
indicates that the majority of reversion occurred during reactivation and that the UL16' 
mutants must be at a selective disadvantage to wt.
Detection of virus directly in the ganglia by PCR would aid further investigation of the 
block in establishment and reactivation of latent infection, as would the use of a mutant 
with a small deletion in UL16 since it would be unable to revert to wt.
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5.6. Analysis of mutants using animal models
Many of the published data do not meet one or more of the important criteria required to 
minimise variation (see Section 5.5), and they also differ from each other in the type of 
animal model used, the site of inoculation, strain of virus, type of mutant and the titre of 
virus inoculated (see Table 10 for details). These factors combine to make it difficult to 
interpret results.
The work by Pyles and Thompson (1994) investigating UL2' mutants is the most 
comprehensive in vivo study in recent literature. They used two insertion mutants and a 
single revertant and they determined the genotype of reactivated viruses. In a contrasting 
study, Balan etal. (1994) produced a single insertion mutant in US7 and another in US8 
but did not produce revertants, and Efstathiou et a l (1989) investigated UL23 using a 
single deletion mutant without a revertant. Although deletion mutants cannot revert to 
wt, they are not without potential problems. For example, the UL50* deletion mutant 
tested by Pyles et al. (1992) had also lost the UL49A promoter and so the phenotype 
attributed to loss of UL50 may have been affected by loss of UL49A expression.
In other studies, UL39* and UL40* mutants were tested in three systems using mice or 
guinea pigs. In one, a revertant was produced confirming the avirulence of the mutant 
(Cameron e ta l, 1988), but in a second, although the mutant was less virulent than wt, 
the revertant was still reduced in virulence compared to wt virus (Jacobson et al, 1989a), 
while in a third study using guinea pigs, no impairment in virulence was reported (Turk 
et a l , 1989). Thus different conclusions can be drawn from different animal models.
Intertypic recombinants or drug resistant mutants have been used in animal models, but 
may be less reliable than insertion or deletion mutants since they may contain secondary 
mutations. It is of particular importance to produce revertants in these cases. Intertypic 
and drug resistant UL30* mutants have been used in the mouse eye model (Oakes et a l, 
1986; Day et al, 1987a, b) but revertants were not produced. An intertypic recombinant 
used in a mouse model indicated that UL56 plays a role in neurovirulence (Becker et a l, 
1986; Rosen et al, 1986), but, a UL56* insertion mutant tested in the mouse showed that 
this gene is not necessary for intraperitoneal virulence or for the establishment and 
reactivation from latency (Nash and Spivak, 1994). This again indicates the variable 
results which may be obtained by the use of different kinds of mutants and of different 
sites of inoculation.
Since many workers do not comply with the basic criteria required to minimise variation 
in animal experiments, results in the literature must be viewed cautiously. In this work,
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an attempt has been made to carry out the analysis of the UL16' mutants in vivo using 
more than one mutant in more than one experiment, producing a revertant and by 
analysing the genotype of reactivated viruses. The results show that UL16 plays a role in 
neurovirulence and in latency.
 ♦ -----
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